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Abstract 
Acute myeloid leukemia (AML) is the most aggressive form of hematological 
malignancies. Despite advances in treating AML, development of resistance to 
nucleoside analog therapy remains one of the major obstacles in AML treatment. Various 
factors, including SNPs in genes, epigenetics, etc. play a role in mediating variability in 
response to nucleoside analog therapy. Recent studies have shown that microRNAs can 
also serve as regulators of gene expression that can contribute to variability in response to 
therapeutic agents. Thus the main objective of the thesis was to determine the role of 
microRNAs as predictors of variability in nucleoside analog response.  
To our knowledge no studies have been reported that identify microRNAs as predictors 
of response to cytarabine therapy in AML patients. In chapter II we used a translational 
approach of conducting in vitro and clinical study to identify microRNAs that were 
predictive of overall survival in AML patients. Our study conclusively identified that 
miR107-Myb, miR-378-granzyme B and miR10a-MAP4K4 as miRNA-mRNA pairs that 
can be used as predictors of overall survival in AML patients. Additionally, we also 
showed that the miRNAs mechanistically regulate the expression of these mRNAs by 
binding to the 3’- untranslated region of these mRNAs. miRNAs can also cause 
variability in response to cytarabine therapy by regulating the expression of the genes 
involved in disposition of cytarabine. In chapter III we identified that miR-24 and miR-
34a as regulator of DCTD (an enzyme involved in inactivation of cytarabine) and DCK 
(activating enzyme), respectively. These miRNAs along with other miRNAs can be used 
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as part of biomarker signature that can be used to predict the overall survival in AML 
patients.   
In chapter IV, we determined the impact of cytarabine treatment on in vivo cytarabine-
induced changes in leukemia cell transcriptome and miRNA expression, to evaluate their 
impact on clinical outcome. In the first part of this chapter, we identified key genes (such 
as tumor suppressors DKK3, TRIM33, PBRM1, an oncogene SET, cytidine-deaminase 
family members APOBEC2 and APOBEC3G) influenced by cytarabine infusion that 
were also predictive of response. In the second part of this chapter, using data from 
clinical studies, we identified several miRNAs that were altered by cytarabine treatment. 
The changes in the expression of these miRNAs resulted in alteration in gene expression 
that correlated with the overall survival in AML patients. Additionally, using cell lines 
we were able to identify various miRNA – mRNAs that were altered by drug treatment, 
indicating that the therapy itself can influence the predictive ability of miRNAs as 
biomarkers. 
Significant data has been published on cytarabine as it is the standard of care in AML 
patients, however, there is limited knowledge about newer nucleoside analogs such as 
clofarabine. In chapter V, using in vitro methods, we identified several microRNAs, such 
as miR-16, miR-515 cluster, etc., that can be used as predictors of response for 
clofarabine therapy. Our data clearly suggests that there are several distinct microRNAs 
that can be used as predictors of response to clofarabine therapy in AML patients. We 
propose doing a clinical study to evaluate the clinical utility of these miRNAs as 
predictors of response. 
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In summary, using a translational approach, we were able to identify miRNAs and 
several miRNA-mRNA pairs that can be used as biomarkers of response to cytarabine 
therapy. Additionally, we also identified that drug therapy itself can influence the 
outcome in AML patients. These findings are clinically important as they will help 
provide a new strategy to optimize dosing of nucleoside analogs in AML patients which 
in turn would lead to better overall survival while reducing the side effects. 
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1.1. Acute Myeloid Leukemia 
1.1.1. Introduction and Background: The word ‘leukemia’ is derived from the Greek 
words ‘leukos’ and ‘heima’ meaning ‘white blood’, which is mainly due to the initial 
observation of the abnormally high white blood cells in the patients, a characteristic 
feature of leukemia. Leukemias are broadly classified based on how quickly the disease 
progresses (acute and chronic) and the type of bone marrow cells that are affected 
(myeloid and lymphoid). The four most common types of leukemia are acute myeloid 
leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia 
(CML) and chronic lymphocytic leukemia (CLL). The other types of leukemias that do 
not strictly fall in the above categories include hairy cell leukemia, T-cell prolymphocytic 
leukemia, large granular lymphocytic leukemia, adult T-cell leukemia, etc. 
Acute myeloid leukemia (AML) is a hematological malignancy, which results due to a 
series of genetic changes occurring in myeloid progenitor cells of the bone marrow. As a 
result of these malignant genetic transformations, there is an alteration of the normal 
hematopoietic growth and differentiation, resulting in accelerated production and 
accumulation of large numbers of poorly differentiated, immature and abnormal myeloid 
cells in the bone marrow and peripheral blood. Though these cells are capable of dividing 
and proliferating, they cannot differentiate into mature hematopoietic cells, disturbing the 
normal hematopoiesis process. Thus, AML mainly develops due to multiple genetic 
mutations leading to uncontrolled proliferation along with abnormal maturation.  
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AML is the most common form of acute leukemia in adults with an incidence rate of 
4.0501 cases per 100,000 patients. AML also has a highest mortality rate of 2.85 cases 
per 100,000 patients as compared to other leukemias. 
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Figure 1.1: Prevalence and Incidence of AML 
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According to the Cancer Facts & Figures published by the American Cancer Society 
(ACS), the prevalence of AML is 35,726, as of January 2010. It is estimated that around 
18,860 new AML cases in both adults and children would be diagnosed in the US in 2014 
and approximately 10,460 deaths would be attributed to AML. It was reported that the 5-
year relative survival rates from 2003 to 2009, for AML were 24.9% overall and 64.8% 
children and adolescents younger than 15 years (Figure 1.1). Although AML can occur at 
any age, the median age for diagnosis of AML is mainly around 69 years (SEER 
statistics). Even though AML is not common in children and adolescents, AML 
constitutes around 20% of the childhood acute leukemias [1]. 
1.1.2. Classification of AML: AML mainly refers to the malignancies originating from 
the myelocytes or granulocytes, but could also be applied to leukemias of myeloid, 
monocytic, erythroid, or megakaryocytic origin. Hence, AML is considered to be a 
heterogeneous disease, which includes several subtypes with different morphology, 
immunophenotype and cytogenetic characteristics. Classification of AML into different 
subtypes helps decide the prognosis and guide the treatment regimen. The first 
classification of AML was proposed by French-American-British (FAB) co-operative 
group in 1976 and revised in 1985 and 1991, and was largely based on the 
cytomorphological characteristics of the cells [2-7]. The FAB classification divides AML 
into eight subtypes depending mostly on how the leukemia cells lineage and the maturity 
of the cells (Table 1.1) [5].  
The FAB classification of AML was the first to provide a uniform approach to classify 
AML and is still used to stratify AML patients into different subtypes. However, the FAB 
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classification failed to take into account the underlying genetic abnormalities and 
immunologic characteristics that are generally associated with AML.  
Table 1.1: French-American-British (FAB) Classification of AML 
FAB Subtype Morphology 
M0 Undifferentiated acute myeloblastic leukemia 
M1 Acute myeloblastic leukemia with minimal maturation 
M2 Acute myeloblastic leukemia with maturation 
M3 Hypergranular acute promyelocytic leukemia 
M3 variant Hypogranular variant acute promyelocytic leukemia 
M4 Acute myelomonocytic leukemia 
M4 eos Acute myelomonocytic leukemia with dysplastic eosinophilia 
M5a Acute monoblastic leukemia 
M5b Acute monocytic leukemia 
M6 Erythroleukemia 
M7 Megakaryoblastic leukemia 
 
However the morphologic, immunologic and cytogenetic (MIC) classification, which was 
introduced by the MIC Cooperative Study Group in 1986 [8-10] tried to overcome this 
shortcoming and took into consideration the importance of cytogenetic characteristics of 
AML, along with the morphology and immunology of the disease, for its classification. 
This MIC classification provided additional insight into the clinical significance of 
cytogenetics for AML classification, which is depicted in the Table 1.2 [10, 11].
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Table 1.2: Morphologic, Immunologic and Cytogenetic (MIC) Classification of AML 
  Immunologic markers  
MIC group FAB CD34 CD33 CD13 CD11 CD15 CD14 Karyotype 
M2 / t (8; 21) M2 +/- + + + + +/- t (8; 21) (q22;q22) 
M3 / t (15; 17) M3, M3v _ + + +/- +/- - t (15; 17) (q22;q12) 
M5a / del (11q23) M5a (M5b, M4) +/- + + + + + t /del(11) (q23) 
M4Eo / inv (16) M4Eo +/- + + + + + del / inv(16)(q23) 
M1 / t (9; 22) M1 (M2) + + + +/- +/- +/- t (9;22)q(34;q11) 
M2 / t (6; 9) M2/M4 with basophilia +/- + + + + +/- t (6;9)(p21-22;q34) 
M1 / inv (3) 
M1 (M2, M4, M7) with 
thrombocytosis 
+/- + + +/- +/- +/- inv (3)(q21q26) 
M5b / t (8;16) M5b with phagocytosis +/- + + + + + t (8;16)(p11;p13) 
M2 Baso / t (12p) M2 with basophilia +/- + + + + +/- t /del(12)(p11-13) 
M4/+4 M4 (M2) +/- + + + + +/- +4 
 
 8 
The World Health Organization (WHO) proposed another method of classification of 
AML in 2001. WHO classification is based on the combination of morphological 
features, clinical syndrome, immunophenotype, cytogenetic and other biological features 
of AML [11, 12]. Table 1.3 lists the different groups in to which AML is classified 
based on WHO classification. 
Table 1.3: Classification of AML based on WHO guidelines 
Acute myeloid leukemia with recurrent genetic abnormalities 
AML with t(8;21)(q22;q22); RUNX1-RUNX1T1 
AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 
APL with t(15;17)(q22;q12); PML-RARA 
AML with t(9;11)(p22;q23); MLLT3-MLL 
AML with t(6:9)(p23;q34); DEK-NUP214 
AML with inv(3)(q21q26.2) or t(3.3)(q21;q26.2); RPN1-EVl1 
AML (megakaryoblastic) with t(1:22)(p13;q13); RBM15-MKL1 
AML with mutated NPM1  
AML with mutated CEBPA 
Acute myeloid leukemia with myelodysplasia-related changes 
Therapy-related myeloid neoplasms 
Acute myeloid leukemia, not otherwise specified (NOS) 
AML with minimal differentiation 
AML without maturation 
AML with maturation 
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Acute myelomonocytic leukemia 
Acute monoblastic and monocytic leukemia 
Acute erythroid leukemia 
Acute Megakaryoblastic leukemia 
Acute basophilic leukemia 
Acute panmyelosis with myelofibrosis 
Myeloid sarcoma 
Myeloid proliferations related to Down’s syndrome 
Transient abnormal myelopoiesis 
Myeloid leukemia associated with Down syndrome 
Blastic plasmacytoid dendritic cell neoplasm 
Acute leukemias of ambiguous lineage 
Acute undifferentiated leukemia 
Mixed phenotype acute leukemia with t(9;22)q(34;q11.2); BCR-ABL1 
Mixed phenotype acute leukemia with t(v;11q23); MLL rearranged 
Mixed phenotype acute leukemia, B/myeloid, NOS 
Mixed phenotype acute leukemia, T/myeloid, NOS 
Natural killer (NK) cell lymphoblastic leukemia/lymphoma 
 
1.1.3. Prognosis of AML: The major prognostic factors related to AML are mainly to 
predict the treatment related mortality and resistance to chemotherapy [13, 14]. The 
prognosis of AML depends on both patient-related factors and disease-related conditions. 
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The important patient-related factors that predict the treatment related mortality are age, 
organ function of the patient and performance status. According to the Surveillance, 
Epidemiology and End Results database (SEER) it is estimated that AML is more 
frequently diagnosed in elderly patients, with a median age of diagnosis being 69 years in 
the US population. Also, older patients have worse treatment outcomes as compared to 
younger patients diagnosed with AML. In addition to age being an independent predictor 
of poor prognosis, older patients also present with additional factors such as 
comorbidities, adverse cytogenetic abnormalities and poor performance status [15]. The 
prognostic factors such as cytogenetics, molecular abnormalities, and minimal residual 
disease mainly predict resistance to chemotherapy. Cytogenetic abnormalities have been 
strong predictors of the clinical outcomes in both pediatric and adult AML patients [16]. 
Based on cytogenetic features, AML is divided into three risk distinctive risk groups, 
which are used to design treatment strategies, and predict clinical response. Three distinct 
risk groups of AML include favorable, intermediate and adverse. Many genetic studies 
have also shown the significance of genetic mutations on the clinical response in both 
pediatric and adult leukemias. These genetic mutations were detected in AML patients 
especially with normal karyotype. The standardized stratification of AML was proposed 
by European Leukemia Net (ELN) taking into account both cytogenetic and molecular 
genetic data [14]. 
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Table 1.4: Classification of patients based on Cytogenetics 
Prognostic risk group Cytogenetic abnormality and affected gene 
Favorable t(8;21)(q22;q22); RUNX1RUNX1T1 
 inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 
 Mutated NPM1 without FLT3-ITD (normal karyotype) 
 Mutated CEBPA (normal karyotype) 
Intermediate-I* Mutated NPM1 and FLT3-ITD  (normal karyotype) 
 Wild-type NPM1 and FLT3-ITD (normal karyotype) 
 
Wild-type NPM1 and without FLT3-ITD (normal 
karyotype) 
Intermediate-II t(9;11)(p22;q23); MLLT3-MLL 
 
Cytogenetic abnormalities not classified as favorable or 
adverse 
Adverse inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1 
 t(6;9)(p23;q34); DEK-NUP214 
 t(v;11)(v;q23); MLL rearranged 
 -5 or del(5q); -7; abnl(17p); complex karyotype 
 
*Includes all AMLs with normal karyotype except for those included in the 
favorable subgroup; most of these cases are associated with poor prognosis, but 
they should be reported separately because of the potential different response to 
treatment. 
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1.1.4. Treatment of AML: There are various treatment options available for AML and 
the choice of treatment depends on the molecular subtype of the disease, the cytogenetics 
of the leukemic cells and also the age of the patient [17, 18].  These factors are important 
to be taken under consideration since they can influence the responsiveness to 
chemotherapy and the risk of relapse of the disease. The treatment of AML is primarily 
divided into three phases – remission induction (or induction) chemotherapy, post-
remission (or consolidation) chemotherapy and maintenance chemotherapy (Figure 1.2). 
The primary goal of the induction therapy is to achieve complete remission, which is 
defined as 5 % blasts in bone marrow. The subsequent more intensive consolidation 
therapy aims at destroying the residual leukemic blasts and preventing relapse of the 
disease.  
The induction treatment of AML takes into account the age and cytogenetics of the 
patients [15]. The induction therapy for older patients (greater than 60 years of age) with 
good performance status, minimal comorbidities, and favorable cytogenetics involves 
continuous infusion of standard dose of cytarabine (100-200 mg/m2) for 7 days along 
with 3 days of anthracycline. Older patients who cannot undergo intensive chemotherapy 
are usually given low dose cytarabine.  
In younger patients, remission induction therapy includes cytarabine given in 
combination with an anthracycline, like daunorubicin or idarubicin. The standard of care 
for the induction treatment usually consists of a combination of 3 days of daunorubicin 
and 7 days of cytarabine (3+7). Cytarabine is given in a daily standard dose of 200 mg/m2 
by continuous infusion or twice per day bolus or high dose of 2-3 gm/m2. Even though 
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cytarabine-based induction regimens form the backbone of AML treatment, around 20 to 
45% patients do not achieve complete remission (CR) with standard induction 
chemotherapy and the majority of the patients who achieve CR are known to relapse [19-
21]. If residual blasts are detected in bone marrow of patients, standard-dose cytarabine 
or high-dose cytarabine with anthracycline is the most common salvage therapy.  
Consolidation treatment usually consists of multiple cycles of high dose cytarabine 
followed by maintenance therapy.  
Maintenance chemotherapy is usually considered to be less myleosuppressive than 
induction or consolidation thermotherapy [22, 23]. The primary goal of starting AML 
patient on maintenance chemotherapy is to further reduce the leukemic cell burden and 
prevent relapse. [24-26]. However the significance and benefits of maintenance 
chemotherapy in the treatment of AML is thought to be controversial and depends on the 
intensity of the induction and consolidation chemotherapies [20, 25].  
 
Figure: 1.2: Overall Dosing Strategy in AML patients 
 
In order to further optimize AML chemotherapy, newer cytotoxic drugs and targeted 
therapies are being explored which could be incorporated into the current chemotherapy 
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regimens, since further dose intensification of the current treatment is unlikely to improve 
clinical outcome [27-29]. Hypomethylating agents 5-azacitidine or decitabine have been 
used as induction remission therapy for older patients [30-33]. Other nucleoside analogs 
like clofarabine, cladribine, fludarabine, troxacitabine and sapacitabine have also been 
investigated in various induction regimens for AML patients [34-40]. Clofarabine, which 
is approved by FDA for relapsed pediatric, ALL, has shown promise as a single agent 
therapy for older patients in phase II clinical trial with overall remission rate of 46% and 
a 30-day mortality rate of 10% [41] as well as in combination with cytarabine [42]. Apart 
from the nucleoside analogs, other targeted therapies for AML include antibody directed 
chemotherapy with gemtuzumab ozogamicin, a humanized anti-CD33 antibody) [43-46] 
and lintuzumab, a humanized monoclonal antibody with a human immunoglobin G1 
framework [47, 48], are also being investigated to improve therapy for AML patients.  
The section below (Section 1.2) provides an overview of the two of the most important 
chemotherapy drugs used for the treatment of AML, namely cytarabine and clofarabine 
(broadly classified as nucleoside analogs). 
 
1.2. Nucleoside Analogs 
Nucleoside analogs are a family of anti-metabolites that resemble the endogenous 
nucleosides. Nucleoside analogs are extensively used as antiviral drugs as well as 
anticancer agents. As anticancer chemotherapeutic agents, nucleoside analogs are widely 
used for the treatment of solid tumors, hematological malignancies, and autoimmune 
disorders. Cytarabine is the most commonly used nucleoside analog for the treatment of 
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AML while, clofarabine is a relatively newer nucleoside analog that is still under 
investigation in various clinical trials in patients with AML. 
1.2.1. Cytarabine: Cytarabine (1-ȕ-D-arabinofuranosylcytosine), also known as 
cytosine arabinoside or ara-C, is an analog of deoxycytidine, which forms the backbone 
of AML treatment. Cytarabine differs from the physiological nucleoside by the presence 
of a hydroxyl group in the ȕ-configuration at the 2’-position of the ribose sugar (Figure 
1.3). 
 
Figure 1.3: Cytarabine 
 
Standard dose cytarabine (100-200 mg/m2) achieves steady-state plasma levels of 0.5 -1 
ȝM [49, 50]. At this concentration the expression of equilibrative nucleoside transporter 
(hENT1), which is the influx transporter involved in the cellular uptake of cytarabine, is 
the rate-limiting factor in its uptake. With high dose cytarabine (2-3 gm/m2) plasma 
concentrations greater than 50 ȝM are achieved and at these concentrations, simple 
diffusion rates exceed the carrier-mediated transport [51, 52]. Once inside the cell 
cytarabine is phosphorylated by deoxycytidine kinase (dCK) to cytarabine 
monophosphate, which is rate limiting step in the phosphorylation of cytarabine (Figure 
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1.4). Cytarabine monophosphate is further phosphorylated by cytidine monophosphate 
kinase (CMPK) and nucleoside diphosphate kinase to the diphosphate and the active, 
triphosphate form of cytarabine. Cytarabine is rapidly metabolized by cytidine deaminase 
(CDA) to its biologically inactive metabolite, 1-ȕ-D-arabinofuranosyluracil (arabinoside 
uridine), while the monophosphate form of cytarabine is deaminated by the action of 
deoxycytidylate deaminase (DCTD). The 5’-nucleotidase enzymes (NT5C2/3) are 
responsible for dephosphorylation of cytarabine, thus opposing the action of dCK. 
Cytarabine triphosphate acts as an inhibitor of DNA polymerase-Į as well as it also 
serves as a substrate for this enzyme and competes with deoxycytidine triphosphate 
(dCTP) for incorporation into the growing DNA strand (Figure 1.4) [53-55]. The 
triphosphate form of cytarabine also inhibits DNA polymerase-ȕ and subsequently 
inhibits DNA repair [56-58]. Cytarabine cytotoxicity is mainly due to the combination of 
inhibition of DNA polymerase and from incorporation of the cytarabine triphosphate into 
the growing DNA strand, in competition with endogenous deoxycytidine triphosphate 
(dCTP). This ultimately leads to chain termination of the DNA strand inhibiting DNA 
synthesis [54, 59, 60]. Both the concentration and duration of exposure of active 
triphosphate metabolite of cytarabine are critical for the mechanism of action of this 
nucleoside analog [61]. Typically cytarabine is administered as standard low dose of 
100mg/m2/day continuous IV infusion for 7 days or 100mg/m2 IV every 12 hours for 7 
days, or as high dose of 2-3 gm/m2 IV infusion for over 1-3 hours every 12 hours for 2-6 
days. The steady state plasma concentrations achieved after standard low dose cytarabine 
are 0.5-1ȝM, while high dose cytarabine achieves steady state plasma concentrations of 
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greater than 10ȝM. Activity of cytarabine is primarily decreased by its rapid deamination 
by CDA to biologically inactive metabolite, 1-ȕ-D-arabinofuranosyluracil and greater 
than 80% of the drug undergoes renal excretion. Systemic elimination of cytarabine is 
biphasic, with initial plasma half-life (t1/2 Į) of 7 to 20 minutes and terminal half-life (t1/2 
ȕ) of 2 to 3 hours [61-63]. 
 
Figure 1.4: PK/PD pathway of Cytarabine 
 
1.2.2 Clofarabine: Clofarabine (CAFdA, 2-chloror-9-(2’-deoxy-2’-fluoro-D-
arabinofuranosyl) adenine is a second generation purine nucleoside analog which was 
designed as a hybrid molecule to overcome the limitations of the first generation purine 
analogs, cladribine and fludarabine (Figure 1.5) [64, 65]. Similar to other purine 
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nucleoside analogs, clofarabine is transported into the cell by equilibrative nucleoside 
transporters, hENT1 and hENT2, as well as concentrative nucleoside transporter hCNT3 
[64]. Like cytarabine, clofarabine needs to be converted to its active triphosphate 
metabolite by various enzymes. Conversion of clofarabine monophosphate to 
diphosphate metabolite is believed to be the rate-limiting step in the activation of this 
purine analog [66]. 
 
Figure 1.5: Clofarabine 
Clofarabine triphosphate is known to inhibit both DNA polymerases and ribonucleotide 
reductases, thus inhibiting DNA synthesis and repair [67]. Clofarabine also induces 
apoptosis through induction of DNA strand breaks and disruption of mitochondrial 
integrity, resulting in release of proapoptotic proteins [68]. Clofarabine is currently 
approved for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL). 
Clofarabine has also been studied as a single agent or a combination agent with 
cytarabine for the treatment of AML. A study in older AML patients with an induction 
regimen consisting of clofarabine and high dose cytarabine showed promising results 
with good response rate (overall response rate of 60%) and with an acceptable toxicity 
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profile [69]. Another study compared the effects of clofarabine plus cytarabine with 
cytarabine alone in patients 55 years old with refractory or relapsed AML [70]. The 
response rate and event free survival (EFS) was significantly improved in the clofarabine 
plus cytarabine arm compared to the cytarabine alone arm, although there was no 
difference in the overall survival (OS) between the two arms. For AML, clofarabine 
monotherapy is usually 20mg/m2 IV once daily for 5 days, with cycles repeated every 4 
to 6 weeks [71] or salvage therapy includes 40mg/m2/day IV over 1 hour for 5 
consecutive days every 3 to 6 weeks [72].  
The cellular elimination kinetics of the phosphorylated clofarabine metabolites shows 
triphasic kinetics with terminal half-life (t1/2 ȕ) of 8 to 24 hours and a very long Ȗ half-life 
(>24 hours) indicating prolonged cellular retention [66, 73]. 
 
1.3. Factors affecting activation of Nucleoside Analogs and Clinical Response in 
AML patients: 
Nucleoside analogs are transported into the cells by nucleoside transporters and are 
converted to their active metabolites by the action of various enzymes. The most useful 
parameter for predicting the efficacy of nucleoside analogs, apart from its plasma 
concentrations, is the active triphosphate levels in the leukemic cells [74-77]. In vitro 
studies by Kufe DW et al. have shown that leukemic cells resistant to cytarabine have 
lower levels of active triphosphate metabolite of the drug as compared to the sensitive 
cells [78]. In addition, in a separate clinical study, higher cytarabine triphosphate levels 
were observed in patients with AML who were responsive to the cytarabine treatment as 
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compared to the CML patients who were not responsive to this treatment [79]. Apart 
from predicting the sensitivity of the treatment, intracellular triphosphate levels for 
cytarabine have also been associated with clinical response with high-dose cytarabine 
treatment [74]. Evidence has shown that serious toxicities and side effects, such as 
myelosuppression, thrombocytopenia, cardiac toxicity, etc., are also related to the active 
phosphorylated metabolites inside the leukemic cells [80, 81].  
Thus, it is obvious that with respect to the nucleoside analogs the intracellular levels of 
the active phosphorylated metabolites are crucial for predicting the efficacy and clinical 
outcome. The primary factors that regulate the intracellular triphosphate levels are the 
levels/activity of the nucleoside transporters, levels of the activating (kinases) and 
inactivating enzymes and the intracellular deoxynucleotide pools, which are regulated by 
ribonucleotide reductases. Factors that could affect the expression of these transporters 
and enzymes, could in turn potentially affect the levels of the active metabolite of 
nucleoside analogs. Some of the important factors that might potentially affect the 
expression and/or activity of nucleoside analog pathway genes are inherited genetic 
polymorphisms, acquired somatic mutations, regulation or altered regulation by 
microRNAs, inter-patient differences in methylation levels as well as a much less studied 
aspect of drug-induced changes in the expression of the genes. 
1.3.1. Genetic Polymorphisms: Single nucleotide polymorphisms (SNPs) in the genes 
encoding the drug transporters, activating and inactivating enzymes as well as the 
pharmacodynamic (PD) targets of these drugs can influence the clinical outcome of the 
patients treated with these nucleoside analogs. SNPs and small insertions or deletions in 
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these genes could result in amino acid changes that could in turn influence the protein 
and/or the activity of the respective genes. Presence of SNPs in the regulatory regions of 
these genes can have an effect on the transcription of the mRNA, leading to changes in 
the gene expression levels [82]. 
Genetic variation in the key enzymes and transporters involved in the metabolic pathway 
of nucleoside analogs are described below and provided in table 1.5. Variability in 
expression of human equilibrative nucleoside analog transporter (hENT1) has been 
associated with differential transcriptional regulation, with SNPs in the proximal 
promoter region (-1345 C>G, -1050 G>A, -706 G>C) associated with loss of binding 
sites for transcription factors [83]. The phosphorylation of nucleoside analogs by DCK 
being the rate-limiting step in the activation of nucleoside analogs, the expression of this 
kinase is important with respect to the outcome of AML patients. Studies have shown 
that variability in treatment outcome in AML patients treated with cytarabine correlated 
with DCK mRNA expression [84]. The regulatory SNPs (í360 C>G and í201 C>T) in 
the promoter of DCK were found to be associated with the mRNA expression of DCK 
[85]. Sequencing the DCK promoter and coding exons identified three nonsynonymous 
SNPs (Ile24Val, Ala119Gly and Pro122Ser); the variant forms of which demonstrated 
reduced DCK activity [86]. A SNP in the 3’ untranslated region (UTR) of DCK 
(rs4643786) was found to be associated with DCK mRNA expression in both European 
and African ancestry panels of cell lines as well as with lower leukemic blast cell 
intracellular levels of cytarabine triphosphate [86]. Similarly, various other studies have 
reported the significance of SNPs in other important nucleoside pathway genes, like 
 22 
NT5C2, CDA, DCTD and RRM1/2 with respect to nucleoside analogs cytotoxicity and 
/or response [87-92].  
The table below (Table 1.5) provides an overview of the studies by our group and others 
on various genetic polymorphisms in cytarabine genes and their relevance in AML. 
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Table 1.5: Important single nucleotide polymorphisms (SNPs) in the nucleoside analog metabolic pathway genes  
 
Gene 
Gene 
symbol 
SNPs Relevance PMID 
Deoxycytidine 
kinase 
DCK rs2306744 
SNPs -360C>G and -201C>T (rs2306744) in DCK were 
associated with higher mRNA expression and higher 
transcriptional activity. In AML patients, it was found that -
360G/-201T haplotype was associated with favorable response. 
15564883 
Deoxycytidine 
kinase 
DCK rs4694362 
In Korean AML patients, the CC genotype was a significant 
poor prognostic factor for poor overall survival. 
22964418 
Deoxycytidine 
kinase 
DCK rs111454937 
AA genotype was more frequent in Chinese AML patients with 
higher platelet count and A allele frequency was significantly 
higher in the group <40 years, lower WBC count patients group 
and group with platelet count >60×109/L. 
22884143 
Deoxycytidine 
kinase 
DCK rs72552079 
In Chinese AML patients, the TC genotype showed significantly 
improved Ara-C based chemotherapy response. 
22884143 
Deoxycytidine 
kinase 
DCK rs11554389 
In Chinese AML patients, the TC genotype showed significantly 
improved Ara-C based chemotherapy response. 
22884143 
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Cytidine  
deaminase 
CDA 
rs2072671 
 rs532545 
In FLT3-ITD positive AML patients, the CDA 79C/C 
(rs2072671) and CDA -451T/T (rs532545) genotypes were 
associated with shorter overall survival compared to other 
genotypes. 
23873772 
Cytidine  
deaminase 
CDA rs2072671 
Plasma CDA activity was significantly decreased in samples 
homozygous for the A79C SNP (CC) compared with samples 
homozygous for the ancestral allele (AA). 
23287564 
Cytidine  
deaminase 
CDA rs60369023 
Significantly improved Ara-C based chemotherapy response in 
Chinese AML patients. 
22884143 
Cytidine  
deaminase 
CDA rs3215400 
In AML patients, there was a significantly higher CDA RNA 
expression in patients homozygous for -33/-31 delC mutant as 
compared with those with heterozygous or wild type genotypes. 
22304580 
Cytidine  
deaminase 
CDA rs75720390 
AML patients with intron 2 (TCAT) 5/5 and (TCAT) 5/4 
genotypes showed significantly higher CDA expression as 
compared to those with wild type (TCAT) 4/4 repeats. 
22304580 
Cytidine  
deaminase 
CDA 
rs71864371 
rs1048977 
The 3'-UTR 816 in/delC variants in LD with synonymous 
coding SNP 435C>T in exon 4 was found to be significantly 
associated with lower CDA RNA expression compared to the 
wild type in AM patients. 
22304580 
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Cytidine  
deaminase 
CDA rs532545 
AML patients with the CDA C-451T/promoter SNP TT-
genotype had significantly higher lactate dehydrogenase levels 
when compared with the CC or CT-genotypes (P=0.01). 
19458626 
Cytidine  
deaminase 
CDA 
rs2072671 
rs602950 
AML patients with AA genotype for CDA A79C SNP and AA 
genotype for CDA A-92G SNP had lower incidences for grade 
III/IV liver toxicity when compared with the other respective 
genotypes. 
19458626 
Nucleoside 
diphosphate  
kinase 1 
NME1 rs2302254 
Caucasian AML patients with the T_T genotype for promoter 
SNP -835C/T had a significantly lower platelet count and better 
ECOG performance status compared to the patients with C_C 
genotype. This study also identified an increased risk of 
neurotoxicity for T_T genotype. 
22035418 
Ribonucleotide 
reductase M1 
RRM1 
rs1042919 
rs1561876 
In AML patients receiving cytarabine and cladribine, these 
SNPs are associated with intracellular CTP level, response after 
remission induction therapy, risk of relapse and overall survival. 
24024897 
Solute carrier 
family 29 
(nucleoside 
transporters), 
member 1 
SLC29A1 rs3734703 
In AML patients, the AA and AC genotype for SLC29A1 SNP 
rs3734703 in combination with TYMS rs2612100 (AA 
genotype) was found to be significantly associated with shorter 
relapse free survival. 
22964418 
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ATP-binding 
cassette, sub-family 
C, member 3 
ABCC3 rs4148405 
The SNP rs4148405 was found to be associated with 
significantly shorter disease free survival in AML patients, with 
the minor allele (G) being associated with shorter time to 
relapse. 
23677058 
ATP-binding 
cassette, sub-family 
B, member 1 
ABCB1 
rs1128503 
rs2032582 
AML patients with 1236 C/C genotype for SNP rs1128503 or 
2677 G/G genotype for SNP rs2032582 showed poorer survival 
as compared to patients with other genotypes for that the 
respective SNPs. 
20938465 
 
* Table from Book Chapter- Pharmacogenetic Studies in Pediatric Acute Myeloid Leukemia. Book Title: Genome-Wide Association 
Studies: From Polymorphism to Personalized Medicine. (Cambridge University Press) Bhise NS, Chauhan L, Lamba JK. 
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1.3.2. MicroRNAs – Introduction and Discovery: MicroRNAs (miRs) are 
endogenous, single stranded, small noncoding RNAs which are about 22 nucleotides in 
length that regulate gene expression by binding to specific mRNA target sequences and 
promoting their degradation or translational repression. Various bioinformatics 
predictions estimate that microRNAs are known to regulate approximately 30% to 60% 
of the human protein coding genes [93-95]. Various studies have implicated a role of 
microRNAs in many biological process and molecular functions [96]. The discovery of 
the effects of lin-4 RNA and its effect on the lin-14 gene led to the discovery of 
microRNAs. In 1993, the joint efforts of Victor Ambrose and Gary Ruvkun laboratories 
discovered that, in C.elegans, small 22 nucleotide RNA called lin-4, which does not 
encode for any protein, had antisense complementarity to 3’UTR sites of lin-14 gene. 
However, in 2000 another short noncoding RNA, let-7 was found to be conserved across 
various species. This discovery drew the interest of other researchers in these small 
noncoding RNAs. The discovery of microRNAs added another dimension to the central 
dogma of molecular biology, that DNA is transcribed into RNA which is then translated 
into proteins which then carry out various biological functions.  The discovery of 
microRNAs changed this understanding that RNA molecules are mere ‘secondary 
players’ by transcribing information from DNA, since microRNAs can in fact regulate 
the gene expression too.  
1.3.2.1.  MicroRNA Biogenesis: MicroRNA genes are encoded in the intergenic 
regions of the genome or in the annotated transcripts, such as introns of protein coding 
genes, introns of noncoding genes or exons on noncoding genes [97-99]. The 
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transcription of most of the primary transcripts of the microRNAs is mainly by 
polymerase II (pol II) and while polymerase III (pol III) is known to play a role to a lesser 
extent (Figure 1.6) [99]. The primary transcripts of the microRNAs are referred to as 
primary precursors of miRNA or pri-miRNAs [100]. These pri-miRNAs are large stem-
loop structures, containing 7-methylguanosine cap and a poly (A) tail [98, 99]. Inside the 
nucleus, the pri-miRNAs are cleaved into 70- to 100-nucleotide hairpin shaped 
microRNA precursors or pre-miRNAs by nuclear microprocessor protein complex 
formed by RNase III enzyme Drosha (RNASEN) and DGCR8 (DiGeorge syndrome 
critical region 8), also known as Pasha-partner of Drosha (Figure 1.6) [101-103]. 
Following nuclear processing by Drosha, the pre-miRNAs are then exported in the 
cytoplasm by Exportin-5 and co-factor, Ran guanosine triphosphate (Ran-GTP) complex 
[104, 105]. In the cytoplasm, the pre-miRNAs then undergo further processing by another 
RNase III endonuclease enzyme, Dicer [106]. The Dicer cleaves the pre-miRNAs into 
about 22- to 24-nucleotide miRNA duplex, leaving the 5’ phosphate and a 2-nucleotide 
overhang (Figure 1.6). The double stranded RNA-binding domain proteins TRBP (Tar 
RNA binding protein) and PACT (protein activator of PKR) facilitate the Dicer mediated 
cleavage of pre-miRNA [107, 108]. This microRNA duplex produced by Dicer comprises 
of one mature miRNA strand or guide strand and another similar sized fragment derived 
from the opposite strand, called as miRNA* or passenger strand [109]. In this miRNA-
miRNA* duplex, the strand with the less stable base pairing at its 5’ end in the duplex is 
selected as the guide strand and loaded onto Argonaute (Ago) proteins to form RNA-
induced silencing complex (RISC) [110, 111]. The guide strand of the miRNA-miRNA* 
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duplex is believed to undergo rapid degradation. However some reports have indicated 
that the miRNA* strand could also loaded into the RISC and be functional [112].  
  
Figure 1.6: Biogenesis of microRNAs (Adapted from Winter J, 2009) 
1.3.2.2. MicroRNA function and their role in Cancer 
MicroRNAs have been extensively studied with regards to various diseases since their 
discovery.  Specifically, the understanding of the influence of microRNAs in 
pathogenesis of various human cancers has increased. The first report implicating the role 
of microRNAs in cancer, specifically chronic lymphocytic leukemia (CLL) was in 2002 
[113]. This study reported that miR-15a and miR-16-1 are located at chromosome 13q14, 
a region frequently deleted in CLL, thus suggesting an association between these 
microRNAs and CLL. Thereafter the same group identified a significant number of 
 30 
microRNAs located at fragile sites and in regions altered in cancers, including regions of 
amplification or loss of heterozygosity or break points, identifying microRNAs as new 
class of regulators in human cancers [114]. Many studies have also reported disease 
specific expression profiles with important diagnostic and prognostic implications in 
various cancers, like B cell CLL [115], breast cancer [116], primary glioblastoma [117], 
hepatocellular carcinoma [118], gastric and colon cancers [119], papillary thyroid 
carcinoma [120], and endocrine pancreatic tumors [121]. With availability of various 
microRNA expression profiling techniques, many researchers have identified specific 
microRNAs up- or down-regulated in various cancers relative to normal tissues [122, 
123]. In addition, microRNA expression profiling has also been used to classify large 
panel of tumor types based on their global microRNA expression levels. These researcher 
believe that this system of classification is of significant clinical importance in predicting 
cancer type/stage as compared to classification based on mRNA expression profile [123]. 
MicroRNAs have also been implicated to play an important biological functional role in 
the development of cancer. MicroRNAs have been shown to act as oncogenes (oncomirs) 
or tumor suppressors and are involved in various pathways that are specifically 
deregulated in various cancers [124]. The first reports addressing the biological role of 
microRNAs in cancer was demonstrated by genetic studies in C.elegans where the 
authors showed that let-7 family member, miR-84 negatively regulates the expression of 
let-60, an ortholog of human oncogene RAS [125]. Similar to their C. elegans ortholog, 
the human KRAS and NRAS oncogenes were found to be regulated by human let-7 
family members. Accordingly, in lung tumor samples the decreased expression of 
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microRNA let-7 correlated with increased protein levels of RAS oncogene, explaining 
the functional significance of let-7 as tumor suppressor [125]. The tumor suppressor role 
of microRNAs miR-15a and miR-16-1, which were frequently found to have low 
expression in CLL, appears to be partly mediated by their ability to decrease the 
expression of anti-apoptotic protein Bcl2 found to be overexpressed in CLL promoting 
cell survival [126, 127]. The expression of these microRNAs was found to promote 
apoptosis in leukemia cell lines, which explains that the loss of function of miR-15a and 
miR-16-1 in CLL leads to increase Bcl2 expression and prevents cell apoptosis. The 
oncogenic role of microRNAs is evidenced by studying the miR-17 cluster encoded in a 
region frequently amplified in B-cell lymphomas [128]. The increased expression of 
miR-17 cluster in B-cell lymphoma mouse models expressing c-myc transgene, lead to 
increased lymphomagenesis [129]. Similarly, many such microRNAs have been studied 
and implicated to play an important role in various cancers. These and other studies 
provide evidence that miRNA deregulation is not just a consequence of the malignant 
transformation, which results in loss of normal cellular identity, but in fact miRNAs have 
unique oncogenic and tumor suppressor roles which are critical in pathogenesis of cancer.  
1.3.2.3. Role of MicroRNAs in Acute Myeloid Leukemia 
Various miR-expression profiling and functional studies have implicated that microRNAs 
play an important role in regulation of normal hematopoietic process [130, 131]. Many 
studies have shown that deregulated expression of these microRNAs can contribute to 
leukemogenesis.  The expression of miR-181 was found to be higher in B cells and 
induction of expression of this microRNA in hematopoietic stem cells stimulated their 
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differentiation into B-lineage cells [132]. Another microRNA, miR-328 was found to 
stimulate the differentiation of myeloid cells by promoting the expression of C/EBPĮ, a 
master regulatory transcription factor [133]. On the other hand, inhibition of C/EBPĮ 
mRNA and protein expression by miR-124a inhibits the differentiation of the cells 
toward the myeloid lineage [134].  
In addition, microRNA expression signatures have been shown to distinguish ALL 
patients from AML patients, with 27 differentially expressed microRNAs identified 
between ALL and AML [135]. Among the most significantly differentially expressed 
microRNAs, let-7b and miR-223 were down regulated and miR-128a/b was upregulated 
in ALL as compared to AML. Cytogenetic risk groups in AML have also been shown to 
have differential microRNA expression signatures. Patients with cytogenetically normal 
AML (CN-AML) and favorable C/EBPĮ mutations had higher expression of miR-181 
family members [135]. A specific microRNA signature was identified for AML with 
specific translocations, inversions or mutational subtypes. Specifically AML patients 
with t(8; 21) and inv(16) had higher levels of microRNAs let-7b and let-7c [136]; and 
lower levels of miR-126/126* [137] in their leukemic cells as compared to other patients. 
AML patients with normal cytogenetics and mutation in nucleophosmin (NPM1) gene 
frequently had elevated expression of miR-21 and subsequent downregulation of its 
target protein PDCD4 (programmed cell death 4) [138]. 
These and other studies focused on profiling microRNAs in AML have highlighted the 
complexity of this disease with miRNAs as another level of patient classification on top 
of cytogenetics and molecular abnormalities. These regulators can, not only influence the 
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expression of genes in AML subtypes but have also been shown to influence clinical 
outcome.  
1.3.2.4. Role of MicroRNAs in Anticancer Drug Resistance 
Anticancer drug resistance is a complex phenomenon since it could be either due to the 
intrinsic nature of the cancer cells or it may be due to the acquired resistance to the 
various process that are commonly targeted by these anticancer agents like insensitivity 
to drug-induced apoptosis, increased DNA repair, decreased drug accumulation, and 
induction of drug-detoxifying mechanisms [139]. Deregulation of microRNA expression 
in various cancers has been known to affect the expression of target mRNAs and/or 
proteins affecting various cellular processes, which might affect the chemosensitivity of 
cancer cells to various anticancer drugs. In order to understand the role of microRNAs in 
anticancer drug resistance, NCI-60 panel of cancer cell lines were screened for the effects 
of three microRNAs, let-7i, miR-16 and miR-21 on the chemosensitivities of various 
anticancer agents [140]. It was found that microRNAs could have diverse effects on the 
chemosensitivity an anticancer agent in cancers. Specifically it was found that increasing 
the levels of miR-21 in A549 cell line lead to increased sensitivity for cytarabine, which 
was opposite to what was observed with other anticancer agents, where decreased 
expression of miR-21 resulted in increased sensitivity of these agents, in this as well as 
other studies [140-142]. However, another study showed that inhibiting the expression of 
endogenous miR-21 enhanced the sensitivity of leukemic cell line (HL-60) to cytarabine 
primarily by increasing apoptosis [143]. Expression of miR-21 was associated with 
activation of PI3K/Akt/mTOR pathway and inhibition of miR-21increased sensitivity and 
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apoptosis induction by gemcitabine in cholangiocarcinoma and pancreatic cancer [141, 
144]. The expression of miR-32 was observed to be markedly induced after treatment 
with 1, 25-dihydroxyvitamin D3 (1,26D) and this microRNA was also found to 
downregulate the expression of proapoptotic factor, Bim. Inhibiting the expression of 
miR-32 lead to increased sensitivity of AML cells to cytarabine [145]. Thus, microRNAs 
could alter cellular responses to anticancer drugs by affecting the cellular apoptotic 
response or survival pathways. MicroRNAs could also affect the chemosensitivity of 
cancer cells by affecting the drug targets, drug transporters and drug metabolizing 
enzymes. Increased expression of microRNA miR-27a and miR-451 was observed in 
multidrug resistant ovarian and cervical cancer cells as compared to their parental cell 
lines. Inhibition of these microRNAs increased the sensitivity of these cell lines to 
doxorubicin [146, 147]. Expression of another efflux pump, breast cancer resistant 
protein (BCRP) was found to be repressed by miR-328 in breast cancer cell lines, which 
lead to increased sensitivity of these cell lines to mitoxantrone [148]. Recently, a study 
showed that transfection of miR-130b mimic lead to significant downregulation of 
mRNA expression of various cytochrome P450s (CYP450s) namely, CYP1A1, 1A2, 
2A6, 2C19, 2C8, and 2C9, phase II metabolizing enzymes like glutathione S-transferase 
alpha 2 (GSTA2), N-acetyltransferases (NAT1 and NAT2) and transporter solute carrier 
family 22 (Organic Anion Transporter), Member 7 (SLC22A7) and nuclear receptors, 
constitutive androstane receptor (CAR) and farnesoid X receptor. Additionally it was also 
demonstrated that miR-130b negatively regulated the activity levels of various CYP450s 
[149]. Another study showed that miR-148a negatively regulates the protein levels of 
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transcription factor pregnane X receptor (PXR) and miR-148a-dependent decrease in 
PXR levels attenuated the CYP3A4 induction [150]. These studies are a few of the many 
evidences, which demonstrate the significance of microRNAs in regulation of drug 
metabolism by regulating the expression/levels of transporters and drug metabolizing 
enzymes.  
MicroRNAs are also known to have influence the anticancer drug resistance due to the 
single nucleotide polymorphisms (SNPs) that can influence microRNA functions. A SNP 
near the miR-24 binding site in the 3’UTR region of the dihydrofolate reductase (DHFR) 
gene resulted in loss of miR-24 mediated regulation of DHFR. The resulting increase of 
DHFR mRNA half-life was found to be associated with methotrexate resistance [151]. 
Drug resistance might also be associated with loss of microRNA binding sites on the 
3’UTR of mRNA due to deletions. The inhibition of ABCG2 gene by miR-519c was lost 
in drug resistant cell lines harboring shorter 3’UTRs due to the loss of microRNA target 
sites, leading to overexpression of ABCG2 [152].  
1.3.3. Drug-induced Changes 
Anti-leukemic drugs, mainly nucleoside analogs act intracellularly by incorporating into 
the growing DNA strand. Due to this reason the intracellular uptake, activation, 
inactivation or changes in the dNTP pools could have an effect on the development of 
cellular resistance to these nucleoside analogs [153]. Although the intracellular 
triphosphate levels of these nucleoside analogs correlate with patient response in AML 
and small increases in the active triphosphate did show increased AML cytotoxicity, prior 
attempts in AML patients to increase cytarabine dosing did not improve clinical 
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outcomes [154]. Thus, mechanisms of resistance to nucleoside analogs could potentially 
involve additional mechanisms. A study on acute lymphoblastic leukemia (ALL) patients, 
analyzed the gene expression signatures before and after treatment with methotrexate and 
mercaptopurine, in order to understand the genomics of cellular responses to cancer 
treatment. Genes involved in apoptosis, mismatch repair, cell cycle control and stress 
response were identified to be differentially expressed in response to the different 
treatment groups [155]. Understanding the changes in gene expression post 
chemotherapeutic treatment can help in understanding the tumor adaptive response, 
which might be contributing to development of drug resistance. However these studies 
are very challenging to perform due to unavailability of specimens from patients after 
initiation of chemotherapy.  A few global gene expression studies during neoadjuvant 
chemotherapy in primary breast cancer patients revealed that there was a distinct 
clustering of gene patterns post treatment, in patients with good pathological response to 
treatment compared to poor responders [156, 157]. Another study in breast cancer 
patients evaluated the chemotherapy-induced gene expression changes in vivo, post 
doxorubicin and docetaxel treatment, to provide insights into the resistance mechanisms 
of each drugs [158]. This study showed that the genes involved in protein and 
macromolecule metabolism were upregulated whereas those involved in cell cycle and 
DNA/RNA metabolism were downregulated in response to these two drugs.  
So far there has been gap in our understanding of in vivo or in vitro gene expression 
changes in cancer cells after treatment with nucleoside analogs specifically in AML. 
Understanding the acute treatment-induced changes in the nucleoside analog pathway 
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genes in leukemic cells would offer new insights into additional mechanisms contributing 
resistance to these chemotherapeutic agents. The transcriptional response to nucleoside 
analog chemotherapy by assessing gene expression changes after drug treatment would 
also help better understand the cellular responses to injury, including the molecular 
pathways that initiate or block apoptosis and help identify additional drug targets. 
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1.4. Research Study Objectives 
Despite extensive knowledge regarding the role of microRNAs as regulators of various 
cellular processes in cancer (prognostic markers for AML) and influencing changes in 
chemosensitivity of anti-cancer agents in in vitro systems; there have been very few 
studies that have systematically evaluated the role of microRNAs as predictors of 
chemosensitivity to nucleoside analogs in AML patients. 
Thus, the major aim of this thesis project was to identify the role of microRNAs as 
potential markers of resistance to nucleoside analogs in the treatment of AML. The main 
objectives of this thesis are to: 
1. Identify the microRNAs associated with chemosensitivity of cytarabine and 
determine the translational utility of these microRNAs as biomarkers for predicting 
response to cytarabine in AML patients. 
2. Assess the effect of microRNAs on the expression of nucleoside analog 
pharmacokinetic and pharmacodynamic pathway genes and in turn assessing their 
potential impact on variability in response to nucleoside analogs. 
3.  Study the effect of in vivo cytarabine-induced changes in gene expression and to 
investigate the impact of these gene expression changes on clinical outcomes in AML 
patients. 
4. Identify the microRNAs as predictors of chemosensitivity of a second generation 
nucleoside analog clofarabine in AML cell lines representing different risk groups. 
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CHAPTER II 
MicroRNA-mRNA Pairs Predictive of Outcome in AML: From in vitro Cell-
based Studies to AML Patients 
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2.1. Abstract 
Cytarabine is the primary chemotherapeutic agent used for treatment of AML.  Disease 
relapse after initial remission remains one of the most pressing therapeutic challenges in 
the treatment of AML.  Relapsed disease is often resistant to cytarabine and subsequent 
salvage therapy is ineffective.  Recent studies have shown that some miRNAs are 
associated with prognosis but have not yet explored the role of miRNAs in cellular 
response to cytarabine. We identified 20 miRNAs that associate with the in vitro 
cytarabine chemo-sensitivity or apoptotic response of eight AML cell lines. Out of the 20 
miRNA, data on 18 miRNAs was available in AML patients from TCGA database. Our 
stepwise-integrated analyses (step 1- microRNA-target mRNA that were significantly 
correlated in AML patients; step -2 mRNAs from step 1 with significant association with 
OS) identified 23 unique miRNA-mRNA pairs predictive of OS in AML patients. As 
expected HOX genes (HOXA9, HOXB7 and HOXA10) were identified to be regulated 
by miRs as well as predictive of worse OS. Additionally, miR107-Myb, miR-378-
granzyme B involved in granzyme signaling and miR10a-MAP4K4 were identified to be 
predictive of outcome through integrated analysis. Although additional functional 
validations to establish clinical/pharmacologic importance of microRNA-mRNA pairs are 
needed, our results from RNA EMSA confirmed binding of miR-10a, miR-378 and miR-
107 with their target genes GALNT1, GZMB and MYB respectively.  Integration of 
pathogenic and pharmacologically significant microRNAs and microRNA-mRNA 
relationships identified in our study opens up opportunities for development of 
targeted/microRNA-directed therapies. 
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2.2. Introduction 
Acute myeloid leukemia (AML) is a hematological malignancy characterized by the 
presence of immature abnormal myeloid cells in bone marrow. It is a heterogeneous 
disease with various subtypes classified based on the morphology, immunophenotype and 
cytogenetics that are associated with outcome [1]. In spite of advances in recent years, 5-
year overall survival is roughly 60% for children and ~25% for adults (Cancer Facts and 
Figures, American Cancer Society).  Cytarabine (1-ȕ-arabinofuranosylcytosine, ara-C), a 
nucleoside analog, is the most widely used chemotherapeutic agent used in combination 
with an anthracycline for treatment of AML. Cytarabine requires intracellular activation 
to form an active triphosphate metabolite that triggers apoptosis by inhibiting DNA 
synthesis.  Although chemotherapeutic regimens including cytarabine induce complete 
response in 65 to 80% of AML patients, the majority of these patients suffer from disease 
relapse within 2 years of diagnosis. [2]. This can be partly attributed to the development 
of resistance of leukemic cells to cytarabine-based chemotherapy regimens. [3, 4].  
Several factors such as molecular and cytogenetic subtype, differential gene-expression 
profiles, and epigenetics can account for development of resistance in AML [5-10]. We 
have previously identified gene expression signatures in AML patients predicting 
beneficial and detrimental patterns associated with cytarabine-based response [11]. 
Others have identified gene-expression differences between cytarabine-sensitive and -
resistant cell lines in order to understand the molecular mechanisms underlying 
cytarabine resistance [12, 13]. 
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MicroRNAs (miRNAs, miRs) are non-coding RNAs of 22-25 nucleotides that regulate 
gene expression.  MicroRNAs bind to the complimentary sequence of messenger RNAs 
(mRNAs).  In many cases, this binding suppresses mRNA translation or promotes mRNA 
degradation, thereby reducing expression at the protein level [14]. It has been shown that 
miRNAs play an important role in various cancers by regulating genes involved in cell 
proliferation, differentiation, and apoptosis [15-18]. Likewise, several recent studies have 
identified various miRNAs that differentiate the disease subgroups, associate with disease 
development, and associate with clinical prognosis of AML [19-25]. However, these 
valuable contributions have not yet carefully examined the roles of miRNAs in the 
cellular response of AML to cytarabine.  Therefore, in this study, we characterized the 
association of miRNA expression with apoptotic response to cytarabine to identify 
candidate miRNAs for further evaluation of their relationship with mRNAs and overall 
survival in The Cancer Genome Atlas  (TCGA) cohort of 200 AML patients.  
 
2.3. Materials and Methods 
Figure 2.1 shows overall study design. 
Cell Culture and Reagents: The AML cell lines HL-60, MV-4-11, Kasumi-1, THP-1, 
AML-193, and KG-1 were obtained from ATCC (Manassas, VA), while ME-1 and 
MOLM-16 cell lines were obtained from DSMZ (Braunschweig, Germany). All the cell 
lines were cultured in the media as recommended by the supplier and were maintained in 
a humidified incubator at 37°C with 5% CO2. The cells were passaged every 2 to 3 days 
in order to maintain them in logarithmic growth phase. Cytarabine and the 3-(4, 5-
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dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) reagent were purchased 
from Sigma Aldrich (St. Louis, MO). Stock concentrations for cytarabine (5mg/ml) were 
prepared in sterile water and stored in -20°C in aliquots.  
2.3.1. Cytotoxicity Assay: Cytarabine cytotoxicity was determined using the MTT 
assay. Briefly, AML cell lines were plated in 96-well plate at seeding density of 2.5×105 
cells/ml and incubated at 37°C overnight. After 24h of recovery time, the cells were 
exposed to varying concentrations (200, 100, 50, 5, 0.5, 0.01 and 0 ȝM) of cytarabine. 
Cell viability was determined 48h post cytarabine treatment by incubation with MTT 
reagent followed by measuring the absorbance at 570nm using Synergy plate reader 
(BioTek, USA). The percent cell survival at each concentration was calculated using the 
Gen5™ Software version 1.11 (Winooski, VT). The area under the survival curve (AUC) 
was calculated by the trapezoidal method using the GraphPad Prism software version 6 
(La Jolla, California). 
2.3.2. Apoptosis Assay: The apoptotic activity of AML cell lines following treatment 
(48 h) with varying concentration of cytarabine (as indicated above) was determined 
using the Caspase-Glo® 3/7 assay as per manufacturer’s instructions (Promega, USA). 
48h post cytarabine treatment, luminescence was read using Synergy plate reader 
(BioTek, USA). The luminescence produced is directly proportional to the caspase 
activity. The caspase activity at each concentration was normalized to the control and the 
area under the relative caspase activity curve (AUC) was calculated by the trapezoidal 
method using the GraphPad Prism software version 6 (La Jolla, California).  
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2.3.3. MicroRNA Expression Analysis: For determination of microRNA expression, 
total RNA was isolated using mirVana™ miRNA Isolation kit (Life Technologies, USA) 
as per the manufacturer’s protocol. The RNA quality and concentration was measured 
using NanoDrop 2000 UV-Vis spectrophotometer (ThermoScientific, USA). A total of 
100 ng of purified total RNA was used for nCounter miRNA sample preparation 
reactions according to manufacturer’s instructions and was assayed for determination of 
800 human microRNA expressions using the nCounter Human v2 miRNA Expression 
Assay kit (Nanostring Technologies, USA). Preparation of small RNA samples involved 
multiplexed ligation of specific tags (miRtags) to the target microRNAs that provide 
unique identification for each microRNA species. After ligation, the detection was done 
by hybridization to microRNA: tag specific nCounter capture and barcoded reporter 
probes. Data collection was carried out using the nCounter Digital Analyzer (Nanostring 
Technologies, USA) at The University of Minnesota Genomics Center, following 
manufacturer’s instructions to count individual fluorescent barcodes and quantify the 
target microRNA molecules present in each sample. MicroRNA expression data 
normalization was performed using the nSolver™ Analysis Software (Nanostring 
Technologies) according to the manufacturer’s instructions. In particular, the data was 
normalized using the expression of the top 100 codesets. Further, to account for the 
background correction, mean of negative controls plus two standard deviation (SD) 
method was used. In order to avoid using the microRNAs with a very low expression, we 
further filtered out the microRNAs with expression counts <30 (2 times the mean ± 2 SD 
of negative control value), in order to account for the background noise. Total 412 
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microRNAs with expression counts >30 were evaluated for differential expression 
between sensitive and resistant cell lines and for their correlation with cytarabine 
chemosensitivity.  
2.3.4. The Cancer Genome Atlas (TCGA) Data: The clinical outcome data, mRNA 
expression and microRNA expression data for AML patients was extracted from The 
Cancer Genome Atlas (TCGA) Data Portal (cancergenome.nih.gov/) [26]. Out of the 200 
AML patients in TCGA database, 197 patients had gene expression profiling data 
available and 187 patients had microRNA expression data available. 186 patients had 
both gene expression and microRNA expression data available. Out of the 186 AML 
patients, 13 patients lacked valid survival information and 2 patients lacked 
cytogenetically defined risk information.  Thus, data for a total of 186 patients were used 
to evaluate miRNA-mRNA associations, 173 patients used to evaluate mRNA-OS 
associations and miRNA-OS associations (171 for stratified analyses).   
2.3.5. Statistical Analysis: For each miRNA, Spearman’s rank-based correlation was 
used to measure the association with cytarabine treatment response or apoptosis in the 
eight cell lines.  For each miRNA-mRNA pair with predicted binding sites defined by 
miRBase (www.mirbase.org; release 21), Spearman’s rank-based correlation was used to 
evaluate the association of miRNA expression with mRNA expression on the TCGA 
AML cohort.  The p-value for the Spearman statistic was determined by 10,000 
permutations.  For each miRNA or mRNA, Cox regression (or Jung’s statistic) was used 
to evaluate the association of expression with overall survival (OS).  FDR was estimated 
by Pounds and Cheng’s robust FDR method [27]. 
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Electrophoretic Mobility Shift Assays: The functional validation for binding 
efficiencies between selected microRNAs and mRNAs was performed using the 
electrophoretic mobility shift assays (EMSAs) as described previously [28]. The binding 
free energy between the respective mRNA and microRNA pair (demonstrating inverse 
relationship) was predicted using the RNAhybrid software. The microRNA 
oligonucleotides were labeled with cy5™ dye on their 5’ ends. The 2’ O-methyl-modified 
mRNA oligonucleotides were labeled with IRDye®800 (LI-COR Biosciences, USA) dye 
on their 5’ ends. The labeled oligonucleotides were synthesized by Integrated DNA 
Technologies (Coralville, USA). RNA EMSA experiment was performed using the 
LightShift Chemiluminescent RNA EMSA Kit (ThermoScientific, USA) according to the 
manufacturer’s protocol. The mRNA oligonucleotide was heated for 10 minutes at 80°C 
and then placed on ice in order to relax the secondary structures. In each 20ȝl binding 
reaction, 200nM microRNA oligonucleotide and /or mRNA oligonucleotide were mixed 
with RNA EMSA binding buffer and incubated at 25°C for 25 minutes. The reaction 
mixtures were separated on a 15% polyacrylamide gel by electrophoresis at 4°C. The 
binding reactions were electrophoretically transferred onto nylon membrane and the 
resulting mobility shifts were imaged using and Odyssey CLx Infrared System (LI-COR 
Biosciences, USA). 
 
2.4. Results 
2.4.1. Cytarabine chemosensitivity of AML cell lines: The AML cell lines showed 
considerable variability in cytarabine sensitivity as measured by cytotoxicity AUC and 
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apoptosis AUC in the MTT assay (Table 2.1; Supplementary Fig. 2.1A-1H). Based on the 
cytotoxicity AUC, HL-60, MV-4-11, KG-1 and ME-1 were classified as sensitive 
(cytarabine AUC < 12000), while MOLM-16, AML-193, Kasumi-1 and THP-1 were 
classified as resistant cell lines (cytarabine AUC > 12000).    
2.4.2. MicroRNAs associated with cytarabine chemo-sensitivity in AML cell lines: 
Of the 800 human microRNAs quantitated using the nCounter Nanostring platform we 
excluded 388 miRNAs due to very low expression and 412 miRNA were analyzed 
further. Twenty miRNAs were associated with cellular viability (9 miRs) or caspase 
activation (11 miRs) in AML cell lines post treatment with cytarabine (Table 2.2). 
Expression of miR-25-3p, miR-148b-3p, miR-107, miR-374-5p, miR-425-5p were 
positively associated with AUC for cell survival post-cytarabine treatment and miR-16-
5p, miR-24-3p, miR-196a-5p and miR-155-5p were negatively associated with AUC for 
cell survival post-cytarabine treatment (p< 0.05). (Selected miRNAs are shown in 
supplementary Fig. 2.2) Expression levels of miR-10a-5p, miR-29a/b-3p, miR-30e-5p, 
miR-33a-5p, miR-378a/g were positively and expression levels miR-197-3p, miR-27b-
3p, miR-324-5p and miR-421 were negatively associated with AUC for caspase3/7 
activation (apoptosis) post cytarabine treatment (Table 2.2, p<0.05).  
2.4.3. Pairs of significantly correlated mRNAs and miRNAs that associate with 
overall survival of AML Patients: Of 20 miRNAs identified above, data on 18 were 
available in AML patients from TCGA database and were tested for associations with 
risk group and outcome. As shown in Supplementary Table 2.1, seven of these miRNAs 
(miR-10a, miR-16, miR-196a, miR-197, miR-421, miR-155 and miR24) demonstrated 
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significant difference in expression levels among the three risk groups. In risk stratified 
analysis miR107, miR-155, miR-196a, miR-25 and miR29b were associated with worse 
OS whereas miR-25 was predictive of better OS in AML patients at p<0.05.  
Using miRBase (www.mirbase.org; release 21), we determined that 5006 probe sets 
representing 2830 gene with binding sites for these 18 miRNAs. These 5006 mRNAs and 
18 miRNAs belong to 7132 distinct miRNA-mRNA pairs. Using the analysis strategy 
outlined in Fig. 1, we found that 23 of the 7132 miRNA-mRNA pair’s satisfied criteria 
listed below (Table 2.3):  
(a) significant association between miRNA and target mRNA (p < 0.05; 1532 pairs) 
and 
(b) mRNA expression associated significantly with overall survival in an unstratified 
Cox regression model (p < 0.001; FDR < 0.05). 
These 23 pairs included 16 unique genes and 10 unique miRNAs (Table 2.3 -some 
mRNAs and some miRNAs belonged to multiple pairs).  A positive correlation of mRNA 
and miRNA was observed for 10 of these pairs and a negative correlation was observed 
for the other 13 pairs.  
Among mRNA-OS associations COL3A1, GALNT1, GALNT7, LTK, MAP4K4, MYB, 
PAPOLG, RPL35A, TMEM87A and WDR48 were associated with better OS and HOX 
family genes (HOXA9, HOXA10, HOXB7), GZMB, SE1L3 and an oncogene PIM1 
were associated with inferior outcome (Table 2.3). Since nine of these genes 
demonstrated significant association with risk groups we also performed risk-stratified 
analysis and all but 3 genes HOXA9, HOXA10 and LTK were significantly associated 
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with OS in risk stratified analysis, indicating that for these genes the observed association 
with OS might be driven by risk group characteristics. Fig. 2.2 shows the representative 
correlation plots as well as overall curves for miR10a-GALNT1, miR10a-MAP4K4 and 
miR16-Pim1, miR378-GZMB and miR107-MYB.  
We further utilized Ingenuity Pathway analysis tool to map the 16 unique genes identified 
in integrative analysis and as shown in Fig. 2.3 these genes were associated with cell 
proliferation, apoptosis, RNA expression, and quantity of hematopoietic progenitor cells, 
hematological cancer and myeloid leukemia.  
2.4.4. Functional validation using RNA Electrophoretic mobility shift assays (RNA 
EMSA): To further validate the miRNA-mRNA pairs discovered as above, we performed 
RNA EMSAs. We first selected miRNA-mRNA pairs from Table 2.3 that demonstrated 
significant inverse relationships. Binding free energy for these miRNA-mRNA pairs was 
calculated using RNAhybrid software The 3’UTR sequence of mRNA was obtained from 
the UCSC Genome browser and microRNA sequence was obtained from miRBase 
software. Of miRNA-mRNAs demonstrating minimum free energy of binding <-24 
kcal/mol miR107-MYB; miR378a-GZMB and miR10a-GALNT1 were validated by 
RNA EMSAs. EMSA results confirmed binding for miR-107-MYB, miR-10-GALNT1 
and miR-378- GZMB and are shown in Fig. 2.4A, 2.4B and 2.4C respectively. As shown 
in lane 3 in Fig. 2.4A, 2.4B and 2.4C, the EMSA results for miR-107, miR-10a and miR-
378 demonstrate binding of these miRNAs with their respective mRNA target sequences 
confirming the thermodynamic stability of these complexes predicted in the in silico 
analysis. In addition, we observed competition of binding in mRNA-microRNA 
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complexes after adding excess unlabeled specific miRNA probe (Fig. 2.4A-C, lane 4), 
excess unlabeled mRNA probe (Fig. 2.4A-C lane 5) but not by adding excess unlabeled 
non-specific probe (Fig. 2.4A-C, lane 6).  
 
2.5. Discussion 
AML is a heterogeneous disease with dismal outcome. Additional complexity is added by 
very heterogeneous nature of AML with cytogenetic abnormalities used for risk 
classification in AML patients. Although cytarabine has been the backbone of AML 
chemotherapy for more than 50 years, there are still gaps in our understanding of the 
molecular mechanisms contributing to development of drug resistance in AML. Although 
advances in supportive care have improved, the treatment strategies have not changed 
much with cytarabine being still the main player. Thus, understanding the molecular 
mechanisms underlying cytarabine resistance will be of great interest in developing 
predictive models of outcome as well as for developing novel therapeutic strategies 
Recent research has shown the significant role of microRNAs in normal hematopoiesis 
[29-31] as well as microRNA deregulation in AML. MicroRNAs (miR-125, miR-146, 
miR-142, miR-155, miR-29, miR- 181, let-7a etc.) of potential prognostic significance 
have been identified [32], however the role of microRNAs in development of resistance 
to cytarabine and thus inferior clinical outcome has not been investigated in detail. In this 
study we report results of our genome-wide evaluation to identify microRNAs associated 
with cytarabine sensitivity in 8 AML cell lines as well as their impact on clinical outcome 
in AML patients (Fig. 2.1 outlines overall study design and results).  
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We screened expression levels of 800 human microRNAs in eight AML cell lines and 
after filtering out microRNAs with very low expression, evaluated 412 microRNAs for 
association with cytarabine chemo-sensitivity, measured as cell viability and apoptosis 
induction following cytarabine treatment. Twenty unique microRNAs were predictive of 
cytarabine chemo-sensitivity in AML cell lines, and 18 of these were further evaluated in 
AML patients from TCGA database. Seven of these were differentially expressed among 
AML risk groups (favorable, intermediate and poor; p<0.05) and after risk stratification 5 
miRNAs (miR-107, miR-155, miR-25, miR-29b and miR-196a) were associated with OS 
(Supplementary Table 2.1). All but miR-25 were associated with worse OS in AML 
patients.  
Among the miRNAs associated with OS, miR-155 is located in a non-coding RNA 
transcript cluster called B-cell integration cluster (BIC), which has been shown to 
cooperate with c-Myc [33, 34]. miR-155 is considered as an oncomiR with implications 
in pathogenesis of AML [16, 31]; it has been associated with SHIP1 (negatively regulator 
of PI3K/AKT pathway) and CEBP-ȕ [35, 36]. Our results shows that miR-155 is 
associated with cytarabine sensitivity which is not in consensus with its association with 
inferior outcome, thereby indicating that miR-155 (which is also differentially expressed 
among risk groups) might have significant impact on disease pathogenesis but might not 
be impacting drug response. miR-29 family members are regulators of myeloid 
differentiation and have been shown to be deregulated in AML [37-39]. MiR29a/29b 
have been associated with expression levels of oncogenes MCL1, CDK6, IGFR and 
JAK2 [38, 40] as well as have been shown to target DNA modifying genes DNMTs and 
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TET2 [41, 42].  
In step-wise integrated analysis we identified 23 miRNA –mRNA pairs predictive of 
survival in AML patients and these pairs were mapped to 16 unique mRNAs.  
We further validated miR107-MYB, miR-10a-GALNT1 and miR378-GZMB miRNA-
mRNA pairs using electrophoretic mobility shift assays (Fig. 2.4), which confirmed the 
binding of these oligos as supported by in silico analysis indicating miRNAs in regulating 
gene expression of these target genes by binding to specific seed sequences. 
As expected HOX genes (HOXA9, HOXA10 and HOXB7) were predictive of worse 
outcome. miR-196a-1 which was associated cytarabine in vitro sensitivity in AML cell 
lines was positively correlated in expression with HOXA9 and HOXB7 as well as with 
AML risk groups. miR-196a-1 gene co-localizes with HOXB gene cluster between 
HOXB8 and HOXB13, positive correlation observed in AML patients between HOXB7 
and mir-196a might be due to transcriptional co-regulation. miR-196a has been 
previously shown to be positively correlated with several HOX family members 
including HOXB7 and HOXA9 [43]. In addition to miR-196a, we observed significantly 
negative correlation between miR-16-HOXA10, miR-421-HOXA9 and miR-30e-
HOXB7.  
Among other miR target genes that were associated with worse OS were PIM-1 (pim1 
oncogene), GZMB (granzyme B), and SEL1L3 (Sel-1 Suppressor Of Lin-12-Like 3). 
Pim1 is a serine/threonine protein kinase that has role in cell survival and cell 
proliferation. HoxA9 is transcriptional activator of Pim-1, which is further involved in 
regulation of MYC transcriptional activity, regulation of cell cycle progression and 
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phosphorylation and inhibition of proapoptotic proteins (BAD, MAP3K5, FOXO3) 
thereby by contributing to its oncogenic activity. Pim-1 is also involved in inactivating 
MAP3K5 by phosphorylation thereby inhibiting MAP3K5-mediated phosphorylation of 
JNK and JNK/p38MAPK subsequently reducing caspase-3 activation and cell apoptosis. 
Pim-1 seems like a potential target for drug discovery, in fact in pediatric preclinical 
models, Pim1 inhibitor SGI-1776 has been shown to induce complete response to 
subcutaneous MV4:11 leukemia[44] as well as inhibit proliferation in other malignancies 
such as CLL, B cell lymphoma, multiple myeloma etc. [45-47]. 
GZMB was negatively regulated by miR-378 and higher expression was associated with 
worse OS in AML. GZMB is a key player in Granzyme signaling pathway, which is a 
lymphocyte granular serine protease that cleaves its substrates at Asp residues. GZMB is 
expressed in cytotoxic T lymphocytes (CTL) and NK cells and is primary mediator of 
apoptosis by CTL in cell-mediated immune response. GZMB seems to play critical role 
antibody –dependent cellular cytotoxicity [48]. 
Among miR target genes that were associated with good response were family members 
of Polypeptide N-Acetylgalactosaminyltranferases (GALNT1 and GALNT7), MAP4K4, 
TMEM87A and COL3A1. GALNT1 was correlated negatively in expression with miR-
10a, miR-16-2 and positively with miR-30e, which also demonstrated positive correlation 
with GALNT7 expression.  MAP4K4 belongs to serine/threonine protein kinase family 
and has been specifically implicated in activation of MAPK8/JNK pathway.  
Both MYB and TMEM87 were inversely associated with miR-107, which was associated 
with cytarabine resistance in cell lines as well as worse overall survival in AML patients 
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(Tables 2.2 and 2.3). Oncogenic role of miR-107 in regulating tumor invasion and 
metastasis in gastric cancer by targeting DICER1 [49] and in colorectal cancer by 
targeting metastasis suppressors death-associated protein kinase (DAPK) and Krüppel-
like factor 4 (KLF4) [50] has been proposed. In AML patients, we observed negative 
correlation of DICER with miR-107 (p<0.01) although DICER expression was not 
predictive of outcome. Although TMEM87A a transmembrane protein has not been well 
studied, MYB, a V-Myb Avian Myeloblastosis Viral Oncogene Homolog has been 
implicated in leukemogenesis. Myb is reported to be overexpressed in AML and results 
from recent studies shows its potential role in interplay between C/EBP  activity for 
transcriptional regulation of FLT3 expression [51]. Recent report in luminal breast cancer 
demonstrated for the first time the potential tumor suppressor role of c-Myb gene, [52], 
which is in concordance with TCGA results with Myb expression associated with better 
OS thereby warranting further investigation of Myb gene on its impact on treatment 
outcome in AML.  
In summary, although several studies have established prognostic significance of 
microRNAs (miR-155, miR-29, miR-16, miR 223 etc.) in AML, role of microRNAs in 
cytarabine chemosensitivity and development of resistance as a contributor of inferior 
outcome has not been well studied. In this report we performed genome-wide microRNA 
profiling of 8 AML cell lines and identified 20 miRNAs predictive of differential AML in 
vitro chemo-sensitivity (by measuring both cytarabine induced cell death and apoptosis). 
These were further investigated in AML patients using data from TCGA database, and in 
an integrated three way analyses of miRNA- target mRNA pairs with significant 
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association and OS we identified 23 microRNA-mRNA-OS pairs of therapeutic 
importance in AML patients. Although additional functional validation studies to 
establish clinical/ pharmacological importance of microRNA-mRNA pairs are needed, 
our preliminary data on RNA EMSAs confirmed binding of miR-107-MYB, miR10a-
GALNT1 and miR-378-GZMB. Integration of pathogenic and pharmacologically 
significant microRNAs and microRNA-mRNA relationships opens up opportunities for 
development of targeted/microRNA-directed therapies. 
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Figure 2.1: Overall schema of the proposed study. Study Design for identification of 
microRNAs influencing cytarabine chemo-sensitivity and survival in AML patients. 
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(A) miR-10a and GALNT1 
 
 
(B) miR-10a and MAP4K4 
 
 
(C) miR-16 and PIM-1 
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(D) miR-378 and GZMB 
 
 
(E) miR-107 and MYB 
 
 
 
Figure 2.2: Representative plots showing correlation between miRNA- target mRNA 
and survival curves of miRNA and mRNA expression with OS in AML patients 
from TCGA database. A) Correlation plot of miR-10a-GALNT1 mRNA levels and 
Kaplan Meier survival curves of miR10a and GALNT1 expression with OS. B) 
Correlation plot for miR-10a-MAP4K4 mRNA levels and Kaplan Meier survival curves 
of miR-10a and MAP4K4 expression with OS.  C) Correlation plot of miR-16 and Pim1 
mRNA levels and Kaplan Meier survival curves of miR-16 and PIM1 expression with OS 
D) Correlation plot of miR-378 and GZMB mRNA levels and Kaplan Meier survival 
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curves of miR-378 and GZMB expression with OS. E) Correlation plot of miR-107 and 
MYB mRNA levels and Kaplan Meier survival curves of miR-107 and MYB expression 
with OS. 
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Figure 2.3. Network analysis. Ingenuity Pathway analysis tool was utilized to evaluate the genes identified in miRNA-mRNA-OS 
analysis.  Several genes mapped to biological processes of relevance to hematological malignancies, myeloid leukemia as well as to 
cell proliferation and apoptosis, RNA expression. Genes associated with better OS are in green and ones with worse OS are in red. 
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Figure 2.4. (A) Validation of binding interaction between miRNA-mRNA by RNA Electrophoretic Mobility Shift Assays: 
Validation of binding interaction between MYB mRNA and hsa-miR-107 by RNA EMSAs. RNA EMSA with cy5-labeled hsa-
miR-107 oligonucleotide and 2’-O-methyl modified and IRD-800 labeled MYB mRNA oligonucleotide. Lanes 1 and 2 show the 
mobility of the labeled mRNA or microRNA oligonucleotide. Lane 3 shows the mobility of the labeled hsa-miR-107 
oligonucleotide with MYB mRNA oligonucleotide. Lanes 4 and 6 show the mobility of labeled MYB mRNA oligonucleotide in 
presence of unlabeled excess specific competitor (hsa-miR-107) and excess unlabeled non-specific competitor (NC) 
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(B) 
 
 
Figure 2.4. (B) Validation of binding interaction between miRNA-mRNA by RNA Electrophoretic Mobility Shift Assays: 
Validation of binding interaction between GALNT1 mRNA and hsa-miR-10a-5p by RNA EMSAs. RNA EMSA with cy5-labeled hsa-
miR-10a-5p oligonucleotide and 2’-O-methyl modified and IRD-800 labeled GALNT1 mRNA oligonucleotide. Lanes 1 and 2 show 
the mobility of the labeled mRNA or microRNA oligonucleotide. Lane 3 shows the mobility of the labeled hsa-miR-10a-5p 
oligonucleotide with GALNT1 mRNA oligonucleotide. Lanes 4 and 6 show the mobility of labeled GALNT1 mRNA oligonucleotide 
in presence of unlabeled excess specific competitor (hsa-miR-10a-5p) and excess unlabeled non-specific competitor (NC) 
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(C) 
 
Figure 2.4. (C) Validation of binding interaction between miRNA-mRNA by RNA Electrophoretic Mobility Shift Assays: 
Validation of binding interaction between GZMB mRNA and hsa-miR-378a-5p by RNA EMSAs. RNA EMSA with cy5-labeled hsa-
miR-378a-5p oligonucleotide and 2’-O-methyl modified and IRD-800 labeled GZMB mRNA oligonucleotide. Lanes 1 and 2 show the 
mobility of the labeled mRNA or microRNA oligonucleotide. Lane 3 shows the mobility of the labeled hsa-miR-378a-5p 
oligonucleotide with GZMB mRNA oligonucleotide. Lanes 4 and 6 show the mobility of labeled GZMB mRNA oligonucleotide in 
presence of unlabeled excess specific competitor (hsa-miR-378a-5p) and excess unlabeled non-specific competitor (NC) 
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Supplementary Figure 2.1. Characterization of AML Cell lines for Cytarabine chemosensitivity. AML cell lines (n = 8) were 
cultured in the respective media and standard culturing conditions. Cytarabine-induced cytotoxicity (blue line) was determined by 
MTT assay after 48h of drug treatment and AUC was calculated using the cell survival data. Cytarabine-induced apoptosis (red line) 
was determined using Caspase 3/7 assay after 48h of drug treatment and relative caspase AUC was calculated. 
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Supplementary Figure 2.2: miRNA and cytarabine cell cytoxicity. Correlation plots showing association of selective miRNAs with 
cell survival AUC post cytarabine treatment of 8 AML cell lines.  
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Supplementary Figure 2.3: Network of microRNAs and important biological processes. MiRNAs predictive of in vitro cytarabine 
chemosensitivity in cell lines as well as with OS in AML patients were analyzed using Ingenuity pathway analysis tools and pathways 
identified are depicted in the network. 
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Table 2.1: Characterization of AML Cell lines for Cytarabine Chemosensitivity 
Cell Lines  Cytogenetics /Molecular Abnormality 
Cytarabine 
Cytotoxicity  
AUC (± SD) 
Cytarabine 
Apoptosis  
AUC (± SD) 
Kasumi-1 t(8;21)(q22;q22) ĺ RUNX1/AML1-RUNX1T1/ETO fusion gene; TP53 mutant gene 14713 (± 582) 409.3 (± 20) 
THP-1 t(9;11)(p21;q23) ĺ MLL-AF9 fusion gene; CDKN2A, KDM6A, NRAS mutant genes 17170 (± 1341) 1544.5 (± 2) 
MOLM-16 t(6;8)(q21;q24.3) and t(9;18)(q13;q21) 12021 (± 480) 490.2 (± 18) 
AML-193 +der(17)t(17;17)(p13.1;q21.3) 12988 (± 366) 852.4 (± 34) 
MV-4-11 FLT3 ITD mutation, t(4;11)(q21;q23) ĺ MLL-AF4 fusion gene 5011 (± 442) 458.4 (± 22) 
ME-1 inv(16)(p13q22) ĺ CBFB-MYH11 fusion gene 6497 (± 280) 753.6 (± 33) 
KG-1 NRAS mutation, P53 mutation, RB1 rearrangement 5939 (± 464) 472.5 (± 16) 
HL-60 CDKN2A, NRAS, TP53 mutant genes 4597 (± 397) 555.6 (± 29) 
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Table 2.2: MicroRNAs significantly associated with cytarabine-induced cytotoxicity 
AUC and cytarabine-induced apoptosis (Caspase 3/7 activity). 
  MicroRNA Spearman r P value 
Cytarabine-induced cell cytotoxicity AUC 
hsa-miR-107 0.7619 0.028 
hsa-miR-148b-3p 0.7381 0.037 
hsa-miR-155-5p -0.8095 0.015 
hsa-miR-16-5p -0.7381 0.037 
hsa-miR-196a-5p -0.7857 0.021 
hsa-miR-24-3p -0.8095 0.015 
hsa-miR-25-3p 0.7857 0.021 
hsa-miR-374a-5p 0.7381 0.037 
hsa-miR-425-5p 0.7619 0.028 
Cytarabine-induced Apoptosis AUC 
hsa-miR-10a-5p 0.7857 0.021 
hsa-miR-197-3p -0.8571 0.007 
hsa-miR-27b-3p -0.7186 0.045 
hsa-miR-29a-3p 0.8810 0.004 
hsa-miR-29b-3p 0.7857 0.021 
hsa-miR-30e-5p 0.7381 0.037 
hsa-miR-324-5p -0.9048 0.002 
hsa-miR-33a-5p 0.8095 0.015 
hsa-miR-378a-3p 0.8095 0.015 
hsa-miR-378g 0.7381 0.037 
  hsa-miR-421 -0.7619 0.028 
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Table 2.3: MiRNAs-mRNA pairs predictive of  overall survival (OS) in AML Patients (data from TCGA) 
miRNA-mRNA Pair miRNA-mRNA correlation 
mRNA-risk 
group mRNA-OS 
miRNA mRNA probe mRNA gene mRNA Chr 
Spearman 
Correlation Kruskal-Wallis Unstratified Cox Model 
r p value p value FDR HR p value FDR 
mir-107 212202_s_at TMEM87A chr15q15.1 -0.208 0.004 0.000 0.001 0.386 0.000 0.045 
mir-107 204798_at MYB chr6q23.3 -0.235 0.001 0.050 0.075 0.430 0.000 0.004 
mir-10a 201724_s_at GALNT1 chr18q12.2 -0.418 0.000 0.000 0.000 0.327 0.000 0.006 
mir-10a 218181_s_at MAP4K4 chr2q11.2 -0.445 0.000 0.046 0.072 0.558 0.001 0.045 
mir-10a 222273_at PAPOLG chr2p16.1 -0.174 0.018 0.429 0.350 0.392 0.000 0.013 
mir-148b 218181_s_at MAP4K4 chr2q11.2 0.240 0.001 0.046 0.072 0.558 0.001 0.045 
mir-16 213150_at HOXA10* chr7p15.2 0.441 0.000 0.000 0.000 1.216 0.000 0.041 
mir-16 201724_s_at GALNT1 chr18q12.2 -0.217 0.003 0.000 0.000 0.327 0.000 0.006 
mir-16 212314_at SEL1L3 chr4p15.2 0.263 0.000 0.000 0.000 1.446 0.001 0.046 
mir-16 209193_at PIM1 chr6p21.2 0.247 0.001 0.002 0.006 1.713 0.000 0.045 
mir-196a 214651_s_at HOXA9* chr7p15.2 0.293 0.000 0.000 0.000 1.166 0.001 0.046 
mir-196a 204779_s_at HOXB7 chr17q21.32 0.223 0.002 0.000 0.000 1.276 0.001 0.046 
mir-196a 201852_x_at COL3A1 chr2q32.2 0.252 0.001 0.152 0.170 0.783 0.000 0.045 
mir-196a 213687_s_at RPL35A chr 3q29 -0.174 0.018 0.300 0.276 0.399 0.000 0.042 
mir-197 212202_s_at TMEM87A chr15q15.1 -0.184 0.012 0.000 0.001 0.386 0.000 0.045 
mir-197 218181_s_at MAP4K4 chr2q11.2 0.159 0.030 0.046 0.072 0.558 0.001 0.045 
mir-29b 207106_s_at LTK* chr15q15.1 -0.184 0.012 0.000 0.000 0.790 0.001 0.046 
 72 
Table 2.3 (Continued): MiRNAs-mRNA pairs predictive of  overall survival (OS) in AML Patients (data from TCGA) 
miRNA-mRNA Pair miRNA-mRNA correlation 
mRNA-risk 
group mRNA-OS 
miRNA mRNA probe mRNA gene mRNA Chr 
Spearman 
Correlation Kruskal-Wallis Unstratified Cox Model 
r p value p value FDR HR p value FDR 
mir-29b 56919_at WDR48 chr3p22.2 -0.169 0.021 0.068 0.095 0.514 0.000 0.009 
mir-30e 204779_s_at HOXB7 chr17q21.32 -0.325 0.000 0.000 0.000 1.276 0.001 0.046 
mir-30e 201724_s_at GALNT1 chr18q12.2 0.208 0.004 0.000 0.000 0.327 0.000 0.006 
mir-30e 218313_s_at GALNT7 chr4q34.1 0.329 0.000 0.106 0.132 0.417 0.000 0.024 
mir-378 210164_at GZMB chr14q12 -0.205 0.005 0.199 0.207 1.439 0.001 0.046 
mir-421 214651_s_at HOXA9* chr7p15.2 -0.277 0.000 0.000 0.000 1.166 0.001 0.046 
 
* Except for HOXA9, HOXA10 and LTK all other genes were also significantly associated with OS (p<0.05) in risk stratified 
analysis. FDR was estimated by Pounds and Cheng’s robust FDR method.  
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Supplementary Table 2.1: Association of miRNA target genes with Overall Survival (Risk stratified and non risk stratified) 
microRNA 
miR-Risk 
group  
(P value) 
miR-Risk 
group 
(BH95q) 
miR-OS 
(Hazard 
Ratio) 
miR-OS    
(P value) 
miR-OS 
(BH95q) 
miR-OS 
Risk 
stratified 
(HR) 
miR-OS 
Risk 
stratified 
(P value) 
miR-OS 
Risk 
stratified 
(BH95q) 
hsa-mir-10a 1.693E-12 0.0000 1.1440 0.0030 0.0208 1.0860 0.1121 0.2615 
hsa-mir-16 2.163E-07 0.0000 1.5620 0.0114 0.0481 1.1940 0.3617 0.5843 
hsa-mir-196a 7.793E-06 0.0001 1.2210 0.0029 0.0208 1.1580 0.0271 0.1209 
hsa-mir-197 0.0004 0.0019 1.3870 0.1687 0.2952 1.2030 0.4507 0.6761 
hsa-mir-421 0.0006 0.0025 0.8890 0.2158 0.3211 0.9500 0.6267 0.7223 
hsa-mir-155 0.0130 0.0391 1.4390 0.0019 0.0208 1.3120 0.0288 0.1209 
hsa-mir-24-2 0.0277 0.0727 1.6250 0.0181 0.0544 1.4740 0.0801 0.2103 
hsa-mir-374a 0.0829 0.1934 1.0020 0.9907 0.9907 1.1180 0.5264 0.6910 
hsa-mir-148b 0.1040 0.2183 1.0660 0.7502 0.8753 1.2100 0.3570 0.5843 
hsa-mir-107 0.1259 0.2305 1.5550 0.0966 0.2253 2.0430 0.0085 0.1209 
hsa-mir-29a 0.1317 0.2305 1.2390 0.2294 0.3211 1.3770 0.0698 0.2095 
hsa-mir-378 0.1697 0.2741 1.2470 0.1453 0.2849 1.2570 0.1622 0.3407 
hsa-mir-324 0.2036 0.2850 1.1010 0.6380 0.7881 1.1550 0.5000 0.6910 
hsa-mir-425 0.2269 0.2978 0.8670 0.2572 0.3375 0.9620 0.7708 0.7708 
hsa-mir-30e 0.3016 0.3726 1.0350 0.9061 0.9703 0.9080 0.7395 0.7708 
hsa-mir-29b 0.3613 0.4215 1.6630 0.0077 0.0407 1.5690 0.0176 0.1209 
hsa-mir-25 0.4188 0.4481 0.6370 0.0373 0.0979 0.6210 0.0359 0.1258 
hsa-mir-27b 0.7951 0.7951 0.7330 0.1950 0.3150 0.7370 0.1911 0.3648 
P values < 0.05 are shaded and bold 
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CHAPTER III 
MicroRNAs Mediated Regulation of Expression of Nucleoside Analog Pathway 
Genes 
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3.1. Introduction: 
Nucleoside analogs (NA) are a class of chemotherapeutic agents that structurally 
resemble the endogenous purine or pyrimidine nucleosides. These therapeutic agents 
mimic the endogenous nucleosides with respect to their uptake and metabolism and are 
incorporated into the newly synthesized DNA leading to inhibition of DNA synthesis and 
chain termination. Some of the nucleoside analogs also inhibit or block the enzymes that 
are required for the synthesis of purine or pyrimidine nucleotides and RNA synthesis, 
leading to the activation of the caspase cascade and cell death. The nucleoside analogs 
are extensively used for the treatment of both, hematological malignancies and solid 
tumors. The pyrimidine nucleoside analog, cytarabine, is one of the most widely used 
chemotherapeutic drugs for the treatment of acute myeloid leukemia (AML). While 
clofarabine, a purine nucleoside analog is one of the newer nucleoside analogs used for 
the treatment of AML.  
One of the major obstacles in the treatment of AML is development of resistance to 
nucleoside analogs. There is a growing need to understand the mechanisms that lead to 
development of resistance to these nucleoside analogs in order to help identify strategies 
that would effectively treat patients with relapsing or refractory disease. One of the 
primary mechanisms of resistance to nucleoside analogs is insufficient intracellular 
concentration of the active triphosphate metabolite. This insufficient triphosphate levels 
could be due to inefficient cellular uptake of the drug, reduced levels of the activating 
enzyme, increased levels of inactivating enzymes and/or due to increased levels of 
endogenous deoxynucleotide (dNTP) pools [1-4]. Resistance could also develop due to 
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inability to achieve sufficient alterations in the DNA strands or the dNTP pools, either 
due to altered interaction with DNA polymerases or by lack of inhibition of 
ribonucleotide reductases, or due to inadequate p53 exonuclease activity. Since the 
expression and activity of drug transporters and metabolizing enzymes in the activation 
pathway of nucleoside analogs plays an important role in development of resistance to 
the NAs, it is essential to understand the factors influencing the expression and activity of 
these proteins. 
MicroRNAs are a group of novel gene regulators, which have been recently recognized to 
play an important role in cancers due to their tumor suppressive and oncogenic functions 
[5]. MicroRNAs are known to regulate the expression of the target genes by binding to 
the specific sequence on the 3’ untranslated region on the genes. Role of microRNAs in 
regulating the expression of various drug metabolizing enzymes like CYP3A4 etc., drug 
transporters like BCRP and various drug targets [6-8] has been established. However, 
comprehensively evaluation of the effect of microRNAs on the genes involved in the 
transport, activation and inactivation genes of nucleoside analogs has not been done. 
Hence, the aim of this study was to assess the effect of microRNAs on the expression of 
nucleoside analog PK and PD pathway genes and in turn assessing their potential impact 
on resistance to nucleoside analogs.  
 
3.2. Materials and Methods 
3.2.1. Cell culture and Reagents: The AML cell lines HL-60, MV-4-11, Kasumi-1, 
THP-1, AML-193 and KG-1 cell lines were obtained from American Type Culture 
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Collection (ATCC) (Manassas, VA), while MOLM-16 and ME-1 cell lines were obtained 
from DSMZ (Braunschweig, Germany). Kasumi-1, ME-1 and MOLM-16 cell lines were 
cultured in RMPI-1640 medium supplemented with 20% fetal bovine serum (FBS), THP-
1 cell line was cultured in RPMI-1640 medium supplemented with 10% FBS, MV-4-11 
cell line was cultured in IMDM medium supplemented 10% FBS, HL-60 and KG-1 cell 
lines were cultured in IMDM medium supplemented with 20% FBS, while AML-193 cell 
lines was cultured in IMDM medium supplemented with 5% FBS, 0.005 mg/ml insulin, 
0.005 mg/ml transferrin and 5 ng/ml GM-CSF. All the cell lines were maintained in a 
37°C humidified incubator with 5% CO2. The cells were passaged every 2 to 3 days in 
order to maintain them in logarithmic growth phase.  
3.2.2. RNA Isolation: Total RNA was isolated from the AML cell pellets using RNeasy 
Plus Mini Kit (QIAGEN, USA) according to the manufacturer’s protocol and stored in -
80°C until further analysis. The RNA quality and concentration was measured using 
NanoDrop 2000 UV-Vis spectrophotometer (ThermoScientific, USA). The ratio of 
absorbance at 260 nm and 280 nm was used to assess RNA sample purity and 
A260/A280 ratio of 1.8-2.1 was considered to be indicative of highly purified RNA. 
RNA was normalized to 0.2ȝg/ȝl with nuclease-free water before being used for 
performing reverse transcription reactions, as recommended by the manufacturer. The 
total RNA was reverse transcribed to cDNA using High Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems, USA) according to manufacturer’s protocol.  
3.2.3. Gene Expression Analysis: The expression of nucleoside analog genes was 
determined using the TaqMan® Low Density Array (TLDA) cards (Applied Biosystems, 
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USA). Each TLDA card was custom designed with pre-loaded gene expression assays for 
measuring the mRNA expression of selected nucleoside analog metabolic pathway genes- 
(n=14) deoxycytidine kinase (DCK), cytidine deaminase (CDA), solute carrier family 29, 
member 1 (SLC29A1), solute carrier family 28, member 1 (SLC28A1), solute carrier 
family 28, member 3 (SLC28A3), deoxycytidylate deaminase (DCTD), 5’-nucleotidase, 
cytosolic II (NT5C2), 5’-nucleotidase cytosolic III (NT5C3), cytidine 5’-triphosphate 
synthase (CTPS), cytidine monophosphate kinase (CMPK), nucleoside diphosphate 
kinase 1 (NME1), ribonucleotide reductase M1 (RRM1), ribonucleotide reductase M2 
(RRM2), ribonucleotide reductase M2B (RRM2B). Each TLDA card consists of eight 
separate loading ports that fill into 48 separate wells, for a total of 384 wells per card. 
Thus, each card could analyze the expression of 24 different genes for 8 different samples 
in duplicates. Each cDNA sample was added to equal volume of 2X TaqMan Universal 
PCR Master Mix and 100 ȝl of the sample-specific PCR mix was added to the fill 
reservoir on the TLDA card. The card was centrifuged twice for 1 minute at 1200 rpm to 
distribute the sample-specific PCR reaction mix to the reaction wells. The card was 
sealed using the TaqMan Array Micro Fluidic Card Sealer and placed on microfluidic 
card thermal cycling block of Applied Biosystems 7900HT Fast Real-time PCR System 
(Applied Biosystems). Thermal cycling conditions were as follows: 2 minutes at 50°C, 
10 minutes at 94.5°C, 30 seconds at 97°C, 1 minute at 59.7°C for 40 cycles. The target 
mRNA expression levels were normalized to GAPDH and the expression values of 
nucleoside analogs pathway genes were calculated using comparative CT method [9].  
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3.2.4. MicroRNA Expression Analysis: For determination of microRNA expression, 
total RNA was isolated using mirVana™ miRNA Isolation kit (Life Technologies, USA) 
as per the manufacturer’s protocol. The RNA quality and concentration was measured 
using NanoDrop 2000 UV-Vis spectrophotometer (ThermoScientific, USA). A total of 
100 ng of purified total RNA was used for nCounter miRNA sample preparation 
reactions according to manufacturer’s instructions and was assayed for determination of 
800 human microRNA expression using the nCounter Human v2 miRNA Expression 
Assay kit (Nanostring Technologies, USA). Preparation of small RNA samples involved 
multiplexed ligation of specific tags (miRtags) to the target microRNAs that provide 
unique identification for each microRNA species. After ligation, the detection was done 
by hybridization to microRNA: tag specific nCounter capture and barcoded reporter 
probes. Data collection was carried out using the nCounter Digital Analyzer (Nanostring 
Technologies, USA) at The University of Minnesota Genomics Center, following 
manufacturer’s instructions to count individual fluorescent barcodes and quantify the 
target microRNA molecules present in each sample. MicroRNA expression data 
normalization was performed using the nSolver™ Analysis Software (Nanostring 
Technologies) according to the manufacturer’s instructions. In particular, initially the 
data was normalization using the expression of the top 100 codesets was used. Further, to 
account for the background correction, mean of negative controls plus two-standard 
deviation (SD) method was used. In order to avoid using the microRNAs with a very low 
expression, we further filtered out the microRNAs with expression counts <30 (2 times 
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the mean ± 2 SD of negative control value), in order to account for the background noise. 
Total 412 microRNAs with expression counts >30 were included for further analysis. 
3.2.5. AML Patient Sample Data from The Cancer Genome Atlas (TCGA): The 
microRNA expression and mRNA expression of the nucleoside analog pathway genes in 
AML patients was extracted from The Cancer Genome Atlas (TCGA) Data Portal 
(cancergenome.nih.gov) [10]. Out of the 200 AML patients in TCGA database, 197 
patients had gene expression profiling data available and 187 patients had microRNA 
expression data available. 186 patients had both gene expression and microRNA 
expression data available. 
3.2.6. Electrophoretic Mobility Shift Assays: The functional validation for binding 
efficiencies between microRNAs and mRNAs was performed using the electrophoretic 
mobility shift assays (EMSAs). The binding free energy between the respective mRNA 
and microRNA pair was predicted using the RNAhybrid software. The microRNA 
oligonucleotides were labeled with cy5™ dye on their 5’ ends. The 2’ O-methyl-modified 
mRNA oligonucleotides were labeled with IRDye®800 (LI-COR Biosciences, USA) dye 
on their 5’ ends. The labeled oligonucleotides were synthesized by Integrated DNA 
Technologies (Coralville, USA). RNA EMSA experiment was performed using the 
LightShift Chemiluminescent RNA EMSA Kit (ThermoScientific, USA) according to the 
manufacturer’s protocol. The mRNA oligonucleotide was heated for 10 minutes at 80°C 
and then placed on ice in order to relax the secondary structures. In each 20ȝl binding 
reaction, 200nM microRNA oligonucleotide and /or mRNA oligonucleotide were mixed 
with RNA EMSA binding buffer and incubated at 25°C for 25 minutes. The reaction 
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mixtures were separated on a 12% polyacrylamide gel by electrophoresis at 4°C. The 
binding reactions were electrophoretically transferred onto nylon membrane and the 
resulting mobility shifts were imaged using and Odyssey CLx Infrared System (LI-COR 
Biosciences, USA). 
3.2.7. Bioinformatic Analysis: Prediction of microRNA binding sites was performed 
using multiple prediction programs, which use different criteria for prediction of binding 
sites: TargetScan (www.targetscan.org), miRanda (www.microRNA.org), PICTAR 
(pictar.mdc-berlin.de), miRWalk (www.umm.uni-heidelberg.de/apps/zmf/mirwalk). 
Binding free energy calculations were performed using RNAhybrid software. The 3’UTR 
sequence of mRNA was obtained from the UCSC Genome browser and microRNA 
sequence was obtained from miRBase software. 
3.2.8. Statistical Analysis: The nonparametric Spearman correlation was used to 
measure the correlation of mRNA expression with microRNA expression. Statistical 
significance was determined when p-value was < 0.01. 
 
3.3. Results 
3.3.1. Effect of microRNA on the expression of nucleoside analog pathway genes in 
AML Cell lines:  We determined expression of 800 microRNAs and 13 genes involved 
in PK/PD pathway of nucleoside analogs (Figure 3.1) in cytogenetically different AML 
cell lines (n = 8). In order to identify the microRNAs associated with the expression of 
nucleoside analog pathway genes, we correlated the microRNA expression and mRNA 
expression using the spearman correlation analysis. Table 3.1 lists the correlation of 
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nucleoside analog pathway genes and respective microRNAs at p <0.01. Figure 3.2 
depicts the network of microRNAs correlated with the respective PK/PD pathway genes 
of the nucleoside analogs. 
The expression of DCK (the rate-limiting enzyme in the nucleoside analog pathway) 
correlated with the expression of miR-34a-5p expression (spearman r = -0.88; p-value < 
0.01) and miR-96-5p expression (spearman r = -0.91; p-value < 0.01). The expression of 
deactivating enzyme DCTD was found to be correlated with miR-24-3p expression 
(spearman r = -0.93; p-value < 0.01). Interestingly, in our previous study (Chapter II) we 
identified that expression of microRNA miR-24-3p was correlated with cytarabine-
induced cell cytotoxicity (spearman r = -0.81, p-value < 0.05) which is in agreement with 
the current observation. The expression of CMPK, a kinase responsible for 
phosphorylation of the monophosphate form of nucleoside analog was negatively 
correlated with the expression of miR-1301, miR-1323, miR-320e, miR-381, miR-507, 
miR-584-5p, miR-605, miR-762, miR-769-3p, miR-891a (all p-values < 0.01). RRM2 
expression was found to be negatively associated the expression of miR-151a-3p (p-value 
< 0.01).  
3.3.2. Bioinformatic prediction of binding of microRNAs and mRNAs: MicroRNAs 
are known to guide the RNA-induced silencing complex (RISC) to the specific sequence 
(usually in located in the 3’UTR) on the target mRNA. Using various bioinformatic 
prediction programs (TargetScan, miRanda, PICTAR, miRWalk) we determined if the 
microRNAs that were correlated with gene expression had binding sites on 3’-UTR of 
target genes.  MicroRNAs miR-1323, miR-30d-5p, miR-381, and miR-605 were 
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predicted to have binding sites on CMPK gene, while microRNA miR-24-3p was found 
to have binding site on DCTD by multiple prediction programs. Additionally, miR-181-
5p, let-7g-5p and miR194-5p were also found to have binding sites on CTPS1, RRM2 
and RRM2B genes, respectively.  
3.3.3. Effect of microRNAs on the expression of nucleoside analog pathway genes 
in AML patients: In order to validate the significant correlations between microRNAs 
and mRNAs identified in AML cell lines, we evaluated the correlation between 
microRNA expression and nucleoside analog pathway gene expression in AML patient 
samples from TCGA database (n=186). We extracted the microRNA expression data and 
nucleoside analog pathway gene expression data for AML patients from TCGA database 
and performed spearman correlation to identify the significant mRNA-microRNA pairs. 
Table 3.2 lists the mRNA-microRNA correlations, which were common in AML cell 
lines and AML patient samples from TCGA database. MicroRNA miR-24-3p was 
inversely correlated with the expression of both the probes for DCTD in AML patient 
samples (r = -0.22; p-value < 0.01 and r = -0.21; p-value < 0.01). In addition, miR-23a, 
miR-181a, miR-149, miR-140 were also found to be significantly correlated with 
expression of CDA, CTPS, NT5C3 and RRM2, respectively, in AML patients. (Table 
3.2). 
3.3.4. Validation of binding efficiencies between mRNAs and microRNAs: 
MicroRNAs are known to bind to the specific seed sequence on the 3’UTR of the 
mRNAs, thereby regulating the expression of their target genes. In order to validate the 
binding between the mRNA-microRNAs identified from the in vitro studies and in AML 
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patient samples, we performed RNA EMSA assays. We decided to validate the 
interaction between DCTD and miR-24, since we identified this mRNA-microRNA pair 
to be significantly inversely correlated in both AML cell line and AML patient samples. 
In addition, various prediction databases predicted microRNA miR-24 to have binding 
site on the 3’UTR of DCTD mRNA. We also decided to validate the interaction between 
DCK and miR-34a. In silico analysis predicted miR-24-3p and miR-34a-5p might form 
complexes with target sequences in the 3’UTR of DCTD and DCK respectively with 
minimum free energies of binding of -27.2 kcal/mol for DCTD and miR-24-3p (Figure 
3.4A) and -25.6 kcal/mol for DCK and miR-34a-5p (Figure 3.5A). The RNA EMSA 
results for IRD-800 ®-labeled DCTD and Cy-5-labeled miR-24-3p show miR-24a-3p 
was able to bind to its target sequence on DCTD 3’UTR (Figure 3.4B, lane 3) as seen by 
the band shift. The thermodynamic stability of this complex correlated with binding 
observed in the RNA EMSA assays. In addition, we found that mRNA-microRNA 
complex formed by DCTD and miR-24a-3p could be eliminated by adding excess 
unlabeled hsa-miR-24a-3p probe (Figure 3.4B, lane 4), but not by adding excess 
unlabeled non-specific probe (Figure 3.4B, lane 6). Adding excess unlabeled mRNA 
probe resulted in binding of all the labeled microRNA giving a greater intensity signal 
(Figures 3.4B, lane 5).  
Similar to the interaction observed between DCTD and miR-24a-3p, we observed that 
miR-34a-5p binds to DCK 3’UTR as seen by shift in the band (Figure 3.5B, lane 3) and 
this interaction was eliminated by addition of unlabeled probe (Figure 3.5B, lane 4). 
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3.4. Discussion 
 Nucleoside analogs are synthetic analogs of endogenous nucleosides that largely used for 
the treatment of hematological malignancies and solid tumors. Cytarabine, a pyrimidine 
nucleoside analog is the backbone of AML chemotherapy, while a second-generation 
purine nucleoside analog, clofarabine is currently being investigated for treatment of 
AML in various clinical trials. Both cytarabine and clofarabine require active transport 
into the cell by nucleoside transporters, followed by activation by various kinases to form 
di- and tri-phosphate metabolites that are incorporated in growing DNA strand and/or 
inhibit various enzymes involved in synthesis of endogenous nucleotides (Figure 3.1). 
However, despite being the backbone of treatment regimen used in AML patients for 
several decades, there is wide variation in AML patients in response to cytarabine. In our 
previous study (Chapter II), we have demonstrated that microRNA expression is 
predictive of response to cytarabine therapy in AML patients and is also significantly 
associated with in vitro chemosensitivity of cytarabine in AML cell lines. In the current 
chapter, we wanted to determine if microRNA mediated regulation of genes involved in 
cytarabine transporter, activation/inactivation could contribute to development of 
resistance in AML. We hypothesized that microRNAs could bind to the 3’UTR of the 
cytarabine metabolic pathway genes, thereby altering their expression, which in turn 
would result in alterations in intracellular levels of active NA triphosphate, resulting in 
chemoresistance. To the best of our knowledge, this is the first study that has determined 
the effect of microRNA on the expression of the entire metabolic pathway of nucleoside 
analogs.  
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In our current study, DCK expression was negatively correlated with the expression of 
miR-34a-5p and miR-96-5p in AML cell lines (p-value < 0.01). DCK is a rate-limiting 
enzyme that is involved in activation of cytarabine, clofarabine and other nucleoside 
analogs. Studies have reported that decreased or complete loss of DCK activity results in 
cellular resistance to cytarabine [11-13]. Also DCK mRNA expression has been shown to 
be positively associated with AML patient outcome, AML patients with higher DCK 
mRNA expression had longer event-free survival than those with lower DCK mRNA 
expression [14]. Various studied have identified multiple single nucleotide 
polymorphisms (SNPs) in the proximal promoter region, coding region as well as the 
intronic region of the DCK gene, which were associated with the DCK mRNA expression 
[15], or DCK activity [16]. Till date only one study has demonstrated the effect of 
microRNA expression on DCK, suggesting a possible role of miR-330 in the post-
transcriptional regulation of DCK [17]. In the current study, using RNA EMSA, we were 
able to show that miR-34a-5p by binding to the 3’-UTR regulates expression of DCK. 
MicroRNA miR-34a has been extensively studied in various cancers [18-22] and it has 
been shown to play an important role as a tumor suppressor by targeting various genes. 
However, the effect of miR-34a on DCK expression has not yet been studied. 
Identification of this additional regulatory mechanism for an important enzyme in the 
activation of nucleoside analogs could help in better prediction of chemosensitivity of 
these drugs. We also identified miR-24-3p to be negatively correlated with the expression 
of DCTD in both AML cell lines and in AML patient samples (p-value<0.01). In 
addition, multiple bioinformatic prediction programs identified a binding site for hsa-
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miR-24-3p on the 3’UTR of DCTD. Our RNA EMSA results confirmed the binding 
interaction between DCTD and miR-24-3p. DCTD is an enzyme involved in deamination 
of the monophosphate form of the nucleoside analog, thus inactivating the drug. The 
levels of DCTD could thus affect the levels of the intracellular active triphosphate 
metabolites of nucleoside analogs. However, the role of DCTD in chemosensitivity of 
nucleoside analogs is poorly defined. Various studies have demonstrated a significant 
role of DCTD in metabolism of the monophosphate metabolite of the nucleoside analogs 
in human leukemia cells [23-25]. Sequencing of this gene identified a nonsynonymous 
SNP affecting the activity of DCTD in vitro [26]. Hence, the limited data on the 
regulation of DCTD gene warrants identification of additional mechanism of regulation 
of this gene. MicroRNA miR-24 is has also been extensively studied in various cancers 
[27-33] and has been shown to enhance metastasis and invasion. Increased expression of 
miR-24 has been associated with increased risk of relapse and poor survival in ALL [31]. 
In addition to miR-24 and miR-34a-5p, we also identified multiple miRNAs that 
correlated with multiple genes in the PK/PD pathway (Table 3.1 and Table 3.2). While, 
these miRNAs individually did not correlate with overall survival in patients from TCGA 
database (Chapter II), they along with other miRNAs can potentially contribute to the 
development of resistance in patients treated with cytarabine or clofarabine. 
In summary, we identified several microRNAs, which were significantly associated with 
the expression of nucleoside analog pathway genes in vitro as well as in vivo. 
Identification of these additional mechanisms of regulation would enhance our 
understanding of the variability in the expression of these enzymes and transporters and 
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in turn, help in better prediction of therapeutic response in AML patients. While 
additional functional studies are required to gain mechanistic understanding of these 
microRNA-mRNA interactions and its effect on the protein levels and activity, this study 
helps identify candidate microRNAs for further studies. 
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Fig 3.1: PK/PD Pathway of Nucleoside Analogs: Cytarabine and Clofarabine 
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Figure 3.2: Constructing microRNA-mRNA network using CyTargetLinker. 
MicroRNAs associated with the nucleoside analog metabolic pathway genes. 
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Figure 3.3: Correlation of microRNAs with nucleoside analog pathway gene expression in AML cell lines and patient samples 
from TCGA database. (A) Correlation between DCTD and hsa-miR-24a-3p. (B) Correlation between DCK and hsa-miR-34a-5p. (C) 
Correlation between CTPS1 and hsa-miR-181a. (D) Correlation between CDA and hsa-miR-23a. (E) Correlation between NT5C3 and 
hsa-miR-149. 
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Figure 3.4: Validation of binding interaction between DCTD mRNA and hsa-miR-24-3p by RNA EMSAs. RNA EMSA with 
cy5-labeled hsa-miR-24-3p oligonucleotide and 2’-O-methyl modified and IRD-800 labeled DCTD mRNA oligonucleotide. Lanes 1 
and 2 show the mobility of the labeled mRNA or microRNA oligonucleotide. Lane 3 shows the mobility of the labeled hsa-miR-24-3p 
oligonucleotide with DCTD mRNA oligonucleotide. Lanes 4 and 6 show the mobility of labeled DCTD mRNA oligonucleotide in 
presence of unlabeled excess specific competitor (hsa-miR-24-3p) and excess unlabeled non-specific competitor (NC) 
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Figure 3.5: Validation of binding interaction between DCK mRNA and hsa-miR-34a-5p by RNA EMSAs. RNA EMSA with 
cy5-labeled hsa-miR-34a-5p oligonucleotide and 2’-O-methyl modified and IRD-800 labeled DCK mRNA oligonucleotide. Lanes 1 
and 2 show the mobility of the labeled mRNA or microRNA oligonucleotide. Lane 3 shows the mobility of the labeled hsa-miR-34a-
5p oligonucleotide with DCK mRNA oligonucleotide. Lanes 4 and 6 show the mobility of labeled DCK mRNA oligonucleotide in 
presence of unlabeled excess specific competitor (hsa-miR-34a-5p) and excess unlabeled non-specific competitor (NC) 
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Supplementary figure 3.1: Comparison of microRNA prediction programs for predicting binding sites on nucleoside analog pathway 
genes.
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Table 3.1: MicroRNAs significantly associated with nucleoside analog pathway genes in 
AML Cell lines 
 
Pathway Genes MicroRNAs Spearman r P value 
CDA hsa-miR-23a-3p 0.9524 0.0011 
DCTD hsa-miR-24-3p -0.9341 0.0011 
CTPS hsa-miR-181a-5p 0.8743 0.0072 
DCK hsa-miR-96-5p -0.9048 0.0046 
DCK hsa-miR-34a-5p -0.8810 0.0072 
NT5C3 hsa-miR-149-5p -0.8810 0.0072 
RRM2 hsa-let-7g-5p 0.9762 0.0004 
RRM2 hsa-miR-151a-3p -0.9524 0.0011 
RRM2 hsa-miR-142-3p 0.9048 0.0046 
RRM2B hsa-miR-194-5p -0.8810 0.0072 
CMPK hsa-miR-1301 -0.9762 0.0004 
CMPK hsa-miR-320e -0.9524 0.0011 
CMPK hsa-miR-1323 -0.9286 0.0022 
CMPK hsa-miR-584-5p -0.9286 0.0022 
CMPK hsa-miR-30d-5p 0.9048 0.0046 
CMPK hsa-miR-381 -0.8810 0.0072 
CMPK hsa-miR-507 -0.8810 0.0072 
CMPK hsa-miR-605 -0.8810 0.0072 
CMPK hsa-miR-762 -0.8810 0.0072 
CMPK hsa-miR-769-3p -0.8810 0.0072 
CMPK hsa-miR-891a -0.8810 0.0072 
NME1 hsa-miR-514b-5p -0.9286 0.0022 
NME1 hsa-miR-542-3p -0.9286 0.0022 
NME1 hsa-miR-570-3p -0.9048 0.0046 
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NME1 hsa-miR-646 -0.9048 0.0046 
NME1 hsa-let-7e-5p 0.8810 0.0072 
NME1 hsa-miR-224-5p -0.8810 0.0072 
NME1 hsa-miR-761 -0.8810 0.0072 
NME1 hsa-miR-767-5p -0.8810 0.0072 
SLC28A1 hsa-miR-548aa -0.9643 0.0028 
SLC28A3 hsa-miR-448 -0.9643 0.0028 
 
 
Table 3.2: Common MicroRNAs significantly associated with nucleoside analog 
pathway genes in TCGA database and in vitro study 
 
Gene Gene Probe ID MicroRNAs Spearman r P value 
CDA 205627_at hsa-mir-23a 0.3731 0.0000 
DCTD 201572_x_at hsa-mir-24-2 -0.2153 0.0032 
DCTD 210137_s_at hsa-mir-24-2 -0.2091 0.0042 
CTPS 202613_at hsa-mir-181a-2 0.2359 0.0012 
NT5C3 240128_at hsa-mir-149 -0.2502 0.0006 
 
 
Table 3.3: Free Energy Calculation Analysis of the interaction between microRNAs and 
mRNAs 
mRNA + microRNA pair Minimum Free Energy (mfe)  (kcal/mol) 
DCTD + hsa-miR-24-3p -27.2 
DCK + hsa-miR-34a-5p -25.6 
DCK + hsa-miR-96-5p -24.3 
NT5C3 + hsa-miR-149-5p -21.4 
CDA + hsa-miR-23a-3p -19.0 
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RRM2 + hsa-miR-151a-3p -26.4 
RRM2B + hsa-miR-194-5p -21.6 
CMPK1 + hsa-miR-1301 -23.6 
CMPK1 + hsa-miR-320e -20.1 
CMPK1 + hsa-miR-1323 -22.3 
CMPK1 + hsa-miR-584-5p -23.7 
CMPK1 + hsa-miR-381 -25.8 
CMPK1 + hsa-miR-507 -19.1 
CMPK1 + hsa-miR-605 -23.1 
CMPK1 + hsa-miR-762 -29.2 
CMPK1 + hsa-miR-769-3p -27.6 
CMPK1 + hsa-miR-891a -22.9 
NME1 + hsa-miR-514b-5p -22.0 
NME1 + hsa-miR-542-3p -19.3 
NME1 + hsa-miR-570-3p -22.2 
NME1 + hsa-miR-646 -25.9 
NME1 + hsa-miR-224-5p -17.9 
NME1 + hsa-miR-761 -24.3 
NME1 + hsa-miR-767-5p -28.8 
SLC28A1 + hsa-miR-548aa -16.3 
SLC28A3 + hsa-miR-448 -23.8 
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CHAPTER IV  
Clinical Significance of In Vivo Cytarabine-induced Gene Expression Signature in 
AML 
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4.1. Abstract 
Despite initial remission, ~60–70% of adult and 30% of pediatric patients experience 
relapse or refractory AML. Studies so far have identified base line gene expression 
profiles of pathogenic and prognostic significance in AML; however, the extent of 
change in gene expression post-initiation of treatment has not been investigated. 
Exposure of leukemic cells to chemotherapeutic agents such as cytarabine, a mainstay of 
AML chemotherapy, can trigger adaptive response by influencing leukemic cell 
transcriptome and, hence, development of resistance or refractory disease. It is, however, 
challenging to perform such a study due to lack of availability of specimens post-drug 
treatment. The primary objective of this study was to identify in vivo cytarabine-induced 
changes in leukemia cell transcriptome and to evaluate their impact on clinical outcome. 
The results highlight genes relevant to cytarabine resistance and support the concept of 
targeting cytarabine-induced genes as a means of improving response. 
 
4.2. Introduction 
In treating AML, refractory disease remains the greatest challenge. Despite initial 
remission, approximately 60-70% of adult patients and 30% of pediatric patients will die 
of relapse and refractory AML [1, 2]. Moreover, standard chemotherapy treatment with 
cytarabine and anthracyclines cause significant adverse events including 
myelosuppression, high risk for infections, need for transfusions, mucositis, 
neurotoxicity, and cardiotoxicity [3, 4]. Anti-leukemia drugs such as cytarabine act intra-
cellularly by incorporation into DNA. Inefficient cellular uptake, reduced intracellular 
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activation, increased degradation, or expansion of the dNTP pools could result in 
development of cellular resistance to cytarabine [5]. Although intracellular cytarabine-
triphosphate levels correlate with AML response and small increases in cytarabine-
triphosphate result in increased AML cell-cytotoxic effect, prior attempts in AML 
patients to increase cytarabine dosing did not improve clinical outcomes [6]. Together, 
these data suggest that cytarabine resistance involves other mechanisms. 
Previously, we used gene-expression array to identify diagnostic AML cell gene-
expression signatures predictive of in vitro and in vivo response to chemotherapy [7]. 
This study demonstrated a validated method of integrating genomic-data at diagnosis 
with important pharmacologic and clinical outcomes. Based on this experience, we 
reasoned that examining gene-expression changes in AML cells after exposure to 
cytarabine would provide additional information regarding intracellular response to 
treatment. However efforts to study in vivo leukemic cell gene expression changes 
induced by chemotherapy has been relatively limited. This is primarily due to technical 
difficulty in obtaining samples at adequate time and in enough quantity to study 
transcriptomic changes. Our study is unique in this aspect as it reports in vivo cytarabine 
induced gene expression levels in leukemic cells obtained at diagnosis and 24 hr post-
cytarabine infusion. Additionally, we also report gene-expression changes corresponding 
to worse outcomes may explain mechanisms of refractory disease and may serve as 
potential targets for enhancing response to cytarabine. 
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4.3. Materials and Methods 
4.3.1. Study Population: Twenty-four de novo AML patients enrolled on AML02 trial 
(clinicaltrials.gov identifier NCT00136084) with matched specimens available at 
diagnosis (pre-treatment) and 24 hours after the start of first dose cytarabine were 
included in this study [6]. Patients with acute promyelocytic leukemia or Down’s 
syndrome were excluded. Patients were randomly assigned to receive induction 1 therapy 
consisting of high-dose (3 g/m2, days 1, 3 and 5) or low-dose (100 mg/m2, days 1-10) 
cytarabine along with daunorubicin (50mg/m2, days 2, 4 and 6) and etoposide (days 2-6) 
by intravenous infusion. Subsequent therapy was adapted based on diagnostic risk 
features and induction 1 response measured as minimal residual disease (MRD) as 
assessed by flow cytometry. The details of study design and clinical outcome are 
described elsewhere [6]. St. Jude Institutional Review Board approved the study, and 
informed consent was obtained from parents/guardians and consents/assents from the 
individuals themselves when appropriate. 
4.3.2. Specimen Collection and AML Cell Enrichment: Bone marrow was aspirated 
at diagnosis (pre-treatment) and 24 h after the start of first dose cytarabine. Enrichment 
for AML cells was performed using Ficoll-Hypaque density-gradient centrifugation, as 
previously described [8]. If necessary, specimens were further enriched to achieve > 80% 
blasts by immunomagnetic sorting (Miltenyi Biotech, Bergisch Gladbach, Germany). 
4.3.3. Gene Expression Profiling: Gene expression profiling of AML cells was 
performed using GeneChip® Human Genome U133 Plus 2.0 Array (Affymetrix, Santa 
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Clara, CA). Details regarding RNA isolation, labeling of cRNA, and scanning of 
Affymetrix arrays have been published previously [9]. 
4.3.4. Pharmacology Measurements: AML cells from diagnostic bone marrow 
specimens were treated in vitro with various concentrations of cytarabine (range, 0.002 – 
2.5 ng/ȝL) followed by MTT assays to determine the median lethal concentration (LC50) 
value as previously described [7, 9]. 
4.3.5. Clinical Outcomes: Patients were classified as having low-risk AML if the AML 
cells harbored t(8;21), inv(16), or t(9;11) chromosome abnormalities. High-risk AML 
included those with del(7), FLT3-ITD mutation, t(6;9), megakaryoblastic AML, 
treatment-related AML, or AML arising from MDS. All other patients were classified as 
standard-risk AML. IWG AML response criteria were used to classify clinical responses 
[10]. Flow cytometry was used to measure minimal residual disease (MRD at day 22), as 
previously described [11]. MRD was defined as 1 or more AML cells per 1000 bone 
marrow mononuclear cells (i.e.,  0.1%). Overall study design, patient characteristics and 
details of endpoints are provided in Table 4.1 and Supplementary Figure-4.1S shows 
overall study schema. 
4.3.6. Statistical Analysis: For each subject and each probe-set, the expression-change 
was defined as the log-transformed MAS5.0 normalized signal of the 24-hour sample 
minus that of the baseline sample so that a positive/negative change indicates that 
expression increased (decreased) from baseline to post-cytarabine infusion. 
An arm-stratified signed-rank test was used to identify probe-sets with significant 
expression changes for both arms and the rank-sum test was used to identify probe-sets 
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with expression changes that differed significantly between cytarabine treatment arms. 
The following statistical testing procedure was performed for each probe-set.  The 
Wilcoxon signed-rank test statistic was computed from the expression changes separately 
for each arm.  We also computed the expected value and variance of these statistics under 
the null hypothesis that the median expression change in the population equals zero.  The 
final z-statistic was computed by subtracting the sum of the null expectations from the 
sum of the signed-rank statistics and dividing the result by the square root of the sum of 
the null variances.  A final p-value was computed by comparing the final z-statistic to the 
standard normal distribution. 
For each probe-set, the rank-sum test statistic was computed to test the null hypothesis 
that the two arms had equal median expression changes.  The p-value was determined by 
comparing the observed statistic to a set of statistics obtained by 10,000 random 
permutations of the assignment of the arm label to ranks of the expression change values.  
The expected value and variance of the rank-sum statistics under the null hypothesis were 
used to z-transform the rank-sum statistic. 
PRojection-Onto-the-Most-Interesting-Statistical-Evidence (PROMISE) [12] was used to 
explore the association of expression changes with LC50, MRD, and EFS.  Event-free 
survival (EFS) was defined as the time elapsed from protocol enrollment to the earliest of 
disease resistance, relapse, death, development of a second malignancy or death, with 
times for subjects living and free of these treatment failures censored at last follow-up.  
For this analysis, MRD was numerically represented as 0 (no detectable disease), 1 
(between 0.1% and 1% of cells are leukemic), or 2 (>1% of cells are leukemic).  An arm-
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stratified Spearman-rank correlation statistic was used to characterize the association of 
expression changes with LC50 and MRD.  The sign of this statistic indicates the direction 
of association of the expression change with these two endpoints.  The statistic of Jung et 
al. [13] was used to characterize the association of expression changes with the duration 
of EFS.  A positive value of this statistic indicates that an increased expression value 
associates with longer EFS.  For each probe-set, the PROMISE statistic was defined as 
the sum of the LC50 association statistic and the MRD association statistic minus the 
EFS association statistic.  A positive value of the PROMISE statistic indicates a 
beneficial pattern of association in the sense that a greater expression change value 
associates with lower LC50 (greater sensitivity to cytarabine), lower MRD (less residual 
disease after one course), and a lower rate of EFS treatment failures.  A negative value of 
the PROMISE statistic indicates a detrimental pattern of association in the sense that a 
greater expression change value associates with greater LC50 (greater resistance to 
cytarabine), greater MRD (more residual disease after one course), and a greater rate of 
EFS treatment failures.  P-values were determined by 10,000 arm-stratified permutations 
of the assignment of the entire expression change profile to the vector of endpoint data 
values. For each analysis described above, the robust FDR method of Pounds and Cheng 
[14] was applied to the p-values to obtain estimates of the false discovery rate.  These 
estimates are reported as q-values. 
4.3.7. In vitro validation by siRNA mediated knock down of selected genes: 
Fourteen genes identified in PR2 analysis, five from PR3 analysis and five that were 
significant in both PR2 and PR3 analysis were targeted by a rapid and high-throughput 
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siRNA-drug modifier screening in THP-1 cell lines. THP-1 cells were transfected with 
three individual siRNAs per selected gene and was tested alongside standard transfection 
controls (three replicate experimental plates were utilized). DCK was used as a positive 
control. Since DCK is a rate-limiting enzyme in activation of cytarabine to cytarabine 
monophosphate, its knock down should increase drug resistance. Post-siRNA 
transfection, cells were treated with different concentrations of cytarabine (0µM; 0.1µM-
IC10; 0.8µM-IC50; and 10µM-IC90) for 48 hours, followed by multi-parametric nuclear 
morphometry assays using automated microscopy to document the individual and 
combined phenotypic effects of siRNA gene silencing and cytarabine on cell growth and 
proliferation. The following definiteness parameters were used to quantify changes in 
nuclear morphometry:  
i) Number of nuclei, absolute number of nuclei per image field, indication of 
cell proliferative activity;  
ii) Condensed nuclei index (% condensed nuclei), the percentage of nuclei 
classified as having condensed chromatin (defined by intensity and 
granularity). Serves as an indication of apoptotic and mitotic nuclei;  
iii) Aberrant nuclei index (% deformed “aberrant nuclei), the percentage of nuclei 
classified as misshapen (defined by circularity and elliptical fit);  
iv) Large nuclei index (% large nuclei), based on a size cut-off.  
v) Small nuclei index (% small nuclei) based on a size cut-off.  
Normalization of all well means was done using corresponding negative controls per cell 
line, time-point and compound concentration. For controls, median and standard 
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deviation of three normalized wells per plate, determination of %CV as an expression of 
intra-plate variation was done. Median and standard deviation of individual normalized 
wells over three replicate plates and determination of %CV as an expression of inter-plate 
variation, were in the acceptable range. Normalized siRNA effect on compound-treated 
cells [normalized well means (IC10; IC50 or IC90) / normalized well means (buffer 
control)] was determined. 
Two methods were utilized to determine siRNA mediated effect.  
• RSA ranking: The hit selection algorithm, RSA or “redundant siRNA activity”, uses 
an interactive hypergeometric distribution formula to calculate the statistical 
significance of the siRNA phenotypic readout and ranking for individual genes 
(indicated by Log P value). By considering the effect of all three siRNA for a gene, 
and not a single high value siRNA, this algorithm is more sophisticated in its 
handling of outliers. Because it uses ranks, it does not depend on an underlying data 
distribution (e.g., Gaussian). RSA analysis using customized scripts (adapted from 
König et al. [15]) was carried out on normalized siRNA effect on compound-treated 
cells for all readouts. For maximum flexibility of downstream analysis, RSA was run 
“in both directions” considering as positives either high or low values (i.e. increase 
or decrease of phonotypic effect under drug treatment vs. buffer control). Hit 
selection 1 (RSA analysis): Normalized siRNA effect on compound-treated cells was 
determined at all inhibitory concentrations levels independently.  
• Cut-off strategy: A simple way to arrive at a list of hits is to apply a cut-off threshold 
(2 x SD of negative control) for the number of nuclei (normalized siRNA effect on 
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compound-treated cells). Two out of three siRNAs per target gene should pass this 
threshold. 
4.4. Results 
Among the patients included in this study, 25% were classified as low-risk AML, 42% as 
standard-risk, and 33% as high-risk. MRD  0.1 was present in 33% of patients after the 
first cycle of cytarabine induction chemotherapy. 
4.4.1. AML Gene Expression Changes Induced by Cytarabine: An arm-stratified 
signed-rank test was used to identify probe-sets with significant expression changes for 
both arms. We identified 51 genes with significant increase and five genes with 
significant decrease in expression after exposure to cytarabine chemotherapy (p  0.001, 
q = 0.34; Table 4.2). Table 4.2 gives the z-statistic, p-value, and robust FDR estimate (q-
value) for the probe-sets with p  0.001.  A positive z-statistic indicates that expression of 
the probe-set showed a significant increase during the cytarabine infusion and a negative 
z-statistic indicates that expression of the probe-set showed significant decrease during 
the cytarabine infusion.  
Several genes hold strong potential for biological and clinical relevance. Specifically, we 
found change in expression of the DNA excision repair genes DDB2 (1.9-fold increase, p 
= 0.0003,q = 0.12) and ERCC1 (1.4-fold decrease, p = 0.0006,q = 0.34) after cytarabine. 
Components of the PI3K/Akt activation pathway, including AKTIP showed increased 
expression after cytarabine (p = 0.0002,q = 0.12). STAT1 and STAT3, signal transducer 
and transcription activators involved in multiple pathways (FLT3 signaling, MAPK and 
Jak/Stat signaling pathways, etc.), were increased post cytarabine treatment (p = 0.0007 
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and 0.001, respectively). Among other genes of significant biological/clinical interest that 
were increased in expression by cytarabine (p < 0.001) included FYN, a member of 
tyrosine kinase oncogene family, MAX-MYC associated protein is an oncoprotein, 
CDKN1A (p21CIP1), a cyclin dependent kinase inhibitor; GTPAses-GIMAP4 and 
GIMAP6, transmembrane receptors (TNFRS10B, TNFRS25, CLEC4A and CD3E) 
involved in regulating caspases, protein phosphatases (PPP2R2B and DUSP5); 
transporters (ATP6V1C1 and SLC4A1), transcription regulators (KMT2A, SIX2,TRIP4, 
ZKSCAN1). Analysis by Ingenuity pathway analysis tool mapped these genes to Tec 
Kinase, JAK/Stat, ERK/MAPK, Prolactin and Ephrin, IL22 and CTLA4 signaling 
pathways (Figure 4.1). 
4.4.2. Effect of cytarabine dose gene expression changes: To determine whether 
cytarabine dose impacted changes in gene-expression, patients were categorized into two 
groups (high dose vs. low dose) according to the cytarabine dose received during first-
induction chemotherapy. The two groups did not differ in age, sex, race, or molecular-
translocations (Table 4.1). Changes in AML cell gene-expression were not different 
between the two treatment groups, after consideration of multiple testing (q = 1.0; 
Supplementary Table 4.1S). This result is congruent with the AML02 clinical trial 
results, which demonstrated no significant differences in day 22 MRD levels or EFS 
between the two randomized doses of cytarabine [6]. 
4.4.3. PROMISE Analysis: We then used the PROMISE statistical procedure to 
identify gene with expression changes that were associated with detrimental outcomes 
(higher LC50, positive MRD at day 22, and a longer event-free survival time period) OR 
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beneficial outcomes (lower LC50, negative MRD, shorter EFS). When analyzing for all 
three outcomes of interest (PR3 analysis), 65 genes were significantly (p  0.001, q=0.32) 
associated with beneficial or detrimental outcome. Thirteen of 65 (20%) genes were 
associated with detrimental response and 52/65 genes were associated with beneficial 
response (p < 0.001, and Figure 4.2A). Because LC50 data was unavailable for some 
study participants (n = 16), we performed PROMISE analysis with two clinical outcomes 
of interest (MRD and EFS: PR2 analysis). In this analysis, we identified 32 genes as 
significantly associated with clinical response (p  0.001, q=0.72,  Figure 4.2B). None of 
identified genes in this study associated with AML risk group assigned at diagnosis (p > 
0.05 for each gene). Genes with significant association at q < 0.3 are summarized in 
Tables 4.3 and 4.4. Figures 4.3A-D illustrates the association of the expression changes 
of selected probe-sets (identified in PR2/ PR3 analysis) with MRD and event free 
survival (EFS). PB1, polybromo1, was the top gene in PR2 analysis with expression 
change predictive of MRD22 and EFS (PR2, p = 0.000; MRD p = 0.0026; EFS p = 
0.0005, Figure 4.3A). PB1 is involved in transcriptional activation and repression of 
genes involved in chromatin remodeling and acts as a negative regulator of cell 
proliferation. Change in TRIM33, a transcriptional repressor with a role in cell 
proliferation, was associated with a favorable outcome (PR3, p = 0.0001, q = 0.117; EFS 
p = 0.0001; MRD p = 0.0238, Figure 4.3B). TRIM33 has been shown to mediate 
erythroid differentiation of hematopoietic stem/progenitor in response to TGFȕ [16]. 
Similarly MLNR expression change was also predictive of clinical outcome,  (PR2, p = 
0.0001; MRD p  0.0001 and EFS p = 0.02, Figure 4.3C). Increased expression of 
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APOBEC2, a cytidine-deaminase family member was associated with a beneficial pattern 
of association (PR3, p < 0.0001, q = 0; EFS p = 0.01; MRD p = 0.009; Figure 4.3D). 
HLA-DQA1- belonging to HLA class II alpha chain paralogues was associated with 
unfavorable outcome (PR2, p = 0.002; EFS p = 0.04 and MRD p = 0.0004); haplotypes 
within this and other members of the HLA family have been implicated in the risk of 
developing CML and ALL [17, 18]. An increase in the expression of RUNX2 (AML3), a 
member of the RUNX family, showed a beneficial association pattern (PR2, p = 0.0006, 
q = 0.51; MRD p = 0.0008). Fusion of the RUNX family gene RUNX1 with ETO is 
considered a low-risk feature that is associated with a better prognosis [19]. Increased 
expression of the nuclear oncogene SET showed a detrimental association pattern (PR3, p 
= 0.0007, q = 0.30; MRD p=0.01). Increased expression of DKK3, a tumor suppressor 
that inhibits WNT oncogenic signaling and is involved in the regulation of mortalization-
related gene expression [20], showed a beneficial association pattern (PR2, p = 0.0008; 
EFS p = 0.0017; MRD p = 0.03). 
4.4.4. In vitro validation of selected genes using siRNA mediated knockdown: After 
identifying inducible genes that were also associated with clinical importance, we next 
questioned whether targeting these genes could modify leukemia response to cytarabine. 
Fourteen genes identified in PR2 analysis, five from PR3 analysis and five that were 
significant in both PR2 and PR3 analysis were targeted by a rapid and high-throughput 
siRNA-drug modifier screening in THP-1 cell lines (Table 4.5). Each gene was targeted 
with three individual siRNAs and was tested alongside standard transfection controls 
(DCK was used as a positive control). Post-siRNA transfection, cells were treated with 
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different concentrations of cytarabine (0µM; 0.1µM-IC10; 0.8µM-IC50; and 10µM-
IC90) followed by multi-parametric nuclear morphometry assay using automated 
microscopy to document the individual and combined phenotypic effects of siRNA gene 
silencing and cytarabine on cell growth and proliferation. siRNA mediated knockdown of 
CHI3L, NFKB2, APOBEC3G, REPIN1, or DOCK6 increased cytarabine-sensitivity; 
while knockdown of ADRBK1, NPAS3, SCARB1, TIGD6, or TNC, increased 
cytarabine-resistance (Table 4.5). 
 
4.5. Discussion 
In this study we examined cytarabine induced in vivo gene expression changes in 
pediatric AML patients. Most of the studies in literature have focused on gene expression 
profiling of the of diagnostic chemo naïve tumor specimens. The knowledge gained from 
gene expression signature identified in diagnostic specimens have opened up 
opportunities for biomarker identification as well as identification of potential targets of 
drug development. In our previous work we have used gene expression array to identify 
an AML cell gene expression signature that predicts intracellular ara-CTP concentration 
and clinical response to chemotherapy [7]. This study demonstrated a validated method 
of integrating genomic data at the time of diagnosis with important pharmacologic and 
clinical outcomes. Based on this experience and the gene expression changes by 
chemotherapy, we reasoned that examining gene expression changes in AML cells after 
exposure to cytarabine would provide relevant information regarding intracellular 
response to treatment. However there is no study to the best of our knowledge that reports 
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in vivo gene expression changes induced by cytarabine. One of the challenges to perform 
such a study is technical difficulty in obtaining clinical samples especially post treatment. 
One of the unique and significant feature of our study was availability of bone marrow 
samples 24hr post initiation of cytarabine infusion, since no other chemotherapeutic agent 
was yet initiated, samples obtained at this time point reflect gene expression differences 
unique to cytarabine. To the best of our knowledge, this is the first study reporting in vivo 
gene-expression changes that occur during cytarabine treatment in pediatric AML 
patients.  
Our analysis of gene expression changes post cytarabine treatment identified genes of 
biological interest such as components of PI3K/AKT pathway such as AKTIP, genes 
involved in DNA repair DDB2 and ERCC1. AKTIP regulates protein kinase B 
(PKB)/Akt signaling (critical for cell growth, glucose-metabolism, and apoptosis) by 
enhancing the phosphorylation of PKB regulatory sites [14]. This result confirms and 
extends findings from our previous work that showed significant correlation between 
diagnostic AML cell gene expression of PIK3C3 (involved in the 
PI3K/PTEN/Akt/mTOR signaling cascade) and worse clinical outcomes [7]. 
Identification of genes that were mapped to Tech signaling is of potential interest given 
that fact that Bruton’s Tyrosine Kinase (BTK), a member of Tec kinase family and a key 
regulator of B-cell Receptor (BCR) is being explored as a potential target in lymphoma 
and leukemia [21]. Pharmacological screening of ibrutinib as inhibitor of BTK kinase has 
shown promising results in AML warranting clinical evaluation [22]. Interestingly we did 
not observed significant impact of cytarabine dose on gene-expression change; this was 
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consistent with the clinical outcome that demonstrated no significant difference between 
the two randomized doses of cytarabine.  
Additionally, gene expression changes corresponding to worse outcomes may explain 
mechanisms of refractory disease and may serve as potential targets for enhancing 
response to cytarabine. The PROMISE method to identify gene expression changes that 
are predictive of clinically meaningful pattern of association with multiple endpoints 
identified 65 genes in PR3 (LC50, MRD and EFS) and 32 in PR2 (MRD and EFS) 
analysis (p < 0.001). Some of the genes of potential interest as novel therapeutic agents 
include: PB1 (aka PBRM1, BAF180), PolyBromo 1 is a bromodomain protein codes for 
a subunit of ATP-depend chromatin remodeling complex (SWI/SNF-A), cytarabine 
induced expression of PB1 to be predictive of better outcome (p < 10-4). PBRM1 
mutations have been found to be frequent in cancer and in renal cell carcinoma 
approximately 40% of tumor samples have been shown to harbor PBRM1 mutations. 
Loss of PB1 expression has been associated with poor prognosis and studies in renal 
carcinoma suggest PBRM1 to be a tumor suppressor by acting as a targeting subunit of 
nucleosome remodeling complex [23-25]. P53 transcriptional activity has also been 
shown to be dependent on PBRM1, thereby resulting in onset of cancer with loss of 
PBRM1 [26-28]. Although PBRM1 has not yet been implicated in pathology or 
prognosis of AML, our results show it as a potential target. Therapeutic manipulation of 
PBRM1 is being explored in renal cell carcinoma and if successful might open up 
opportunities to modify treatment strategies in AML. Another gene belonging to bromo-
domain family is TRIM33, a transcriptional repressor with a role in cell proliferation. 
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TRIM33 is a multifunctional protein implicated in TGFȕ signaling and hematopoietic 
stem cell (HSC) aging by regulating the balance between lymphoid and myeloid derived 
HSCs [29]. In mice lacking TRIM33 premature hematopoietic aging has been implicated 
in predisposition to myeloproliferative disease as CML. TRIM33 has also been shown to 
act in PARP-dependent DNA damage response by timely removal of ACL1 from 
damages chromatin, thereby facilitating DNA repair [30]. Our results are in consensus 
with proposed biological functions of TRIM33 and with supporting evidence form 
literature opens up potential opportunities to develop therapeutic strategies to module 
DNA repair efficiency in tumors lacking TRIM33. Among tumor suppressors, another 
gene of significant clinical value is DKK3, which inhibits WNT oncogenic signaling and 
is involved in the regulation of mortalization-related gene expression [20]. Down-
regulation of DKK3 via promoter hyper-methylation has been associated with poor 
prognosis in ALL [20], which is concordant with our finding that increased expression of 
DKK3 associates with beneficial outcomes. Thus, combining a hypomethylating agent 
such as decitabine with cytarabine might be a strategy to induce expression of DKK3. 
SET, which is a target of translocation in AML and is involved in tumor metastasis, 
chromatin remodeling, apoptosis and the MAP/ERK pathway. SET also inhibits the 
GZMA-activated DNase NME1, a nucleotide diphosphate kinase involved in cytarabine 
activation [31]. SET antagonism has been implicated in overcoming drug-resistance in 
myeloid leukemia [32]. This finding is concordant with our result that increased 
expression of SET is detrimental and suggests JAK2 inhibition as a potential therapeutic 
strategy for AML. 
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DIO2, belongs to family of deiodinases that is involved in thyroid metabolism, 
additionally have been implicated in maintaining balance between proliferation and 
differentiation. A recent study identified seleno-compounds that can module expression 
levels of DIO enzymes, thereby allowing modulation of balance between proliferation 
and differentiation as a therapeutic strategy [33].  
Overall our results for the first time report in vivo cytarabine induced gene-expression 
changes in AML. Since cytarabine was the only drug that patients received at that time, 
the results reflect gene expression changes specific to cytarabine. Drug induced in vivo 
expression changes can often trigger adaptive responses that can contribute to 
development of resistance or refractory disease. Key genes (such as tumor suppressors 
DKK3, TRIM33, PBRM1, an oncogene SET, cytidine-deaminase family members 
APOBEC2 and APOBEC3G) influenced by cytarabine infusion that were also predictive 
of response can serve as potential targets for enhancing therapeutic strategies.  The results 
highlight genes relevant to cytarabine resistance and support the concept of targeting 
genes modulated by cytarabine exposure as a means of improving response. 
Future in depth studies will help in understanding the interplay of these genes/pathways 
to better understand mechanisms of cytarabine resistance in AML. Importantly, novel 
agents directed at these targets may serve as potential therapeutics to improve clinical 
outcomes. In summary, our results identified genes of potential biological and therapeutic 
significance that are influenced by cytarabine treatment, thereby opening up opportunities 
for future research to elucidate the mechanisms underlying AML response/resistance and 
identify targets of development of novel agents.   
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Figure 4.1. Pathway analysis utilizing Ingenuity pathway analysis tool of genes demonstrating significant change in expression 
post-cytarabine infusion in AML patients. (A) Top 10 canonical pathways for genes with significant change in expression post 
cytarabine infusion. Y-axis indicates Log p value (calculated with the right-tailed Fisher's Exact Test) and Ratio (percentage of genes 
in a pathway that were also found in results). The ratio is, therefore, good for looking at which pathway has been affected the most 
based on the percentage of genes uploaded into IPA. (B) The network of these 10 pathways demonstrating interactions between the 
pathways due to shared genes. 
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(A) PR3 Analysis 
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(B) PR2 Analysis
 
Figure 4. 2.Therapeutically beneficial and detrimental patterns of association 
detected by the PROMISE method. (A) The three-endpoint PROMISE analysis (PR3) 
identified 65 probe sets with cytarabine induced changes in expression levels that showed 
a beneficial or detrimental pattern of association with in vitro LC50, MRD and EFS. (B) 
The two-endpoint PROMISE analysis (PR2) identified 33 probe sets with cytarabine 
induced change in expression levels that showed beneficial or detrimental patterns of 
association with MRD and EFS. X-axis values give a log10 p-value with sign defined by 
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the pattern (negative for detrimental and positive for beneficial). Each row represents a 
gene and each column represents a clinical endpoint: MRD and EFS; PR2 indicates the 
statistical values corresponding to the PROMISE analysis. Colors are assigned according 
to the signed log10 p-value. EFS: Event-free survival; MRD: Minimal residual disease; 
PROMISE: Projection onto the Most Interesting Statistical Evidence. 
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Figure 4.3. Association of cytarabine induced change in expression levels of (A) PB1, 
(B) TRIM33, (C) MLNR and (D) APOBEC2 with EFS and MRD (day 22) in AML 
patients. 
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Supplementary Figure 4.1S: Schematic showing overall study design. 
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Table 4.1: Patient characteristics by arm 
Feature HDAC LDAC P value 
Gender 0.089 Female 7 5 
Male 2 10   
Age     0.089 <10 Years 2 10 
>=10 Years 7 5   
WBC     0.657 <50 7 9 
>=50 2 6   
Race   1 Black 1 2 
Other 1 2 
White 7 11   
Cytogenetics     0.277 11q23 4 2 
CBF 3 3 
Normal 1 5 
Other 1 5   
Provisional Risk      0.666 High 2 6 
Low 3 3 
Standard 4 6   
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Table 4.2: List of genes with significant change in expression post ara-C infusion in AML patients. 
Affy probe 
ID 
Gene 
Symbol Gene Name Statistic p-value BH95_q PC06_q 
202284_s_at CDKN1A cyclin-dependent kinase inhibitor 1A [p21, Cip1] 165 0.0000 0.1295 0.1203 
202665_s_at WASPIP HIV-1 Rev binding protein 154 0.0001 0.3179 0.1203 
209294_x_at TNFRSF10B tumor necrosis factor receptor superfamily, member 10b 153 0.0001 0.3179 0.1203 
213316_at KIAA1462 152 0.0001 0.3179 0.1203 
214054_at DOK2 docking protein 2, 56kDa 151 0.0001 0.3179 0.1203 
202872_at ATP6V1C1 ATPase, H+ transporting, lysosomal 42kDa, V1 subunit C1 150 0.0002 0.3179 0.1203 
210105_s_at FYN FYN oncogene related to SRC, FGR, YES 150 0.0002 0.3179 0.1203 
212357_at KIAA0280 150 0.0002 0.3179 0.1203 
201297_s_at MOBK1B MOB1, Mps One Binder kinase activator-like 1B [3][3][2] 150 0.0002 0.3179 0.1203 
221653_x_at APOL2 apolipoprotein L, 2 149 0.0002 0.3179 0.1203 
218373_at AKTIP AKT Interacting Protein 149 0.0002 0.3179 0.1203 
205643_s_at PPP2R2B protein phosphatase 2, regulatory subunit B, beta isoform 149 0.0002 0.3179 0.1203 
212932_at RAB3GAP1 RAB3 GTPase activating protein subunit 1 [3][3][2] 149 0.0002 0.3179 0.1203 
203217_s_at ST3GAL5 ST3 beta-galactoside alpha-2,3-sialyltransferase 5 149 0.0002 0.3179 0.1203 
203409_at DDB2 damage-specific DNA binding protein 2, 48kDa 148 0.0003 0.3179 0.1203 
202270_at GBP1 guanylate binding protein 1, interferon-inducible, 67kDa 148 0.0003 0.3179 0.1203 
215350_at SYNE1 spectrin repeat containing, nuclear envelope 1 148 0.0003 0.3179 0.1203 
214900_at ZKSCAN1 zinc finger with KRAB and SCAN domains 1 148 0.0003 0.3179 0.1203 
219777_at GIMAP6 GTPase, IMAP family member 6 146 0.0004 0.3682 0.2653 
211977_at GPR107 G protein-coupled receptor 107 146 0.0004 0.3682 0.2653 
206765_at KCNJ2 potassium inwardly-rectifying channel, subfamily J, member 2 146 0.0004 0.3682 0.2653 
216069_at PRMT2 protein arginine methyltransferase 2 146 0.0004 0.3682 0.2653 
214006_s_at GGCX gamma-glutamyl carboxylase 145 0.0005 0.3682 0.2834 
219243_at GIMAP4 GTPase, IMAP family member 4 145 0.0005 0.3682 0.2834 
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215255_at IGSF9B immunoglobulin superfamily, member 9B 145 0.0005 0.3682 0.2834 
216841_s_at SOD2 superoxide dismutase 2, mitochondrial 145 0.0005 0.3682 0.2834 
217818_s_at ARPC4 actin related protein 2/3 complex, subunit 4, 20kDa 144 0.0005 0.3682 0.3324 
221042_s_at CLMN calmin [calponin-like, transmembrane] 144 0.0005 0.3682 0.3324 
209457_at DUSP5 dual specificity phosphatase 5 144 0.0005 0.3682 0.3324 
216080_s_at FADS3 fatty acid desaturase 3 144 0.0005 0.3682 0.3324 
218092_s_at HRB HIV-1 Rev binding protein 144 0.0005 0.3682 0.3324 
210734_x_at MAX MYC associated factor X 144 0.0005 0.3682 0.3324 
205456_at CD3E CD3e molecule, epsilon [CD3-TCR complex] 143 0.0007 0.3682 0.3393 
214551_s_at CD7 CD7 molecule 143 0.0007 0.3682 0.3393 
220546_at FLJ11783 143 0.0007 0.3682 0.3393 
209969_s_at STAT1 signal transducer and activator of transcription 1, 91kDa 143 0.0007 0.3682 0.3393 
202748_at GBP2 guanylate binding protein 2, interferon-inducible 142 0.0008 0.3682 0.3419 
202595_s_at LEPROTL1 leptin receptor overlapping transcript-like 1 142 0.0008 0.3682 0.3419 
207705_s_at RP4-691N24.1  142 0.0008 0.3682 0.3419 
208540_x_at S100A11 S100 calcium binding protein A11 pseudogene 142 0.0008 0.3682 0.3419 
214838_at SFT2D2 SFT2 domain containing 2 142 0.0008 0.3682 0.3419 
206511_s_at SIX2 SIX homeobox 2 142 0.0008 0.3682 0.3419 
219423_x_at TNFRSF25 tumor necrosis factor receptor superfamily, member 25 142 0.0008 0.3682 0.3419 
205299_s_at BTN2A2 butyrophilin, subfamily 2, member A2 141 0.0010 0.3682 0.3424 
221724_s_at CLEC4A C-type lectin domain family 4, member A 141 0.0010 0.3682 0.3424 
210968_s_at RTN4 reticulon 4 141 0.0010 0.3682 0.3424 
210569_s_at SIGLEC9 sialic acid binding Ig-like lectin 9 141 0.0010 0.3682 0.3424 
208992_s_at STAT3 signal transducer and activator of transcription 3 141 0.0010 0.3682 0.3424 
203567_s_at TRIM38 tripartite motif-containing 38 141 0.0010 0.3682 0.3424 
203732_at TRIP4 thyroid hormone receptor interactor 4 141 0.0010 0.3682 0.3424 
211422_at TRPM3 transient receptor potential cation channel, subfamily M, member 3 141 0.0010 0.3682 0.3424 
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221747_at* TNS1 tensin 1 4 0.0002 0.3179 0.1203 
203720_s_at* ERCC1 excision repair cross-complementing rodent repair deficiency, complementation group 1 9 0.0005 0.3682 0.3234 
205592_at* IL8 interleukin 8 9 0.0005 0.3682 0.3234 
218225_at* ECSIT ECSIT homolog [Drosophila] 10 0.0007 0.3682 0.3348 
221932_s_at* GLRX5 glutaredoxin 5 10 0.0007 0.3682 0.3348 
 
Note: 
The expected rank (statistic) is 76.5, a statistic greater than 76.5 indicates that there are more positive values in expression 
change (higher median expression at 24 hours). 
*Probes with decrease in expression post-cytarabine. 
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Table 4.3: PROMISE analysis identified genes change in expression post-cytarabine to be predictive of beneficial or detrimental 
patterns of association with clinical endpoints in AML patients (q < 0.3). PROMISE 3 (PR3) analysis utilizing three end-points; LC50, 
MRD22 and EFS 
 
Probe ID Gene Symbol 
LC50 
stat 
MRD22 
stat 
EFS 
stat  
PROMISE 
stat 
LC50 
p value  
MRD22  
p value 
EFS 
p value 
PR3 
p value BH95_q PC06_q 
Risk  
p value 
201088_at KPNA2 0.708 0.568 0.290 -0.522 0.044 0.006 0.136 0.000 0.000 0.000 0.171 
203699_s_at DIO2 -0.708 -0.468 -0.506 0.561 0.040 0.026 0.009 0.000 0.000 0.000 0.472 
205547_s_at TAGLN -0.773 -0.462 -0.447 0.561 0.030 0.026 0.020 0.000 0.000 0.000 0.662 
205569_at LAMP3 -0.773 -0.406 -0.614 0.598 0.028 0.060 0.001 0.000 0.000 0.000 0.686 
206160_at APOBEC2 -0.602 -0.531 -0.493 0.542 0.110 0.010 0.010 0.000 0.000 0.000 0.245 
207366_at KCNS1 -0.773 -0.365 -0.448 0.529 0.024 0.085 0.020 0.000 0.000 0.000 0.879 
209668_x_at CES2 -0.773 -0.537 -0.253 0.521 0.030 0.008 0.203 0.000 0.000 0.000 0.658 
210119_at KCNJ15 -0.773 -0.586 -0.331 0.564 0.027 0.004 0.090 0.000 0.000 0.000 0.531 
220849_at FLJ22659 -0.838 -0.291 -0.549 0.559 0.007 0.177 0.004 0.000 0.000 0.000 0.719 
221793_at DOCK6 -0.708 -0.400 -0.650 0.586 0.043 0.064 0.000 0.000 0.000 0.000 0.886 
201053_s_at PSMF1 0.773 0.403 0.306 -0.494 0.027 0.057 0.116 0.000 0.153 0.118 0.842 
205444_at ATP2A1 -0.773 -0.523 -0.349 0.548 0.029 0.011 0.071 0.000 0.153 0.118 0.259 
207780_at CYLC2 -0.708 -0.435 -0.460 0.534 0.042 0.041 0.017 0.000 0.153 0.118 0.858 
212436_at TRIM33 -0.602 -0.478 -0.668 0.583 0.116 0.024 0.000 0.000 0.153 0.118 0.983 
216708_x_at IGL2 -0.643 -0.520 -0.411 0.525 0.096 0.013 0.033 0.000 0.153 0.118 0.638 
217330_at DISC1 -0.643 -0.307 -0.607 0.519 0.097 0.152 0.001 0.000 0.153 0.118 0.284 
221999_at VRK3 -0.838 -0.504 -0.233 0.525 0.008 0.017 0.246 0.000 0.153 0.118 0.388 
38447_at ADRBK1 -0.643 -0.400 -0.546 0.530 0.091 0.059 0.003 0.000 0.153 0.118 0.809 
208429_x_at HNF4A -0.659 -0.277 -0.549 0.495 0.066 0.200 0.004 0.000 0.217 0.192 0.854 
211920_at CFB -0.643 -0.450 -0.408 0.500 0.097 0.031 0.032 0.000 0.217 0.192 0.943 
214598_at CLDN8 -0.708 -0.579 -0.309 0.532 0.043 0.004 0.114 0.000 0.217 0.192 0.435 
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217857_s_at RBM8A 0.708 0.325 0.530 -0.521 0.042 0.133 0.005 0.000 0.217 0.192 0.476 
202585_s_at NFX1 -0.773 -0.326 -0.427 0.509 0.027 0.132 0.028 0.000 0.278 0.254 0.941 
209966_x_at ESRRG -0.667 -0.417 -0.472 0.519 0.050 0.049 0.013 0.000 0.278 0.254 0.355 
213078_x_at AGPAT7 -0.838 -0.291 -0.372 0.500 0.008 0.172 0.052 0.000 0.278 0.254 0.498 
 
 
Table 4.4: PROMISE analysis identified genes change in expression post-cytarabine to be predictive of beneficial or detrimental 
patterns of association with clinical endpoints in AML patients (q < 0.3). PROMISE 2 (PR2) analysis utilizing two end-points; 
MRD22 and EFS 
 
Probe ID Gene Symbol 
MRD22 
stat EFS stat  
PROMISE 
stat 
MRD22 
p value 
EFS 
p value 
PR2 
p value  BH95_q PC06_q 
Risk  
p value 
221212_x_at PB1 -0.613 -0.635 0.624 0.003 0.001 0.000 0.000 0.000 0.212 
221365_at MLNR -0.611 -0.529 0.570 0.002 0.004 0.000 0.000 0.000 0.284 
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Table 4.5: Effect of siRNA mediated knockdown of selected genes on cytarabine sensitivity in THP1 cells. 
Gene 
symbol 
PROMISE 
analysis 
siRNA-drug modifier 
GENE LEVEL effect 
(RSA ranking based) 
siRNA-drug 
modifier GENE 
LEVEL effect (Cut 
off strategy based) 
Non-neutral 
genes* 
Only one of three 
siRNA influence 
drug response 
ADRBK1 PR3 Increased resistance Increased resistance 
APOBEC2 PR2 and PR3 Increased sensitivity 
APOBEC3G PR2 and PR3 Increased sensitivity non-neutral 
CHI3L1 PR2 Increased sensitivity 
CYLC1 PR2 Increased resistance 
DCK +ve control Increased resistance Increased resistance 
DOCK6 PR2 and PR3 Increased sensitivity 
ENDOD1 PR2 and PR3 Increased resistance 
GDF3 PR2 
GSTA1 PR2 Increased resistance 
KLK13 PR2 
LRRTM4 PR2 Increased resistance 
MARK1 PR3 
MLNR PR2 
NFKB2 PR2 Increased sensitivity 
NPAS3 PR2 Increased resistance non-neutral Increased resistance 
QKI PR3 
RANBP1 PR2 
REPIN1 PR3 Increased sensitivity Increased sensitivity 
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RUNX2 PR2 Increased resistance 
SCARB1 PR2 Increased resistance Increased resistance 
SET PR3 non-neutral 
TIGD6 PR2 Increased resistance Increased resistance 
TNC PR2 Increased resistance 
TRIM33 PR2 and PR3     non-neutral    
 
 
*Note: Non-neutral genes refer to genes, which do yield a detectable RNAi phenotype in the absence of the drug  
(phenotype was sometimes further enhanced post-drug treatment) 
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Supplementary Table 4.1S: List of genes with distinct pattern of expression differences post-cytarabine between LDAC and 
HDAC arms (p < 0.001). 
 
Probe Id  Gene symbol Gene Name  Stat  p-value q-value 
220443_s_at  VAX2 ventral anterior homeobox 2 3.369 0.0006 1 
210139_s_at  PMP22 peripheral myelin protein 22  3.2498 0.0003 1 
200730_s_at  PTP4A1 protein tyrosine phosphatase type IVA, member 1  3.1901 0.0008 1 
201148_s_at  TIMP3 TIMP metallopeptidase inhibitor 3  3.0709 0.0009 1 
203241_at  UVRAG UV radiation resistance associated gene  -3.1901 0.0004 1 
221376_at  FGF17 fibroblast growth factor 17  -3.1901 0.0006 1 
216698_x_at  OR7E47P olfactory receptor, family 7, subfamily E, member 47 pseudo gene -3.3094 0.0006 1 
221378_at  CER1 cerberus 1, cysteine knot superfamily, homolog (Xenopus laevis)  -3.4883 0.0004 1 
 
Note: A positive z-statistic indicates that arm A had a greater median expression change than arm 
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CHAPTER IV [B] 
Drug-Induced Gene Expression and MicroRNA Expression Changes in AML Cell 
lines  
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4.6. Introduction 
Nucleoside analogs are a group of chemotherapeutic drugs, which mimic the endogenous 
nucleotide structurally as well as functionally. Cytarabine, a deoxycytidine analog, is the 
cornerstone of the chemotherapeutic regimens for the treatment of acute myeloid 
leukemia (AML). AML is a very aggressive disease and despite initial remission of the 
disease, the survival rate is very poor, with almost 60% to 70% of adult AML patients 
and 30% of pediatric AML patients die of relapse and/or refractory AML [1, 2]. 
Insufficient cellular uptake of the drug, decreased intracellular activation to the active 
metabolite, increased inactivation or increase of the endogenous deoxynucleotide 
triphosphate pools, which compete with the drug for incorporation in growing DNA 
strand, are potential mechanisms that can result in development of resistance to 
nucleoside analogs, like cytarabine [3]. De novo and acquired resistance to nucleoside 
analogs limit the effectiveness of therapy, and an effort to understand these mechanisms 
are under study. Evidence suggests that AML patients who have increased formation and 
retention of cytarabine triphosphate in leukemic cells experienced increased duration of 
remission after receiving cytarabine-based remission induction and maintenance therapy 
[4, 5]. Attempts to introduce higher doses of cytarabine, did not significantly improve the 
treatment outcomes [6, 7]. Thus, development of resistance to cytarabine could involve 
additional complex mechanisms. Evidence suggests that prolonged in vitro and in vivo 
treatment with cytarabine results in emergence of drug resistance, leading to decreased 
sensitivity and ultimately treatment failure [4, 8-11]. Also, selection of drug-resistant 
leukemic cell population may be associated with changes in malignant properties such as 
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proliferation rate, invasiveness, and immunogenicity. Evidence also indicates that 
chemotherapy with cytarabine and anthracycline results in modulation of wide range of 
proteins including p53 protein activation followed by cell cycle arrest and apoptosis [12-
14]. 
Current search in improving treatment outcomes in AML are primarily focused on 
understanding the factors intrinsic to the leukemic blasts that help predict the outcome in 
patients and their response to the chemotherapy. Studies have determined the specific 
cytogenetic and molecular features, such as core-binding factor mutations, inv (16) and t 
(18; 21) predicting favorable outcome in AML, whereas monsomy 7, del (5q), MLL 
rearrangements and FLT3-ITD mutations to be associated with poor AML prognosis [15, 
16]. Studies have also focused on identifying the gene expression signatures in acute 
myeloid leukemia, in order to better understand the genes with aberrant expression in 
AML blast cells, to identify genes associated with AML prognosis and potential 
therapeutic targets [17]. Multiple independent gene expression-profiling studies in AML 
identified specific gene expression clusters in AML predicting risk stratification along 
with predicting significantly different survival rates [18-20], demonstrating the 
significance of gene-expression profiling in predicting outcomes AML. Gene expression 
profiles in AML blast cells at diagnosis in were evaluated to identify patterns of 
association with various clinical and pharmacological factors of therapeutic importance in 
AML. This study identified genes involved in PI3K/PTEN/AkT/mTOR signaling 
pathway, G-protein-coupled receptor signaling and leukemogenesis to be displaying 
detrimental pattern of association [21]. Another study also able to identify gene 
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expression signature from among the differentially expressed genes between responders 
and non-responders to the first induction therapy, which predicted treatment response in 
these patients [22]. Interestingly, AML disease relapse-specific gene expression signature 
was observed in patients experiencing relapse after high dose cytarabine-based regimens 
compared to untreated AML patients, identifying specific genes and associated pathways 
in contributing to mechanism of recurrent disease [23]. Hence, there is sufficient 
evidence to justify the significance of studying gene expression signatures in AML 
patients in order to better understand the molecular mechanisms of involved in cytarabine 
resistance, in order to improve therapy and possibly reverse drug resistance.  
Gene expression signatures, apart from predicting response to chemotherapy, could also 
help predict information regarding intracellular responses to chemotherapeutic agent. 
Exposure of leukemic cells to cytarabine, which is an antimetabolite, would trigger 
adaptive responses by influencing the cell transcriptomic profile. Understanding these 
chemotherapy-induced gene expression changes might provide additional information 
that might help explain development of acquired resistance to nucleoside analogs like 
cytarabine and hence explain development refractory or relapsed AML. Studies in breast 
cancer patients treated with tamoxifen have identified dynamic gene expression changes 
after early/transient response to tamoxifen treatment, with decreased expression of genes 
involved in cell cycle and proliferation, while continuous/ late response to tamoxifen 
resulted in change in expression of estrogen response genes [24]. In addition, gene 
expression studies in ovarian cancer xenograft models after treatment with carboplatin 
and carboplatin plus paclitaxel, demonstrated distinct transcriptional response following 
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drug treatment, which upregulation of genes involved in DNA repair, cell cycle and 
apoptosis while oxygen-consuming metabolic pathway and apoptosis control genes 
showed decreased expression [25]. However, there is limited knowledge regarding the 
changes in the gene expression in AML cells after exposure to cytarabine. 
Understanding chemotherapy-induced changes in gene expression could potentially have 
an impact on the prognosis of AML as well as help in understanding the mechanisms of 
acquired resistance to cytarabine-based regimens.  
Interestingly, recent evidence also indicated changes in expression of various microRNAs 
in different types of cancers after exposure to cytotoxic stimuli such chemotherapy and 
radiotherapy [26]. Chemotherapy with cisplatin and 5-fluorouracil in esophageal cancer 
was shown to affect the expression of various microRNAs involved in important 
biological networks critical for response to cytotoxic agents [27]. Similarly, rifampin 
treatment in human hepatocytes was demonstrated to both induce and repress the 
expression of hepatic microRNAs, suggesting that rifampin-mediated regulation of drug 
metabolizing enzymes may, in part, be due to altered microRNA expression after 
rifampin treatment [28].  
Since changes in microRNA expression have been shown to be dependent on the type of 
cells as well as the chemotherapeutic drug [29], it is essential to understand the role of 
cytarabine chemotherapy on the expression of microRNAs in leukemic cells. To our 
knowledge, there have been no studies till date investigating the impact of cytarabine-
treatment on changes in gene expression and microRNA expression. In the first section of 
this study, we report the effect of cytarabine treatment at two different concentrations on 
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the changes in microRNA expression in AML cell lines. We also investigated the effect 
of cytarabine treatment on the expression of pathway genes, in order to understand if the 
drug treatment itself can have an impact on its activation or inactivation pathway. Also, 
since it is difficult to obtain matched bone marrow biopsy samples at baseline and post 
cytarabine treatment from AML patients, not many studies have reported the in vivo 
changes in gene expression post cytarabine infusion. We have also reported (Chapter 
IVA) the effect of in vivo cytarabine treatment on the global transcriptome expression 
changes in AML patients. Such information could potentially provide important 
information regarding intracellular responses to treatment as well as development of 
acquired resistance to cytarabine-based regimens. 
 
4.7. Materials and Methods 
4.7.1. Cell Culture and Reagents: The AML cell lines HL-60, MV-4-11, Kasumi-1, 
THP-1, AML-193 and KG-1 cell lines were obtained from American Type Culture 
Collection (ATCC) (Manassas, VA), while MOLM-16 and ME-1 cell lines were obtained 
from DSMZ (Braunschweig, Germany). Kasumi-1, ME-1 and MOLM-16 cell lines were 
cultured in RMPI-1640 medium supplemented with 20% fetal bovine serum (FBS), THP-
1 cell line was cultured in RPMI-1640 medium supplemented with 10% FBS, MV-4-11 
cell line was cultured in IMDM medium supplemented 10% FBS, HL-60 and KG-1 cell 
lines were cultured in IMDM medium supplemented with 20% FBS, while AML-193 cell 
lines was cultured in IMDM medium supplemented with 5% FBS, 0.005 mg/ml insulin, 
0.005 mg/ml transferrin and 5 ng/ml GM-CSF. All the cell lines were maintained in a 
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37°C humidified incubator with 5% CO2. The cells were passaged every 2 to 3 days in 
order to maintain them in logarithmic growth phase. Cytarabine was purchased from 
Sigma Aldrich (St. Louise, MO) and drug dilutions were prepared with sterile water. 
4.7.2. Drug Treatment: The AML cell lines, HL-60, MV-4-11, Kasumi-1, THP-1, 
AML-193, KG-1, MOLM-16 and ME-1 were grown till they reached 80% confluency. 
On the day of the drug treatment the cells were transferred in fresh medium and were 
plated in a 6-well plate at seeding density of 1.0×106 cells/ml. Cytarabine was added to 
the cells at a concentration of 0ȝM (baseline), 1ȝM or 10ȝM. The cells were then 
incubated at 37°C for 24h. The drug concentrations were chosen based on the steady state 
concentrations of the low dose and high dose cytarabine. After 24h, the cell pellets 
collected, washed with PBS and stored in -80°C till further use. 
4.7.3. RNA Isolation: Total RNA was isolated from the AML cell pellets (baseline 
and cytarabine treated samples) using RNeasy Plus Mini Kit (QIAGEN, USA) according 
to the manufacturer’s protocol and stored in -80°C until further analysis. The RNA 
quality and concentration was measured using NanoDrop 2000 UV-Vis 
spectrophotometer (ThermoScientific, USA). The ratio of absorbance at 260 nm and 280 
nm was used to assess RNA sample purity and A260/A280 ratio of 1.8-2.1 was 
considered to be indicative of highly purified RNA. RNA was normalized to 0.2ȝg/ȝl 
with nuclease-free water before being used for performing reverse transcription reactions, 
as recommended by the manufacturer. The total RNA was reverse transcribed to cDNA 
using High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, USA) 
according to manufacturer’s protocol. 
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4.7.4. Gene Expression Analysis: The change in expression of nucleoside analog 
genes after cytarabine treatment was determined using the TaqMan® Low Density Array 
(TLDA) cards (Applied Biosystems, USA). Each TLDA card was custom designed with 
pre-loaded gene expression assays for measuring the mRNA expression of selected 
nucleoside analog metabolic pathway genes (n =14) - deoxycytidine kinase (DCK), 
cytidine deaminase (CDA), solute carrier family 29, member 1 (SLC29A1), solute carrier 
family 28, member 1 (SLC28A1), solute carrier family 28, member 3 (SLC28A3), 
deoxycytidylate deaminase (DCTD), 5’-nucleotidase, cytosolic II (NT5C2), 5’-
nucleotidase cytosolic III (NT5C3), cytidine 5’-triphosphate synthase (CTPS), cytidine 
monophosphate kinase (CMPK), nucleoside diphosphate kinase 1 (NME1), 
ribonucleotide reductase M1 (RRM1), ribonucleotide reductase M2 (RRM2), 
ribonucleotide reductase M2B (RRM2B). Each TLDA card consists of eight separate 
loading ports that fill into 48 separate wells, for a total of 384 wells per card. Thus, each 
card could analyze the expression of 24 different genes for 8 different samples in 
duplicates. Each cDNA sample was added to equal volume of 2X TaqMan Universal 
PCR Master Mix and 100 ȝl of the sample-specific PCR mix was added to the fill 
reservoir on the TLDA card. The card was centrifuged twice for 1 minute at 1200 rpm to 
distribute the sample-specific PCR reaction mix to the reaction wells. The card was 
sealed using the TaqMan Array Micro Fluidic Card Sealer and placed on microfluidic 
card thermal cycling block of Applied Biosystems 7900HT Fast Real-time PCR System 
(Applied Biosystems). Thermal cycling conditions were as follows: 2 minutes at 50°C, 
10 minutes at 94.5°C, 30 seconds at 97°C, 1 minute at 59.7°C for 40 cycles. The target 
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mRNA expression levels were normalized to GAPDH and the change in the expression 
values of nucleoside analogs pathway genes after cytarabine treatment (1ȝM and 10ȝM) 
compared to the baseline gene expression was calculated using comparative CT method 
[30]. 
4.7.5. MicroRNA Expression Analysis: For determination of change in microRNA 
expression after cytarabine treatment, total RNA was isolated using mirVana™ miRNA 
Isolation kit (Life Technologies, USA) as per the manufacturer’s protocol. The RNA 
quality and concentration was measured using NanoDrop 2000 UV-Vis 
spectrophotometer (ThermoScientific, USA). A total of 100 ng of purified total RNA was 
used for nCounter miRNA sample preparation reactions according to manufacturer’s 
instructions and was assayed for determination of 800 human microRNA expression 
using the nCounter Human v2 miRNA Expression Assay kit (Nanostring Technologies, 
USA). Preparation of small RNA samples involved multiplexed ligation of specific tags 
(miRtags) to the target microRNAs that provide unique identification for each microRNA 
species. After ligation, the detection was done by hybridization to microRNA: tag 
specific nCounter capture and barcoded reporter probes. Data collection was carried out 
using the nCounter Digital Analyzer (Nanostring Technologies, USA) at The University 
of Minnesota Genomics Center, following manufacturer’s instructions to count individual 
fluorescent barcodes and quantify the target microRNA molecules present in each 
sample. MicroRNA expression data normalization was performed using the nSolver™ 
Analysis Software (Nanostring Technologies) according to the manufacturer’s 
instructions. In particular, initially the data was normalization using the expression of the 
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top 100 codesets was used. Further, to account for the background correction, mean of 
negative controls plus two standard deviation (SD) method was used. In order to avoid 
using the microRNAs with a very low expression, we further filtered out the microRNAs 
with expression counts <30 (2 times the mean ± 2 SD of negative control value), in order 
to account for the background noise. Total 504 microRNAs with expression counts >30 
at, either baseline, after 1ȝM or 10ȝM were included for further analysis. 
4.7.6. Statistical Analysis: All values are expressed as ± standard deviation (SD). 
Effect of cytarabine treatment was compared by unpaired Student’s t-test. Statistical 
analysis was performed using the GraphPad Prims software version 6.0 (GraphPad 
Software Inc., San Diego, CA). A difference was considered statistically significant when 
the probability was less than 0.05 (p < 0.05).  
 
4.8. Results 
4.8.1. Effect of cytarabine treatment on microRNA expression in AML cell lines:  
Treatment of AML cell lines with cytarabine, at concentrations of either 1 ȝM or 10 ȝM, 
resulted in significant changes in expression of nearly 30 microRNAs. The observed 
changes in microRNA expression were different in sensitive cell lines (HL-60, MV-4-11, 
ME-1 and KG-1) and resistant cell lines (Kasumi-1, THP-1, AML-193 and MOLM-16) 
and were also concentration dependent.  
In sensitive cell lines, expression of 22 microRNAs was significantly decreased post 1 
ȝM cytarabine treatment as compared to the baseline microRNA expression (Figures 
4B.1A and 4B.1B), while treatment at 10 ȝM of cytarabine significantly decreased the 
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expression of hsa-miR-4435, and increased the expression of hsa-miR-410 and hsa-miR-
4508 in sensitive AML cell lines (Figure 4B.2). For hsa-miR-4508, there was ~ 40 % 
decrease in expression following 1 ȝM treatment while, the expression following 
treatment at 10 ȝM was ~ 2 fold higher. Expression of hsa-miR-4435 showed 2-fold 
decrease in expression after both 1 ȝM and 10 ȝM cytarabine treatments, indicating no 
concentration dependent effect (Figure 4B.1A and 4B.2). 
In resistant cell lines the expression of 6 microRNAs was significantly decreased post 1 
ȝM cytarabine (Figure 4B.3), while following treatment with 10 ȝM cytarabine only 3 
microRNAs were significantly altered (Figure 4B.4). Interestingly, there was a 
concentration dependent decrease in expression of hsa-miR-605 with ~ 30 % decrease in 
expression following 1 ȝM treatment and ~ 40 % decrease following 10 ȝM treatment.  
These results indicate that the expression of microRNAs could be both induced or 
repressed post cytarabine treatment and this change in expression is dependent upon the 
concentration of cytarabine.  
4.8.2. Effect of cytarabine treatment on mRNA expression of cytarabine pathway 
genes in AML cell lines: The effect of cytarabine treatment on the expression of 
cytarabine pathway genes was studied after incubation of AML cell lines with 1 ȝM and 
10 ȝM cytarabine (Table 4B.1 and 4B.2, Figure 4B.5). Treatment with 1 ȝM cytarabine 
increased the expression of DCK, CDA and RRM2 mRNA greater than 2-fold in resistant 
AML cell lines (Kasumi-1, AML-193, THP-1 and MOLM-16) as compared to their 
respective mRNA expressions at baseline, while the expression of RRM1 and RRM2B 
was increased greater than 2-fold in sensitive AML cell lines (HL-60, MV-4-11, KG-1 
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and ME-1) as compared to their mRNA expressions at the baseline (Table 4B.1 and 4B.2, 
Figure 4B.5). Interestingly treatment with 10 ȝM cytarabine resulted in greater 2-fold 
increase in expression of DCK, CDA and RRM2 in both sensitive and resistant cell lines 
(Figure 4B.5). Expression of CDA, which is an inactivating gene in the cytarabine 
metabolic pathway, demonstrated a concentration dependent increase after 10 ȝM 
cytarabine treatment in resistant AML cell lines. Expression of RRM1, RRM2B and 
CTPS1 increased only in cytarabine-sensitive cell lines after 10 ȝM cytarabine treatment 
(Table 4B.1).  
 
4.9. Discussion: 
There is increasing evidence that chemotherapy treatment affects the expression of 
various genes [24, 25, 31-34]. Recently, many studies have also identified changes in the 
expression patterns of various microRNAs post treatment with various anticancer agents 
[27-29, 35]. However, not many studies have studied the effect of cytarabine treatment on 
the expression changes of various microRNAs as well as the expression changes of the 
metabolic pathway genes of cytarabine. Since microRNAs are known to modulate the 
expression of various drug metabolizing enzymes and/or transporters, changes in 
microRNA expression post cytarabine treatment can potentially lead to alteration in the 
expression of the target genes of these microRNAs, thereby affecting their biological 
function. Such information could be important to further elucidate the mechanisms of 
acquired resistance to cytarabine treatment. In addition, understanding the effect of 
cytarabine treatment on the expression of its metabolic pathway genes could additionally 
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provide an increased understanding of the effect of cytarabine treatment on its own 
activation/inactivation pathway.   
In this study we determined the effect of cytarabine treatment expression of microRNAs 
(n=800) and PK/PD pathway genes (n=14) of cytarabine in AML cell lines. We evaluated 
the effect of two concentrations, 1 ȝM and 10 ȝM. We selected to test these 
concentrations of cytarabine based on the steady state concentrations (Cp, ss) achieved 
with standard dose cytarabine (100-200 mg/m2) (Cp, ss = 0.5 -1 ȝM) [36, 37] and high 
dose cytarabine (2-3 gm/m2) (Cp, ss ~ 10 to 50 ȝM) [38, 39]. We identified 22 
microRNAs that were significantly downregulated in AML cell lines (HL-60, MV-4-11, 
KG-1 and ME-1) sensitive to 1 ȝM cytarabine treatment, while treatment with 10 ȝM 
cytarabine increased the expression of hsa-miR-410 and hsa-miR-4508 and decreased the 
expression of hsa-miR-4435 in sensitive AML cell lines. In resistant AML cell lines 
(Kasumi-1, THP-1, AML-193 and MOLM-16) treatment with 1 ȝM cytarabine resulted 
in decreased expression of 6 microRNAs, while 10 ȝM cytarabine treatment decreased 
the expression of hsa-miR-769-3p and hsa-miR-605, while expression of hsa-miR-643 
was increased. Our data reveals that cytarabine treatment can result in differential effects 
on microRNA expression in AML cell lines. Out of the microRNAs affected by 
cytarabine treatment, a few demonstrated concentration dependent effect. In resistant cell 
lines, microRNA hsa-miR-605 resulted in ~ 30% decrease in expression following 
treatment with 1 ȝM cytarabine and ~ 40% decrease in expression following 10 ȝM 
cytarabine treatment. MicroRNA hsa-miR-605 expression has been implicated in 
inducing apoptosis by activation of p53 expression by directly repressing Mdm2 
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oncoprotein, an E3 ubiquitin ligase, which negatively regulates p53 by blocking p53 
mediated transactivation (p53: Mdm2 negative feedback loop) [40, 41]. Thus, cytarabine-
induced downregulation in the expression of hsa-miR-605 could potentially affect the 
tumor suppressive activity of p53. Expression of hsa-miR-4435 in sensitive cell lines was 
consistently decreased after cytarabine treatment with 1 ȝM and 10 ȝM, without 
demonstrating any concentration dependent effect. These results indicate that the effect of 
cytarabine treatment could lead to differential effects on the expression of different 
microRNAs in AML cell lines. Interestingly, in sensitive cell lines, the expression of hsa-
miR-4508 was decreased ~ 2.5-fold after 1 ȝM cytarabine treatment; however there was 
~ 2-fold increase in expression of this microRNA after 10 ȝM cytarabine treatment. 
Though the biological relevance of hsa-miR-4508 has not been identified, this novel 
regulation of hsa-miR-4508 by cytarabine warrants further investigation. Thus, our data 
reveals that cytarabine treatment leads to significant change in microRNA expression; 
however, whether this alteration in microRNA expression would lead to significant 
alteration of microRNA targets and their biological functions requires additional 
investigation.  
In addition, we also identified the effect of cytarabine treatment on the expression of 
PK/PD pathway genes of cytarabine in AML cell lines. Post-cytarabine treatment, DCK 
expression was increased 2-fold in resistant cell lines following 1 ȝM treatment and 2.5-
fold and 2-fold in both sensitive and resistant cell lines, respectively following 10 ȝM 
treatment. Though the exact mechanism of this alteration in the activating enzyme in the 
cytarabine pathway awaits further investigations, one of the mechanisms of this 
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regulation could be by microRNAs. Interestingly, in our previous study (Chapter III), we 
identified that the expression of DCK (the rate-limiting enzyme in the nucleoside analog 
pathway) was negatively correlated with the expression of hsa-miR-34a-5p (spearman r = 
-0.881; p-value < 0.01). Cytarabine treatment also affected the expression of hsa-miR-
34a-5p, with 1 ȝM cytarabine significantly decreasing the expression of hsa-miR-34a-5p 
in resistant cell lines. Even though there was a decrease in hsa-miR-34a-5p expression in 
sensitive cell lines post 1 ȝM and 10 ȝM and in resistant cell lines post 10 ȝM cytarabine 
treatment, the decrease in expression was not found to be statistically significant. Hence 
the repression of hsa-miR-34a-5p expression post cytarabine treatment could partly 
explain the increase in DCK expression. Cytarabine treatment was also found to 
significantly alter the expression of the primary deactivating enzyme, CDA and 
ribonucleotide reductases, indicating the importance of understanding the effect of 
cytarabine treatment on the activation/inactivation pathway of cytarabine. 
In conclusion, we provided preliminary data to demonstrate the effect of cytarabine 
treatment on the expression of microRNAs and cytarabine PK/PD pathway genes, 
demonstrating that the expression of microRNAs and mRNAs could be affected by 
chemotherapy. Our results would require further verification and validation, in both in 
vitro as well as in vivo settings to elucidate the mechanism effect of cytarabine. Also, 
since the primary aim of the current study was to understand the effect of cytarabine 
treatment on the expression of microRNAs (and cytarabine pathway genes), we did not 
identify the target mRNAs for the differentially expressed microRNAs affected by 
cytarabine treatment. Future studies would be focused on identifying the specific targets 
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of the microRNAs altered by cytarabine treatment and investigating the important 
biological pathways affected by deregulated microRNAs by cytarabine treatment.  
The current study in AML cell lines also helped us establish an in vitro system to validate 
the important findings from the in vivo study conducted to understand effect of cytarabine 
treatment in AML patient samples (Chapter IV-A). Thus, we demonstrated that 
cytarabine treatment in AML cell lines leads to changes in microRNA and PK/PD 
pathway gene expression after both 1 ȝM and 10 ȝM treatments. Identification of the 
underlying mechanism of modulation of microRNA and mRNA expression would 
ultimately provide increased understanding of the effect of cytarabine treatment and 
development of acquired resistance, thereby helping to improve the treatment outcomes. 
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Figures 4B.1: (A) Change in microRNA expression in sensitive AML cell lines 
after 1 ȝM Cytarabine treatment 
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Figure 4B.1: (B) Change in microRNA expression in sensitive AML cell lines 
after 1 ȝM Cytarabine treatment 
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Figure 4B.2: Change in microRNA expression in sensitive AML cell lines after 10 ȝM 
Cytarabine treatment 
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Figure 4B.3: Change in microRNA expression in resistant AML cell lines after 1 ȝM 
Cytarabine treatment 
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Figure 4B.4: Change in microRNA expression in resistant AML cell lines after 10 ȝM 
Cytarabine treatment 
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Figure 4B.5: Change in mRNA expression in AML cell lines after 1 ȝM and 10 ȝM 
Cytarabine treatment 
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Table 4B.1: Change in mRNA Expression of pathway genes in cytarabine sensitive AML 
cell lines post cytarabine treatment (1 ȝM and 10 ȝM) 
Genes  
Sensitive (mRNA Expression) 
1 ʅM Treatment 10 ʅM Treatment 
Mean SD Mean SD 
DCK 1.49 1.13 2.66 1.71 
SLC29A1 1.44 0.32 1.84 0.70 
CDA 1.81 0.74 2.45 1.57 
NT5C2 1.48 0.21 1.79 0.44 
NT5C3 0.97 0.36 1.26 0.39 
RRM1 2.05 0.67 2.18 0.85 
RRM2 1.95 0.34 2.60 0.72 
RRM2B 6.37 8.67 3.11 3.33 
CTPS1 1.29 0.39 2.39 2.04 
CMPK1 1.15 0.59 1.41 0.82 
DCTD 1.25 0.59 1.24 0.47 
NME1 1.08 0.43 2.68 2.06 
 
Table 4B.2: Change in mRNA Expression of pathway genes in cytarabine resistant AML 
cell lines post cytarabine treatment (1 ȝM and 10 ȝM) 
Genes  
Resistant (mRNA Expression) 
1 ʅM Treatment 10 ʅM Treatment 
Mean SD Mean SD 
DCK 2.06 1.07 2.01 1.05 
SLC29A1 1.54 0.57 1.48 0.53 
CDA 2.33 2.27 5.09 5.39 
NT5C2 1.39 0.32 1.52 0.14 
NT5C3 1.19 0.51 1.49 0.47 
RRM1 1.19 0.48 1.57 0.58 
RRM2 2.52 1.04 2.77 1.16 
RRM2B 1.65 0.94 1.41 0.45 
CTPS1 1.37 0.37 1.32 0.36 
CMPK1 1.03 0.30 1.60 0.79 
DCTD 1.01 0.42 0.95 0.26 
NME1 1.13 0.53 0.98 0.35 
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CHAPTER V 
MicroRNAs associated with Clofarabine Cytotoxicity in Acute Myeloid Leukemia 
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5.1. Introduction 
Acute myeloid leukemia (AML) is a hematological malignancy affecting the myeloid 
progenitor cells in the bone marrow. AML remains the most common form of leukemia 
in adults and the second most common form of leukemia in children. However, despite 
the recent advances in research and treatment strategies, AML continues to have poor 
survival rate [1]. Cytarabine, which was first approved by FDA in the late 1960s, in 
combination with anthracycline remains the cornerstone of treatment for AML. 
Cytarabine-based induction regimens are known to induce complete remission (CR) in 
about 60% to 80% of younger AML patients ( 55-60 years) and long-term disease free 
survival is around 30% [2, 3], while in older AML patients ( 55-60 years) the complete 
remission rate is 40% to 55%, with a poor long-term survival rate (10% to 15%) [4]. One 
of the strategies to improve the outcome involves addition of other nucleoside analogs, 
specifically purine nucleoside analogs, to the cytarabine-based induction regimen [5-7]. 
In particular, combination of fludarabine with cytarabine and idarubicin has been shown 
to result in significantly better complete remission rate (74%) and less hematologic and 
non-hematologic toxicity; as compared to cytarabine, idarubicin and etoposide treatment 
arm (CR of 51%) [5]. Similarly, inclusion of cladribine to the 3+7 regimen of cytarabine 
and daunorubicin was found to result in significantly higher CR rates (64%) compared 
the standard treatment arm comprising of cytarabine and daunorubicin (47%) [6]. 
Treatment of relapsed and refractory AML presents another challenge, since about 20% 
to 40% of AML patients fail to achieve complete remission following standard induction 
regimen, and 50% to 70% of who achieve CR are expected to relapse within 3 years [8, 
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9]. In addition, once the patient has had a relapse with the current therapies their chances 
of long-term disease free survival is less than 10% [10]. Since there is no single standard 
treatment regimen, it is essential to identify new combinations of standard chemotherapy 
regimens or novel agents for the treatment of relapsed or refractory disease. Some 
prospective clinical trials have evaluated the significance of purine nucleoside analogs, 
specifically fludarabine and cladribine in combination with cytarabine for the treatment 
of relapsed or refractory disease [11-14].  
Fludarabine and cladribine when used in combination with cytarabine are known to 
potentiate the cytotoxicity of cytarabine by increasing the accumulation of its 
triphosphate metabolite [11, 15, 16]. The main drawback of cladribine and fludarabine is 
their low oral bioavailability due to their instability in gastric pH and susceptibility to 
bacterial cleavage [17]. In addition, both these purine analogs have been associated with 
moderate myelosuppression and profound and prolong immunosuppression, with high 
doses leading to neurological toxicities [18]. However, the promising results observed in 
clinical studies with combination of fludarabine or cladribine with cytarabine, provided 
rationale for investigation of other purine nucleoside analogs.   
Clofarabine is a second-generation purine nucleoside analog, designed specifically to 
incorporate the favorable characteristics of fludarabine and cladribine and to overcome 
the dose-limiting adverse effects associated with these drugs. Structural modifications in 
clofarabine result in resistance to deamination by adenosine deaminase and decrease its 
susceptibility to phosphorolytic cleavage, leading to enhanced oral bioavailability of 
clofarabine [19, 20]. Structural activity relationships demonstrate that clofarabine 
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incorporates mechanistically favorable properties of both fludarabine and cladribine, such 
as inhibition of DNA polymerases (like fludarabine) and inhibition of ribonucleotide 
reductases (like cladribine) [21-25]. In fact, clofarabine appears to have greater affinity 
for dCK, exceeding fludarabine and cladribine [19, 26]. Clofarabine and cladribine are 
superior to fludarabine in inhibiting ribonucleotide reductase while clofarabine and 
fludarabine are more efficient than cladribine in inhibition of DNA polymerase [27]. In 
addition, clofarabine is known to induce apoptosis by releasing pro-apoptotic 
mitochondrial factor, which was absent in fludarabine. Interestingly, the rate-limiting step 
in activation of clofarabine triphosphate is the conversion of clofarabine monophosphate 
to diphosphate by purine monophosphate kinase, in contrast to other nucleoside analogs, 
where formation of monophosphate form by DCK is the rate-limiting step [24]. 
Clofarabine, due to its favorable PK/PD is preferred over the currently used fludarabine 
and cladribine and has recently been investigated in multiple Phase I and Phase II clinical 
trials as a chemotherapeutic agent for hematological malignancies (clinical trials.gov 
study identifiers: NCT00067028, NCT00334074, NCT01025154 etc.). Use of clofarabine 
as a single agent established the significance of this second-generation purine analog for 
treatment of AML [28, 29]. Initial studies combining fludarabine or cladribine with 
cytarabine had shown promising results, which prompted the efforts to study the 
combination regimens of cytarabine and clofarabine. In addition, in vitro studies in 
leukemic cell lines, had demonstrated the synergy between cytarabine and clofarabine, 
with pre-incubation with clofarabine increasing the cytarabine triphosphate levels by two-
fold [25, 30]. The promising results from the preclinical studies as well as from the initial 
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trials using clofarabine as a single agent, led to investigation of clofarabine in 
combination with cytarabine [31-33]. Phase I-II trial in relapsed and refractory AML 
patients investigated combination of clofarabine with cytarabine in an effort to modulate 
cytarabine triphosphate accumulation [31]. This study reported complete response (CR) 
in 22% patients with an overall response (OR) rate of 38%. Phase II study in previously 
untreated adult AML patients conducted to assess the efficacy of clofarabine and 
cytarabine combination demonstrated an OR rate of 60%, with 52% CR in older AML 
patients [34]. A randomized study comparing clofarabine plus cytarabine versus 
clofarabine alone also showed promising results [33]. The encouraging results from these 
trials resulted in additional combination of clofarabine and cytarabine with 
anthracyclines. Phase I study with primary refractory or first-relapse AML, combination 
of clofarabine with cytarabine and idarubicin showed a high response rate compared to 
the cytarabine plus idarubicin [35]. Although clofarabine has been currently shown to be 
a promising agent for the treatment of AML, there are no studies evaluating the 
significance of microRNA expression in clofarabine cytotoxicity. Our previous studies 
with cytarabine, which shares the PK/PD pathway with clofarabine, have shown that 
microRNAs regulate the expression of genes in PK/PD pathway of clofarabine. Also, 
microRNA deregulation has been implicated in AML pathogenesis and several studies 
have demonstrated the significance of microRNAs in predicting outcome in AML 
patients [36-40]. Since minor structural differences in clofarabine result in significant 
differences in the activity as well as the metabolic and pharmacokinetic profile as 
compared to cytarabine, an independent analysis to study the effect of microRNAs on 
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clofarabine response seems like a reasonable approach. In this study, we report the results 
from genome-wide microRNA expression analysis to identify the microRNAs associated 
with clofarabine cytotoxicity in eight AML cell lines.  
 
5.2. Materials and Methods 
5.2.1. Cell Culture and Reagents: The AML cell lines HL-60, MV-4-11, Kasumi-1, 
THP-1, AML-193 and KG-1 cell lines were obtained from American Type Culture 
Collection (ATCC) (Manassas, VA), while MOLM-16 and ME-1 cell lines were obtained 
from DSMZ (Braunschweig, Germany). Kasumi-1, ME-1 and MOLM-16 cell lines were 
cultured in RMPI-1640 medium supplemented with 20% fetal bovine serum (FBS), THP-
1 cell line was cultured in RPMI-1640 medium supplemented with 10% FBS, MV-4-11 
cell line was cultured in IMDM medium supplemented 10% FBS, HL-60 and KG-1 cell 
lines were cultured in IMDM medium supplemented with 20% FBS, while AML-193 cell 
lines was cultured in IMDM medium supplemented with 5% FBS, 0.005 mg/ml insulin, 
0.005 mg/ml transferrin and 5 ng/ml GM-CSF. All the cell lines were maintained in a 
37°C humidified incubator with 5% CO2. The cells were passaged every 2 to 3 days in 
order to maintain them in logarithmic growth phase. Clofarabine was purchased from 
Sigma Aldrich (St. Louis, MO).  
5.2.2. Cytotoxicity Assay: Clofarabine cytotoxicity was determined using the MTT 
assay. Clofarabine (Sigma Aldrich) solution was prepared in dark by dissolving 
clofarabine powder in DMSO to obtain a stock concentration of 10 mg/ml. AML cell 
lines were plated in 96-well plate at seeding density of 2.5×105 cells/ml and incubated at 
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37°C overnight. After 24h of recovery time, the cells were exposed to varying 
concentrations (5, 2.5, 1, 0.5, 0.05, 0.025 and 0 ȝM) of clofarabine. Cell viability was 
determined 48h post clofarabine treatment by MTT assay by measuring the absorbance at 
570nm using Synergy plate reader (BioTek, USA). The percent cell survival at each 
concentration was calculated using the Gen5™ Software version 1.11 (Winooski, VT). 
The area under the survival curve (AUC) was calculated by the trapezoidal method using 
the GraphPad Prism software version 6 (La Jolla, California). Each cytotoxicity 
experiment was repeated at least 3 times. 
5.2.3. Apoptosis Assay: The apoptotic activity of AML cell lines following treatment 
with varying concentration of clofarabine (as indicated above) was determined using the 
Caspase-Glo® 3/7 assay as per manufacturer’s instructions (Promega, USA). 48h post 
clofarabine treatment, luminescence was read using Synergy plate reader (BioTek, USA). 
The luminescence produced is directly proportional to the caspase activity. The caspase 
activity at each concentration was normalized to the control and the area under the 
relative caspase activity curve (AUC) was calculated by the trapezoidal method using the 
GraphPad Prism software version 6 (La Jolla, California). Each caspase experiment was 
repeated 3 times. 
5.2.4. MicroRNA Expression Analysis: For determination of microRNA expression, 
total RNA was isolated using mirVana™ miRNA Isolation kit (Life Technologies, USA) 
as per the manufacturer’s protocol. The RNA quality and concentration was measured 
using NanoDrop 2000 UV-Vis spectrophotometer (ThermoScientific, USA). A total of 
100 ng of purified total RNA was used for nCounter miRNA sample preparation 
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reactions according to manufacturer’s instructions and the expression of 800 human 
microRNAs was quantified using the nCounter Human v2 miRNA Expression Assay kit 
(Nanostring Technologies, USA). Preparation of small RNA samples involved 
multiplexed ligation of specific tags (miRtags) to the target microRNAs that provide 
unique identification for each microRNA species. After ligation, the detection was done 
by hybridization to microRNA: tag specific nCounter capture and barcoded reporter 
probes. Data collection was carried out using the nCounter Digital Analyzer (Nanostring 
Technologies, USA) at The University of Minnesota Genomics Center, following 
manufacturer’s instructions to count individual fluorescent barcodes and quantify the 
target microRNA molecules present in each sample. MicroRNA expression data 
normalization was performed using the nSolver™ Analysis Software (Nanostring 
Technologies) according to the manufacturer’s instructions. In particular, initially the 
data was normalization using the expression of the top 100 codesets was used. Further, to 
account for the background correction, mean of negative controls plus two standard 
deviation (SD) method was used. In order to avoid using the microRNAs with a very low 
expression, we further filtered out the microRNAs with expression counts <30 (2 times 
the mean ± 2 SD of negative control value), in order to account for the background noise. 
Total 412 microRNAs with expression counts >30 were evaluated for differential 
expression between sensitive and resistant cell lines and for their correlation with 
cytarabine chemosensitivity.  
5.2.5. Statistical Analysis: The differential expression of microRNAs between the 
sensitive and resistant AML cell lines to clofarabine was determined by using Student’s t-
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test of the log-transformed data. Nonparametric Spearman correlation was used to 
measure the correlation of AUCs with microRNA expression. All statistical analysis was 
performed using Graph Pad Prism software. Heat map was generated using the NSolver 
software. 
 
5.3. Results 
5.3.1. Clofarabine chemosensitivity in AML cell lines: The overall study design is 
shown in Figure 5.1. We estimated in vitro clofarabine-induced cytotoxicity and 
clofarabine-induced apoptosis in 8 cytogenetically different AML cell lines in order to 
characterize clofarabine response in different AML cell lines. As, expected we observed 
variation in AML clofarabine cell cytotoxicity AUC, with mean AUC value of 151.96 
(±96.56) (Figure 5.2A). We observed that MV-4-11 cell line was the most sensitive to 
clofarabine and Kasumi-1 cell lines was the most resistant. Cell lines MV-4-11, HL-60, 
THP-1 and KG-1 were classified as sensitive cell lines (AUC <150), while MOLM-16, 
ME-1, AML-193 and Kasumi-1 were classified as resistant cell lines (AUC > 150) (Table 
5.1). Induction of apoptosis as measured by caspase 3/7 activity with increasing 
concentration of clofarabine was complimentary to the observed cell viability; percent 
cell survival after each increasing concentration of clofarabine decreased as the apoptotic 
activity for the respective concentration increased (Figure 5.3A to 5.3H).  
5.3.2. Association of microRNAs with clofarabine chemosensitivity in AML cell 
lines: In order to understand the effect of microRNAs in the chemosensitivity of AML 
cell lines to clofarabine, we performed global microRNA expression profiling of the 
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AML cell lines. We examined the expression of 800 human microRNAs in these cell 
lines using nCounter Nanostring platform. After normalization and background 
correction we filtered out microRNAs with expression counts <30 (2 times the mean ± 2 
SD of negative control value), in order to account for the background noise. Total 412 
microRNAs with expression counts >30 were evaluated for differential expression 
between sensitive and resistant cell lines and for their correlation with clofarabine 
chemosensitivity. The heat map shows the top 25 differentially expressed microRNAs 
between the sensitive and resistant cell lines (Figure 5.4B) based on cell viability assays. 
Higher levels of hsa-miR-335-5p, hsa-miR-1290, hsa-miR-3690, hsa-miR-486-3p, hsa-
miR-525-5p, hsa-miR-148b-3p, hsa-miR-194-5p, hsa-miR-331-3p and lower levels of 
hsa-miR-16-5p, hsa-miR-423-3p, hsa-miR-30b-5p and hsa-miR-548aa were associated 
with clofarabine resistance, p-value < 0.05 as depicted in the volcano plot (Figure 5.5). 
Using cell sensitivity phenotype as a continuous variable, we identified 25 unique 
microRNAs significantly associated with clofarabine-induced cytotoxicity and apoptosis 
AUC (Table 5.2). We identified that cluster of miR-515 family members were positively 
associated with clofarabine-induced cytotoxicity. This microRNA miR-515 cluster along 
with some other microRNAs was also found to be upregulated in cisplatin resistant germ 
cell tumor cell lines compared to the parenteral cell lines [41]. Of the differentially 
expressed microRNAs, hsa-miR-16-5p was found to be significantly overexpressed in 
clofarabine-sensitive cell lines as compared to the resistant cell lines. Interestingly, the 
microRNA hsa-miR-16-5p was also found to be negatively associated with clofarabine-
induced cytotoxicity AUC, indicating increased sensitivity towards clofarabine in cells 
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expressing low levels of hsa-miR-16-5p. On the other hand, higher levels of microRNAs 
hsa-miR-194-5p, hsa-miR-148b-3p, hsa-miR-486-3p, hsa-miR-525-5p, hsa-miR-331-3p 
and hsa-miR-1290 were positively associated with clofarabine resistance.  
 
5.4. Discussion:  
In this study, we identified the microRNAs that were associated with the clofarabine 
chemosensitivity in AML cell lines. We screened for global microRNA expression 
profiles in AML cell lines and identified 30 unique microRNAs associated with 
clofarabine chemosensitivity, among which miR-515 cluster was found to be 
significantly associated with clofarabine cytotoxicity. We also identified 8 microRNAs 
(hsa-miR-335-5p, hsa-miR-1290, hsa-miR-3690, hsa-miR-486-3p, hsa-miR-525-5p, hsa-
miR-148b-3p, hsa-miR-194-5p and hsa-miR-331-3p), which showed increased 
expression in clofarabine sensitive AML cell lines and 4 microRNAs (hsa-miR-16-5p, 
hsa-miR-423-3p, hsa-miR-30b-5p and hsa-miR-548aa), which showed increased 
expression in clofarabine resistant AML cell lines.  
With the increasing interest in clofarabine’s therapeutic utility as demonstrated in the 
ongoing clinical trials, it is important to identify factors that might affect clofarabine’s 
efficacy as a chemotherapeutic agent for the treatment of AML and other hematological 
malignancies. To our knowledge, there has been only one study demonstrating the 
potential impact of genetic polymorphisms (SNPs) and epigenetic modifications on 
clofarabine cytotoxicity in lymphoblastoid cell lines [42]. This study demonstrated the 
impact of integrating the epigenetic information, like DNA methylation with genotype 
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and gene expression information, in order to identify the genes relevant to clofarabine 
cytotoxicity. Using a comprehensive association analysis, this study identified six genes 
associated with clofarabine-mediated cytotoxicity. However the influence of microRNAs 
on clofarabine cytotoxicity was not investigated. Recent evidence indicates the 
importance of microRNAs in regulating the expression of pharmacologically relevant 
genes affecting the drug responses. Kovalchuk and colleagues identified that microRNA-
451 regulates the expression of multidrug resistance 1 (MDR1) gene, in turn regulating 
the cellular resistance to doxorubicin in breast cancer cell lines [43]. MicroRNAs have 
also been demonstrated to regulate the expression of important drug metabolizing 
enzymes like cytochrome P450s [44, 45]. In addition to regulation of gene and/or protein 
expression, microRNAs have also shown to play an important role various malignancies, 
including AML. In our previous study (Chapter II), we identified microRNAs associated 
with cytarabine chemosensitivity and overall survival in AML patients. Hence, it is 
essential to understand the role of these significant class of regulators in contributing to 
the chemotherapeutic response to clofarabine. Even though we have shown the effect of 
microRNAs on cytarabine cytotoxicity (Chapter II), there is evidence, which shows that 
despite the structural similarities between clofarabine and cytarabine, there are 
differences in chemosensitivity to these nucleoside analogs in patients as well as in cell 
lines. For instance, sensitivity of acute lymphoblastic leukemia cell lines of B-lineage, 
were found to be more than 7-fold sensitive to clofarabine compared to cytarabine, while 
the T-lineage cells were not differentially affected [46]. Also, cytarabine-resistant 
leukemia cells were found to be moderately sensitive to clofarabine, and these differences 
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were attributed to the human concentrative nucleoside transporter 3 (hCNT3) which is 
involved in the influx of clofarabine in addition to human equilibrative transporters 
(hENT) 1 and 2, while cytarabine transport is mainly by hENT1 [47]. In addition, studies 
on nucleoside analog transport, revealed differences in hENT1 transport efficiency 
towards clofarabine, cytarabine and other nucleoside analogs [48]. This necessitates the 
importance to independently identify the role of microRNAs in predicting response to 
clofarabine. 
In an effort to better understand the contribution of microRNAs in clofarabine-mediated 
chemosensitivity, screened for microRNA expression (n=800) in cytogenetically different 
AML cell lines and identified the microRNAs significantly associated with clofarabine-
induced cytotoxicity and apoptosis in AML cell lines. We identified 25 microRNAs to be 
associated with clofarabine cell viability and apoptosis AUCs (p-value < 0.05), out of 
which 6 microRNAs were also differentially expressed between the AML cell lines 
sensitive and resistant to clofarabine. MicroRNA hsa-miR-16-5p, which was found have 
increased expression in clofarabine sensitive AML cell lines, was also found to be 
negatively associated with clofarabine-induced cytotoxicity AUC. In our previous study 
(Chapter II), we identified hsa-miR-16-5p was also predictive of cytarabine sensitivity in 
AML cell lines. Interestingly, miR-16 is located in the miR-15a/miR-16 cluster that is 
located at chromosome 13q14.3, a genomic region that is known to be frequently deleted 
in B cell chronic lymphocytic leukemia (B-CLL) [49]. Expression of miR-16 along with 
miR-15 inhibited leukemic cell proliferation and induced apoptosis by targeting multiple 
oncogenes such as Bcl-2, WNT3A, MCL1, and CND1, both in vitro and in vivo [50, 51]. 
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Significance of miR-15/miR-16 cluster as tumor suppressors in leukemic cells could be 
due to their ability to down regulate of the expression of Wilms’ tumor gene (WT1) 
oncogene [52]. These data show the significance of miR-16 in leukemia. Our study 
identified the significance of this important microRNA in clofarabine sensitivity. 
Additional studies to elucidate the exact mechanism of the role of miR-16 in nucleoside 
analog sensitivity are warranted.  
We also identified microRNAs hsa-miR-194-5p, hsa-miR-148b-3p, hsa-miR-486-3p, hsa-
miR-525-5p, hsa-miR-331-3p and hsa-miR-1290 to have increased expression in 
clofarabine resistant AML cell lines, in addition to being positively associated with 
clofarabine-induced cytotoxicity AUC. Thus, indicating that increased expression of 
these microRNAs could potentially contribute to increased clofarabine resistance. 
MicroRNA hsa-miR-486 has been reported earlier to be selectively expressed in Down’s 
syndrome associated AML (DS-AML) compared to non-DS megakaryocytic leukemias 
(AMKLs), and expression of miR-486 is regulated by GATA1 binding [53]. It was also 
demonstrated that miR-486 expression contributes to the survival of CML progenitor 
cells after treatment with BCR-ABL tyrosine kinase inhibitor (TKI) imatinib mesylate, 
and inhibition of miR-486 significantly enhanced imatinib-mediated apoptosis [54]. 
Recent study demonstrated the role of increased expression of miR-331 in predicting 
worse response to therapy and decreased survival of AML patients [55] which is in 
accordance with our results which show increased expression of miR-331 associated 
increased resistance to clofarabine. Our study characterized the role of these and more 
important microRNAs in clofarabine response.  
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Interestingly, we also identified a cluster of miR-515 family members to be positively 
associated with clofarabine-induced cytotoxicity. MicroRNAs hsa-miR-519c and hsa-
miR-520h, miR-515 family members, have been previously validated to be targeting and 
repressing the expression of ABCG2 efflux transporter [56]. This study demonstrated that 
ABCG2-overexpressing resistant subline S1M1 80 cell lines have shorter 3’UTR 
compared to the S1 parental cell line, thereby disrupting the hsa-miR-519c and hsa-miR-
520h binding sites. Recent evidence indicates the role of ATP-binding cassette 
transporter, ABCG2 in playing a role in the efflux of purine nucleoside analogs, like 
clofarabine [57, 58]. In addition, expression of DCK and ABCG2 was shown to impact 
clofarabine metabolism and cytotoxicity [59]. Our results identified expression of miR-
515 cluster predictive of clofarabine chemoresistance, which could partly be explained by 
the effect miR-515 family members on clofarabine metabolic pathway.  
In conclusion, our study identified microRNAs relevant to clofarabine response in AML. 
To our knowledge, this is a first study characterizing significant microRNAs relevant to 
clofarabine cytotoxicity in AML. Additional functional validation and mechanistic 
studies are warranted to elucidate the role of these microRNAs in clofarabine response. 
Also validating these findings in AML patients would strengthen the significance of these 
microRNAs and help in better understanding the factors contributing to the response of 
these chemotherapeutic agents. 
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Figure 5.1: Overall schema of the proposed study 
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Figure 5.2: Clofarabine-induced chemosensitivity AUC in AML cell lines (A) 
Clofarabine-induced cytotoxicity area under the survival curve (AUC) of 8 AML cell 
lines after clofarabine treatment. (B) Clofarabine-induced apoptosis area under the 
survival curve (AUC) of 8 AML cell lines after clofarabine treatment. 
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Figure 5.3: Characterization of AML Cell lines for Clofarabine chemosensitivity. Clofarabine-induced cytotoxicity (represented 
as percent cell survival, blue line) and cytarabine-induced apoptosis (represented as relative caspase-3/7 activity, red line) in (A) HL-
60, (B) MV-4-11, (C) THP-1, (D) KG-1, (E) MOLM-16, (F) ME-1, (G) AML-193, (H) Kasumi-1.
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Figure 5.4: Heatmap of microRNA expression in sensitive and resistant AML cell 
lines. (A) Area under the survival curve (AUC) of 8 AML cell lines after 6 different 
concentrations of clofarabine. (B) Heatmap showing expression of top 25 differentially 
expressed microRNAs between sensitive and resistant AML cell lines.  
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Figure 5.5: Differentially expressed microRNAs between sensitive and resistant cell 
lines to clofarabine 
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Figure 5.6: Correlation of clofarabine-induced cytotoxicity AUC and microRNA expression for the microRNAs, which were also 
differentially expressed microRNAs between sensitive and resistant cell lines to clofarabine.
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Table 5.1: Characterization of AML Cell lines for Clofarabine Chemosensitivity 
Cell Lines  Cytogenetics /Molecular Abnormality Clofarabine-induced Cytotoxicity AUC (± SD) 
Clofarabine-induced 
Apoptosis AUC (± SD) 
MV-4-11 FLT3 ITD mutation, t(4;11)(q21;q23) ĺ MLL-AF4 fusion gene 33.66 (±4) 8.8 (±1.6) 
HL-60 CDKN2A, NRAS, TP53 mutant genes 56.84 (±8) 9.9 (±0.6) 
THP-1 t(9;11)(p21;q23) ĺ MLL-AF9 fusion gene; CDKN2A, KDM6A, NRAS mutant genes 100.58 (±13) 49.9 (±0.3) 
KG-1 NRAS mutation, P53 mutation, RB1 rearrangement 109.10 (±22) 12.1 (±1.0) 
MOLM-16 t(6;8)(q21;q24.3) and t(9;18)(q13;q21) 174.55 (±8) 11.8 (±0.4) 
ME-1 inv(16)(p13q22) ĺ CBFB-MYH11 fusion gene 176.40 (±2) 16.2 (±0.4) 
AML-193 +der(17)t(17;17)(p13.1;q21.3) 245.73 (±9) 19.4 (±1.2) 
Kasumi-1 
t(8;21)(q22;q22) ĺ RUNX1/AML1-
RUNX1T1/ETO fusion gene; TP53 mutant 
gene 
318.85 (±4) 12.1 (±0.9) 
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Table 5.2: MicroRNAs significantly associated with clofarabine-induced cytotoxicity 
AUC and clofarabine-induced apoptosis AUC  
MicroRNAs Spearman r p-value 
Clofarabine-induced cell viability AUC 
hsa-miR-1290 0.9048 0.0046 
hsa-miR-148b-3p 0.9524 0.0011 
hsa-miR-16-5p -0.8810 0.0072 
hsa-miR-194-5p 0.9048 0.0046 
hsa-miR-22-3p 0.8333 0.0154 
hsa-miR-331-3p 0.7619 0.0368 
hsa-miR-486-3p 0.7857 0.0279 
hsa-miR-500a-5p+hsa-miR-501-5p 0.8810 0.0072 
hsa-miR-517a-3p 0.8095 0.0218 
hsa-miR-517c-3p+hsa-miR-519a-3p 0.8571 0.0107 
hsa-miR-518b 0.9048 0.0046 
hsa-miR-518e-3p 0.8095 0.0218 
hsa-miR-519b-3p 0.7381 0.0458 
hsa-miR-519b-5p+hsa-miR-519c-5p 0.7619 0.0368 
hsa-miR-520a-5p 0.9762 0.0004 
hsa-miR-520b 0.8333 0.0154 
hsa-miR-520c-3p 0.7619 0.0368 
hsa-miR-520f 0.8571 0.0107 
hsa-miR-520h 0.7857 0.0279 
hsa-miR-522-3p 0.7619 0.0368 
hsa-miR-525-5p 0.9524 0.0011 
hsa-miR-526a+hsa-miR-520c-5p+hsa-miR-518d-5p 0.9048 0.0046 
Clofarabine-induced Apoptosis AUC 
hsa-miR-27b-3p -0.6988 0.0495 
hsa-miR-301a-3p -0.8503 0.0086 
hsa-miR-3196 0.8144 0.0180 
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CHAPTER VI 
Summary and Discussion 
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Acute myeloid leukemia (AML) is a hematological malignancy and is the most common 
forms of acute leukemia in adults with an incidence rate of 4.0501 cases per 100,000 
patients. AML also has a highest mortality rate of 2.85 cases per 100,000 patients as 
compared to other leukemias and is associated with low 5-year relative survival rates 
(24.9% overall). Apart from low survival, one of the major concerns with AML is 
treatment related mortality and resistance to chemotherapy [1, 2]. Various prognostic 
factors such as cytogenetics, molecular abnormalities, and minimal residual disease 
mainly predict resistance to chemotherapy. Cytogenetic abnormalities have been strong 
predictors of the clinical outcomes in both pediatric and adult AML patients. However, 
despite using cytogenetics, around 20 to 45% patients do not achieve complete remission 
(CR) with standard induction chemotherapy with cytarabine (commonly used nucleoside 
analog) and the majority of the patients who achieve CR are known to relapse [3-5].  
One of the major reasons for failure of cytarabine-based therapy is due to failure to 
achieve adequate intracellular active cytarabine triphosphate concentrations. The primary 
factors that regulate the intracellular triphosphate levels are the levels/activity of the 
nucleoside transporters, levels of the activating (kinases) and inactivating enzymes and 
the intracellular deoxynucleotide pools, which are regulated by ribonucleotide reductases. 
Factors that could affect the expression of these transporters and enzymes, could in turn 
potentially affect the levels of the active metabolite of nucleoside analogs.  
Single nucleotide polymorphisms (SNPs) in the genes encoding the drug transporters, 
activating and inactivating enzymes as well as the pharmacodynamic (PD) targets of 
these drugs can influence the clinical outcome of the patients treated with these 
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nucleoside analogs. Studies have shown that variability in treatment outcome in AML 
patients treated with cytarabine correlated with DCK mRNA expression [6]. The 
regulatory SNPs (í360 C>G and í201 C>T) in the promoter of DCK were found to be 
associated with the mRNA expression of DCK [7]. Sequencing the DCK promoter and 
coding exons identified three nonsynonymous SNPs (Ile24Val, Ala119Gly and 
Pro122Ser), the variant forms of which demonstrated reduced DCK activity [8]. A SNP 
in the 3’ untranslated region (UTR) of DCK (rs4643786) was found to be associated with 
DCK mRNA expression in both European and African ancestry. Additionally, SNPs in 
CDA, RRM2 and hENT1 have also been found to predict the clinical outcome/cytarabine 
triphosphate levels in AML patients. However, apart from SNPs, we were also interested 
in exploring microRNAs as predictors of response to cytarabine in AML patients. 
MicroRNAs (miRs) are endogenous, single stranded, small noncoding RNAs, which are 
about 22 nucleotides in length that regulate gene expression by binding to specific 
mRNA target sequences and promoting their degradation or translational repression. 
MicroRNAs have also been implicated to play an important biological functional role in 
the development of cancer.  
Recently, various in vitro studies have also sought to identify the impact of microRNAs 
on the chemosensitivity to anticancer agents in various cancers. However, the data from 
these studies has been contradictory and disease dependent. Specifically, it was found 
that increasing the levels of miR-21 in A549 cell line leads to increased sensitivity to 
cytarabine, which was opposite to what was observed with other anticancer agents, where 
decreased expression of miR-21 resulted in increased sensitivity of these agents, in this as 
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well as other studies [9-11]. However, another study showed that inhibiting the 
expression of endogenous miR-21 enhanced the sensitivity of leukemic cell line (HL-60) 
to cytarabine, primarily by increasing apoptosis. However, despite the extensive 
knowledge regarding the role of microRNAs as regulators of various cellular processes in 
cancer (prognostic markers for AML) and influencing changes in chemosensitivity of 
anti-cancer agents in in vitro systems; there have been very few studies that have 
systematically evaluated the role of microRNAs as predictors of chemosensitivity to 
nucleoside analogs in AML patients. Thus, the aim of this thesis was to identify 
microRNA/microRNA-signature using in vitro systems and clinical data that can be used 
as a tool for predicting clinical outcome in AML patients. Additionally, we sought to 
mechanistically determine if these microRNAs were influencing the chemosensitivity of 
cytarabine by modulating the genes involved in intracellular activation of cytarabine. 
We used an innovative approach to identify microRNAs predictive of cytarabine 
chemosensitivity using eight AML cell lines and further testing these microRNAs in an 
integrative analysis to identify specific miRNA-target mRNA pairs that were predictive 
of overall survival (OS) in AML. Briefly, we evaluated 412 microRNAs for association 
with cytarabine chemosensitivity in AML cell lines, of these 20 microRNAs were 
evaluated for their association with OS in 200 AML patients from TCGA database. Our 
stepwise-integrated analyses (step 1- microRNA-target mRNA that were significantly 
correlated in AML patients; step -2 mRNAs from step 1 with significant association with 
OS) identified 23 unique miRNA-mRNA pairs predictive of OS in AML patients. As 
expected HOX genes (HOXA9, HOXB7 and HOXA10) were identified to be regulated 
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by miRs as well as predictive of worse OS. Additionally, miR107-Myb, miR-378-
granzyme B involved in granzyme signaling and miR10a-MAP4K4 were identified to be 
predictive of outcome through integrated analysis. Although additional functional 
validations to establish clinical/pharmacologic importance of microRNA-mRNA pairs are 
needed, our results from RNA EMSA confirmed binding of miR-10a, miR-378 and miR-
107 with their target genes GALNT1, GZMB and MYB respectively.  Integration of 
pathogenic and pharmacologically significant microRNAs and microRNA-mRNA 
relationships identified in our study opens up opportunities for development of 
targeted/microRNA-directed therapies. 
Next, we sought to understand the potential mechanism by which microRNAs can 
influence the chemosensitivity to cytarabine. One of the primary mechanisms of 
resistance to nucleoside analogs is insufficient intracellular concentration of the active 
triphosphate metabolite. This insufficient triphosphate levels could be due to inefficient 
cellular uptake of the drug, reduced levels of the activating enzyme, increased levels of 
inactivating enzymes and/or due to increased levels of endogenous deoxynucleotide 
(dNTP) pool [12-15]. MicroRNAs have been shown to regulate the expression of various 
drug-metabolizing enzymes like CYP3A4 etc., drug transporters like BCRP and various 
drug targets [16-18]. However, there have not been any studies, which have 
comprehensively evaluated the effect of microRNAs on the important genes involved in 
the transport, activation and inactivation genes of nucleoside analogs. In our study we 
identified ~ 30 microRNAs which were significantly correlated with mRNA expression 
of various cytarabine pathway genes. Of the microRNAs identified in in vitro study, 5 
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microRNAs were also found to correlate with the gene expression in patients. Using in 
vitro and bioinformatic analysis we were able to show that the regulation of the genes 
was via binding to the 3’-UTR of the target genes. Future studies to understand the 
clinical impact of the microRNA mediated changes in gene expression on activity would 
involve correlating the in vivo microRNA expression with the plasma concentrations of 
cytarabine and/or cytarabine triphosphate. 
Apart from microRNAs, we also investigated if treatment with cytarabine results in 
emergence of drug resistance due to changes in gene expression profile. In chapter IVA, 
we determined the gene expression in patients prior to and post treatment with cytarabine. 
Using PROMISE analysis, we identified more than 50 genes that were either associated 
with detrimental or beneficial response in AML patients treated with cytarabine. Using 
siRNA knockdown technique we were able to mechanistically validate the gene 
expression changes that were correlated with clinical outcome in the AML patients. This, 
to our knowledge is the first study that has identified drug-induced changes in gene 
expression of various adaptive processes that can contribute to development of resistance. 
The results highlight genes relevant to cytarabine resistance and support the concept of 
targeting genes modulated by cytarabine exposure as a means of improving response. 
Future in depth studies will help in understanding the interplay of these genes/pathways 
to better understand mechanisms of cytarabine resistance in AML. Importantly, novel 
agents directed at these targets may serve as potential therapeutics to improve clinical 
outcomes. In the next part of the chapter (chapter IVB) we sought to determine the effect 
of cytarabine treatment on changes in gene expression as well as microRNA expression. 
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In this study, we report the effect of cytarabine treatment at two different concentrations 
on the changes in microRNA expression in AML cell lines. We also investigated the 
effect of cytarabine treatment on the expression of pathway genes, in order to understand 
if the drug treatment itself can have an impact on its activation or inactivation pathway 
Using clinical data and mechanistic studies we were able to identify microRNA and drug 
induced changes in gene expression as being potential mechanisms of resistance to 
cytarabine in AML patients. However, apart from cytarabine, other second generation 
nucleoside analogs with favorable PK/PD properties are also being investigated as 
potential second generation drugs as treatment options in AML patients. Clofarabine is 
one such nucleoside analog that is currently being investigated in various clinical trials. 
Thus, in chapter V we performed in vitro studies to identify microRNAs that could 
predict chemosensitivity to clofarabine. Since we had observed good in vitro/in vivo 
correlation with cytarabine in AML cells lines and AML patients, and there are 
differences in PK pathway of clofarabine, we believe, that an investigational study using 
same in vitro system as was used for cytarabine (AML cell lines) would provide 
microRNA signature that is predictive of chemosensitivity to clofarabine. This 
microRNA signature can then be validated using clinical data from the ongoing clinical 
trials with clofarabine. Similar to as was done for cytarabine; we correlated the global 
microRNA expression profile in AML cells lines with the clofarabine chemosensitivity. 
We identified 25 unique microRNAs associated with clofarabine chemosensitivity, with 
miR-515 cluster significantly associated with clofarabine cytotoxicity. We also identified 
8 microRNAs predictive of clofarabine sensitivity and 4 microRNAs to be predictive of 
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clofarabine resistance in AML cell lines. To our knowledge this is the first in vitro study 
that has identified microRNA signature that is predictive of clofarabine chemosensitivity. 
Additional functional validation and mechanistic studies are warranted to elucidate the 
role of these microRNAs in clofarabine response. Also validating these findings in AML 
patients would strengthen the significance of these microRNAs and help in better 
understanding the factors contributing to the response of these chemotherapeutic agents. 
In conclusion, over the last decade there have been significant efforts to identify genetic 
markers that can be used to explain the variability in response and predict clinical 
outcome in AML patients treated with cytarabine. However, there is still a clear need to 
identify additional mechanistic biomarkers that can help optimize the cytarabine dosing 
regimen that would help improve the clinical outcome and reduce the toxicities. Based on 
our work in this thesis we believe that microRNA signature can be a promising 
prognostic and predictive tool that can be used to individualize treatment therapy with 
cytarabine in AML patients. 
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